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R-ketorolac Targets Cdc42 and Rac1 and Alters Ovarian Cancer
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Abstract
Cdc42 (cell division control protein 42) and Rac1 (Ras-related C3
botulinum) are attractive therapeutic targets in ovarian cancer based on their
established importance in tumor cell migration, adhesion and invasion. Despite a
predicted benefit, targeting GTPases has not yet been translated to clinical
practice. Based on lead identification through high-throughput screening and
computational shape homology approaches, R-ketorolac is identified as a Cdc42
and Rac1 regulator, an activity that is distinct from the anti-inflammatory,
cyclooxygenase inhibitory activity of S-ketorolac. In this dissertation, R-ketorolac
is established as an allosteric inhibitor of Cdc42 and Rac1. Studies on
immortalized human ovarian adenocarcinoma cells (SKOV3ip), and primary,
patient-derived ovarian cancer cells show R-ketorolac is a robust inhibitor of
growth factor or serum dependent Cdc42 and Rac1 and their downstream
effector p21-activated kinases activation. Multiple assays of cell behavior show
v

that R-ketorolac significantly inhibits cell adhesion, migration and invasion. A
clinical trial on ovarian cancer patients shows that ketorolac is enriched in the Renantiomer in peritoneal fluids and GTPase activity is inhibited in ascites-derived
tumor cells. A retrospective study suggests that a single dose of ketorolac in the
perioperative period benefits patient outcomes. In sum, R-ketorolac inhibits
Cdc42 and Rac1 activities and subsequent physiological consequences which
are critical to tumor metastasis and likely contributes to the observed survival
benefit in ovarian patients.
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CHAPTER 1
INTRODUCTION
Ovarian Cancer
Ovarian cancer is the fifth leading cause of gynecological cancer deaths in
the United States with a 45% 5-year survival rate (1). A majority of malignant
ovarian cancer in adult women is epithelial ovarian cancer, which is classified
into distinct morphologic categories, including serous, mucinous, endometrioid,
clear cell, transitional cell, or any combination of these (2, 3). Recent
understanding of the etiology of “ovarian cancer” suggests that it is a general
term for a series of molecularly and etiologically distinct diseases that simply
share an anatomical location. New evidence shows that a majority of serous
ovarian cancers originate from the distal end of dysplastic fallopian tubes, mostly
presenting at an advanced stage disease; whereas early stage carcinomas,
including clear-cell carcinoma, endometrioid, and low-grade serous carcinoma
usually derive from endometriosis or borderline serous tumors (4-7).
Serous ovarian carcinoma is the most common (~70%) and aggressive
epithelial ovarian tumor that is usually diagnosed at advanced stages with a high
relapse rate (8). Due to lack of symptoms and effective early predictive markers,
most patients are diagnosed at late stages with tumor dissemination on multiple
abdominal organs at laparotomy (9, 10). A majority of patients relapse although
tumor cannot be detected after first-line surgery and chemotherapy. Another
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difficulty for ovarian cancer treatment is tumor heterogeneity. Many ovarian
cancers are derived from non-ovarian tissues and share few molecular
similarities among different histotypes (4-7). This leads to failure of most
molecularly targeted therapies that are only effective at some tumor sites, and
explains the high recurrence rate of a tumor that responds to initial treatment but
soon develops chemoresistance (11-13). Thus, in comparison to other epithelial
malignancies, the survival rate of epithelial ovarian cancer has shown little
improvement since precise surgery and target chemotherapy were introduced
over the past 30 years (14-16).
Ovarian Cancer Metastasis and Microenvironment
Often associated with malignant ascites, which facilitates metastasis, most
patients are diagnosed at advanced stages with dissemination throughout the
intraperitoneal cavity (17). Unlike many other epithelial cancers, at early stages,
epithelial ovarian tumors grow and extend to the proximal sites adjacent to the
primary tumors by cell proliferation, migration and colonization (16, 18).
Metastatic spread of ovarian cancer beyond the ovary or fallopian tube is
mediated by disruption of the ovarian tumor capsules and surface shedding of
malignant cells from primary tumors into the peritoneum, where tumor cells
survive as free-floating multicellular aggregates (MCA) in the ascites fluid,
commonly known as spheriods. Subsequently, MCA anchor and attach on
mesothelial extracellular matrix (ECM) and invade into the submesothelial matrix,
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which leads to secondary lesions on peritoneal organs and surfaces at later
stages (19, 20) (Figure 1).
Recent studies have shown that the tumor microenvironment contributes to
the late diagnosis, intraperitoneal dissemination, chemoresistance and frequent
recurrence (21, 22). The tumor microenvironment has a multicellular composition
that includes tumor cells, tumor-infiltrating immune cells and stromal cells with
the peritoneal cavity being considered as a highly receptive environment for
carcinomatosis (22, 23). Mesothelial cells form a protective monolayer that
maintains

normal

serosal

membrane

integrity

and

function.

Peritoneal

mesothelial cells play pivotal roles in protecting organs from tumor dissemination
(24, 25). However, malignant tumor cells anchor on the mesothelium by
overexpressing CA125 which facilitates cell implantation via the interaction with
mesothelin expressed on mesothelial cells, and further invade into the
submesothelial ECM of organs by secreting surface matrix metalloproteases
(MMP) (26). The CD44/hyaluronan/vercican macromolecular complex promotes
tumor cell adhesion on mesothelium and invasion into the ECM (27). Integrins
are involved in cell-ECM and cell-cell interaction, and ascites-associated MCA
formation that are important for tumor migration and invasion (28, 29).
Endothelial cells are critical during tumor progression for tumor growth because
of their functions in neovasculature formation regulated by pro- and antiangiogenic factors (30). Adipocytes have been reported to promote homing and
proliferation of ovarian cancer to the omentum by secreting specific cytokines
(e.g. IL-6, IL-8), chemokines and lipids (31, 32). Immune cells (e.g. macrophages,
-3-

T cells, dendritic cells and B cells) are another key component of tumor
microenvironment because the quality of endogenous immune responses can
have a significant impact on patient outcomes and are usually suppressed in the
tumor microenvironment (33, 34). Cancer associated fibroblasts are a major
component of tumor stroma that facilitate tumor cell growth and metastasis by
expressing mitogenic factors. Moreover, the tumor stromal fibroblasts are
speculated to be derived from ovarian surface epithelium that undergo epitheliato-mesenchymal transition (EMT) (19, 35). In sum, all these components and the
communication between them characterize the unique microenvironment that
regulates ovarian tumor growth, angiogenesis and dissemination.
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Figure 1.

Model of ovarian cancer metastasis. At the earliest stage, the

tumor is limited to one or two ovaries; no tumor is present on the ovarian surface
or in ascites. Once the tumor progresses to later stages - when most patients are
diagnosed – it spreads beyond the confines of the ovaries, extends and invades
to adjacent tissues, such as the uterus, fallopian tubes, and mesothelial lining of
peritoneum. Metastatic spread of the ovarian cancer beyond the ovary or
fallopian tube is mediated by surface shedding of tumor cells and formation of
free-floating multicellular aggregates in the ascites fluid. Subsequent mesothelial
anchoring and invasion of the submesothelial matrix lead to secondary lesions on
peritoneal organs and surfaces. (H. Naora, D. Montell, Nature Reviews Cancer,
2005;5:355-66)
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Overview of Ovarian Cancer Treatment
The first line treatment for epithelial ovarian cancer is major debulking
surgery to remove as much tumor burden as possible, most often followed by
intraperitoneal chemotherapeutic treatment in optimally debulked patients after
recovery from surgery (36). Cytoreductive surgery is initially conducted on
patients with suspected epithelial ovarian cancer to determine a pathological
diagnosis, precisely evaluate disease stage, and optimally excise tumors when
feasible (37-39). After a perioperative period that allows patients to recover from
primary surgery, patients are standardly treated with platinum/taxane based
cytotoxic chemotherapy (40). The chemotherapeutic drugs are given systemically
by intravenous (IV) injection, intraperitoneal (IP) injection or mouth, which allows
the drugs to reach all areas of the body through the circulatory system. Because
ovarian cancer mostly disseminates within the peritoneal cavity, IP chemotherapy
is widely used and involves injecting drugs through a catheter directly into the
abdominal cavity (41). Compared to IV chemotherapy, IP chemotherapy results
in higher local concentrations of drugs in the peritoneal cavity and results in twofold higher drug penetration into tumors (42). Although nearly 75% of patients
initially respond favorably to chemotherapy, a majority of patients subsequently
become chemoresistant, develop largely incurable recurrent disease, and die
within five years (16).
The perioperative period, which is a days-to-weeks period between
cytoreductive surgery and the first chemotherapy, has been reported to be crucial
-6-

for tumor recurrence and metastasis (43). Although the primary tumor is removed
by surgery along with all tumors > 1 mm, due to wide dissemination and
microscopic implants throughout the peritoneum, residual malignant tumor cells
may be present in the circulatory system, distal organs or bone marrow which
leads to disease recurrence (44, 45). During this period, surgery-induced
perturbations (e.g. stress, nutritional status, inflammation and anesthesia) and
consequent paracrine, neuroendocrine and immune responses, including
increased prostaglandins, growth factors and cytokines (e.g. Tumor necrosis
factors (TNF), interleukin factor (IL) 6, IL8) and decreased antiantiogenic factors
(e.g. endostatin), create a pro-metastatic microenvironment, facilitating residual
malignant tumor cell growth, proliferation, and survival (46-50). The malignant
tumor cells are either cancer stem cells or metastatic tumor cells, which are
frequently chemoresistant and represent the major cause of ovarian cancer
relapse and mortality (51, 52). Therefore, targeting tumor cell adhesion, migration
and invasion in the perioperative period presents an important potential window
of opportunity for treatment that has not yet been extensively explored (43, 53).
Rho GTPases
Ras homology guanosine triphosphatases (Rho GTPases) (~21 kDa) are
a family of small signaling G proteins, which were began to be discovered from
1985 as Ras-related proteins (54, 55). To date, there are twenty-two mammalian
genes encoding Rho proteins that have been identified. Cdc42, Rac1 and Ras
homolog gene family, member A (Rho A) are three well characterized members
-7-

of the Rho family GTPases (54, 56). Similar to other regulatory GTPases, Rho
GTPases act as molecular switches by interconverting between an active GTPbound form and an inactive GDP-bound form. Because GDP is tightly bound and
GTP is hydrolyzed very slowly, the cycling between an active and an inactive
conformational state is regulated by three classes of GTPase regulatory proteins:
a) guanine nucleotide exchange factors (GEFs), which facilitate GDP dissociation;
b) GTPase-activating proteins (GAPs), which stimulate GTP hydrolysis; c)
guanine nucleotide exchange inhibitors (GDIs), which sequester GTPases from
nucleotide exchange by shielding the lipids that are critical for membrane
recruitment (54, 56-58) (Figure 2).

-8-
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Figure 2. Rho GTPase activation cycle and roles in signaling pathways. In
response to stimulatory signals, activated GEFs catalyze the exchange of GDP
to GTP on Rho family GTPases. Active GTP-bound Rho GTPases interact with
effector molecules (e.g. PAKs), leading to the activation of signaling cascades
regulating a variety of cellular processes. GAP proteins promote GTP hydrolysis
and inactivation of Rho GTPases. Rho GTPase activity is further inhibited by
GDIs, which sequester the GTPase in the cytosol away from cell membranes.

-9-

Rho GTPase Signaling Pathways and Their Functions
Various extracellular stimuli trigger the activation of Rho GTPases at
different points (Figure 3), such as G protein-coupled receptors, tyrosine kinase
receptors and integrin. The seven-transmembrane-domain heterotrimeric G
protein-coupled receptor family (e.g. bradykinin, Lysophosphatidic acid (LPA)
and bombesin receptors) activate select Rho GTPases by the activation of
heterotrimeric G proteins, which subsequently stimulates the RhoGEFs (59).
Epidermal growth factor (EGF), platelet-derived growth factor (PDGF) and
insulin-like growth factor (IGF) stimulate the activation of Rho GTPase by
increasing GEF activity in a phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)
dependent manner. In addition, Rho GTPases are activated by cell-ECM
adhesion which is mediated by integrins. The cytoplasmic tail of integrin (β1, β3,
β5) activates focal adhesion kinase (FAK), leading to the phosphorylation of
downstream protein p130cas that activates DOCK180 (a Rac GEF) and inhibits
RhoA. Overall, the activation of cell receptors and other molecules influence
intracellular signaling by regulating Rho GTPase activity (60, 61).
Cdc42 and Rac1 activate multiple downstream effectors and initiate the
sequential events which modulate various cell behaviors (Figure 3) (62). For
example, p21-activated kinases (PAKs) interact with Cdc42 and Rac1 through a
p21

binding

domain

(PBD),

which

causes

auto-phosphorylation

and

conformational changes and initiates multiple cellular processes, including Factin polymerization, Mitogen-activated protein kinases (MAPK) signaling, and
- 10 -

apoptosis signaling (63, 64). Other effectors of Cdc42 and Rac1 include the
Wiskott-Aldrich syndrome protein (WASP)/WASP-family verprolin-homologous
protein (WAVE) family and Ras GTPase-activating-like protein (IQGAP), which
regulate actin nucleation through the actin related protein (Arp) 2/3 complex for
actin polymerization (65, 66). In addition, Cdc42 promotes cell division and cell
transformation by inducing the accumulation of EGFR, and facilitating the nuclear
translocation of EGFR which induces EMT and angiogenesis (67). All these
processes are critical for the regulation of cell growth, proliferation, motility and
apoptosis.
Since Cdc42 and Rac1 GTPases play important roles in actin
reorganization, their regulators and effectors have been suggested to control
tumor progression and metastasis (68). The direct effectors of Cdc42 and Rac1 –
PAK1 and PAK4 – are up-regulated in breast cancer and required for actin
cytoskeleton remodeling and tumor cell motility (69). In colorectal cancer cells,
active Cdc42 greatly promotes cells to spread, migrate, and invade via the PAK1myosin light-chain kinase (MLCK) pathway important for tumor metastasis (70).
In breast cancer cells, Rac1 is up-regulated as a consequence of enhanced
upstream signals from multiple pathways (e.g. phosphoinositide-3-kinase (PI3K)
and tyrosine kinase receptors (TKR) such as ErbB1/ epidermal growth factor
receptor (EGFR) in response to EGF or transforming growth factor (TGF)
ligands), which promotes tumor cell growth and proliferation (71, 72). Activated
Cdc42 and Rac1 decrease p53 protein levels leading to increased vascular
endothelial growth factor (VEGF) expression and tumor angiogenesis (73). α6β4
- 11 -

integrin-dependent Rac-PAK1 signaling enhances apoptosis-resistance by
overexpressing nuclear factor kappa-light-chain-enhancer of activated B cells
(NF-κB) protein in mammary acini (74). Rho GTPases stimulate cell cycle
progression by inhibiting retinoblastoma protein (pRb) checkpoint and reduce
epithelial cell polarity by down-regulating E-cadherin expression in various
carcinoma cells (75). In summary, Cdc42 and Rac1 regulate multiple cell
functions that could affect tumor progression and metastasis.
Moreover,
hyperactivated

Cdc42
in

and

epithelial

Rac1

are

cancers

frequently

overexpressed

including

ovarian

or

cancer.

Immunohistochemistry studies show that patients with a high clinical stage
hepatocellular carcinoma (III-IV) had a higher tendency to express Rac1 which is
associated with shorter disease-free survival, compared to patients with low
pathologic grade hepatocellular carcinoma (76). Rac1 expression promotes EMT
and the overexpression correlated with advanced stage of disease and early
tumor recurrence in epithelial ovarian cancer patient (77). Rac1b is a Rac1 splice
variant that adds 19 amino acids and causes hyperactivity through GEFindependent activation (78-80). Rac1b is overexpressed in breast, colorectal and
lung cancer, and constitutes a marker of poor prognosis in KRAS/BRAF WT
metastatic colorectal patients (81-85). Previous work by our group found that
both Cdc42 and Rac1 were overexpressed or hyperactivated in advanced stages
of ovarian cancer patients compared to benign or low grade tumor (86). Thus,
Cdc42 and Rac1 GTPases could be potential pharmacologic targets for the
treatment of ovarian and other epithelial cancers.
- 12 -

In addition to the described canonical Rho GTPases - Cdc42 and Rac1,
other Rho GTPase isomers also play critical roles in cell proliferation,
differentiation and cell migration (87). RhoA, -B and -C directly activate actin
polymerization

in

stress

fiber

formation

by

interacting

with

ROCK-

LIMP/actomyosin pathways. RhoA and RhoC have been found to promote
cancer progress, whereas RhoB acts as a cancer suppressor with its
antiproliferation and proapoptosis effects (88). A similar anti-tumor effect is also
observed for RhoE targeted by p53 (89). RhoG regulates membrane dynamics
involved in cell migration and spreading and microtubule dynamics critical for
platelet granule secretion (90). RhoJ modulates the formation of focal adhesion
and early endocytosis for endothelial chemotaxis, migration, proliferation and
lumen formation, which is responsible for the angiogenesis (91).
Cancer

growth

and

metastasis

are

directly

correlated

with

the

misregulation of Rho family GTPases that generally result in overexpression of
Rho GTPases and aberrant activity of Rho GTPase regulators (e.g. GEF, GAP,
GDI). Recently, mutationally active Rho GTPases have been identified using
high-throughput exome sequencing techniques (92, 93). In about 5-10%
melanoma, Rac1 (P29S) and Rac2 (P29L) mutants are found to activate the
GTPases by enabling GEF-independent conversion to the GTP-bound form (9395). In C. elegans, MIG-2 (S75F), which might be functionally equivalent to RhoG,
and CED-10, which might be functionally equivalent to Cdc42, have been
identified as gain-of –function mutations (96).
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Figure 3. Cdc42 and Rac1 GTPases regulate multiple downstream signaling
pathways. Cdc42 and Rac1 promote cytoskeleton reorganization through
regulation of multiple effectors (e.g. N-WASP/WAVE, IQGAP, PAK) and
associated subsequent signaling proteins (LIMK, Arp2/3), which are pivotal for
cell adhesion, migration and invasion. Cdc42 and Rac1 also mediate the
activation of MAPK signaling pathway through PAK, regulating cell growth,
apoptosis and proliferation.
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Rho GTPase Inhibitors
Since Cdc42 and Rac1 are potential high value therapeutic targets in
ovarian and other cancers, numerous inhibitors targeting the Rho GTPases have
been developed. Statins are 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)
reductase inhibitors that indirectly act as broad spectrum GTPase inhibitors by
interfering with the prenylation required for membrane association and have been
successfully used for the treatment of hypercholesterolemia (97). In recent years,
statins have been found to induce apoptosis and inhibit proliferation in several
cancer cell lines. Cancer risk reduction associated with statins use are reported
for prostate, breast, colorectal, and pancreatic cancers in patients (98-101). The
benefit in ovarian cancer is mixed and subtype specific (102), motivating the
identification and testing of more selective GTPase inhibitors. Secramine inhibits
Cdc42 binding to membranes in a RhoGDI-dependent manner, prevents
membrane associated Cdc42 activation, and subsequently inhibits the formation
of actin cytoskeleton mediated platelet integrin α2β1 (103). CID2950007, an
allosteric inhibitor of Cdc42 nucleotide binding, inhibits Cdc42-related filopodia
formation and cell migration in cell based assays (104). NSC23766 was
discovered as a Rac inhibitor and selectively inhibits the interaction between Dbl
(a Rac GEF) and Rac (105). The compound has been shown to inhibit cell
growth, proliferation and invasion in prostate cancer and hematopoietic stem
cells (105, 106). Novel compounds (e.g. AZA1, AZA197, EHop-016) based on
structural information of NSC23766 have been synthesized and act as Cdc42 or
Rac1 inhibitors to reduce cell migration and proliferation and tumorigenicity in a
- 15 -

xenograft mouse model in prostate and colorectal cancers (107-110). Although
all these Rho GTPase inhibitors were designed and discovered with various
modes of action and are predicted to be of great therapeutic benefit, the limitation
of the Rho GTPase inhibitors lies in their poor selectivity between cancerous and
normal

cells.

Therefore,

these

identified

compounds

may

not

be

pharmacologically suitable for human use and none have as yet been translated
to clinical application.
NSAIDs and Their Roles in Cancer Therapy
Non-steroidal

anti-inflammatory

drugs

(NSAIDs)

are

potent

cyclooxygenase (COX) inhibitors that cause reduced synthesis of prostaglandins
from arachidonic acid. Many of the NSAIDs are marketed as racemates,
composed of 1:1 mixtures of R and S-enantiomers. The two enantiomers often
exhibit remarkable pharmacologic and toxicologic differences. The S-enantiomer
has been shown to preferentially interact with COX (111) and is generally
considered the active component in racemic drug formulations.
Recently, besides their analgesic function, several NSAIDs have been
reported to have significant benefit for patient survival in various cancers.
Growing evidence suggests that NSAIDs have a variety of molecular targets and
may contribute to cancer prevention in both COX-dependent and COXindependent manners. For example, aspirin has been reported to reduce colon
cancer risk by inhibiting the upregulated expression of COX-2, which promotes
tumorigenesis in 40-45% of colon cancer (112). The evidence for COX- 16 -

independent pathways is that COX-2 negative epithelial cells exhibit similar IC50
values as COX-2 positive counterparts in terms of cell growth inhibition with
celecoxib treatment (113). Furthermore, R-ibuprofen, which does not have COX
inhibitory activity, is equally potent as the COX inhibitory S-ibuprofen in inhibiting
PDGF-induced mitogenesis in colon cancer cells and colon cancer development
in an animal model (114, 115). Numerous targets, in addition to COX, have been
identified as potential mediators responsible for the chemopreventive action of
NSAIDs, e.g. inhibition of IκB kinase (IKK)β/NF-κB mediated transcriptional
activation and cell survival, reduction of protein kinase G (PKG) mediated
angiogenesis, and downregulation of matrix metalloproteinase (MMP)2 and
MMP9 mediated invasion (116-120). Although multiple targets have been
identified for the anti-tumor effect of NSAIDs, there is no evidence of these
potential targets being directly related to the clincially observed benefits on
cancer patient outcomes.
Rationale of the Study
Using findings obtained from a high throughput screen of the 2007
Prestwick Chemical Library® (2007) of 100% off patent drugs contained 888 small
molecules (Prestwick, Washington DC, USA) and cheminformatics approaches,
the R-enantiomers of a limited number of NSAIDs, R-ketorolac and R-naproxen
were identified as inhibitors of Cdc42 and Rac1 (121). Ketorolac is an FDA
approved drug that is administrated as a racemic mixture for post-surgery pain
management. S-ketorolac inhibits COX-1 and COX-2 enzymes, whereas R- 17 -

ketorolac shows >100-fold less activity on both COX-1 and COX-2 (122). Snaproxen, but not R-naproxen is an FDA approved drug having analgesic, antiinflammatory, and antipyretic activity. Such activity is also mediated via inhibition
of the COX enzymes (123, 124).
The central goal of this study is to confirm and characterize the Renantiomers of selected NSAIDs, ketorolac and naproxen, as bona fide Cdc42
and Rac1 GTPase inhibitors and establish their anti-tumor impacts in ovarian
tumor cells and ovarian cancer patients. R-ketorolac, as a FDA-approved drug in
racemic form, has potential to be repurposed as an anti-tumor drug for ovarian
cancer therapy. Chapter 2 identifies the mechanism of R-ketorolac and Rnaproxen on Cdc42 and Rac1 nucleotide binding using a flow cytometry based in
vitro nucleotide binding assay. Chapter 3 utilizes cell-based assays to
characterize the inhibitory effect of R-ketorolac on cell adhesion, migration and
invasion using immortalized ovarian cancer cell lines and primary human ovarian
cancer cells. Chapter 4 utilizes a clinical trial to establish a novel pharmacologic
activity of ketorolac for therapeutic benefit in ovarian cancer patients .

Hypothesis
R-ketorolac inhibits Cdc42 and Rac1 GTPase activities and associated
downstream cascades that are central to cell adhesion, migration and invasion,
which will have beneficial effect in reducing ovarian tumor metastasis and
progression.
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Significance and Innovation
Compared to traditional drug development pipeline requirements, the
overall time and cost of repurposing R-ketorolac will be greatly reduced because
of the significant number of toxicology and safety assessments that have already
been completed. The mechanistic study of signaling pathways inhibited by
ketorolac will demonstrate Cdc42 and Rac1 as potential therapeutic targets for
ovarian and other epithelial cancers therapies. Biochemical and structural studies
of the mechanism of GTPase activity inhibition by selected NSAIDs will provide
guidance for the development of new anti-tumor chemical entities.

- 19 -

CHAPTER 2
R-KETOROLAC INHIBITION OF CDC42 AND RAC1 NUCLEOTIDE
BINDING
Abstract
Cdc42 and Rac1 GTPases are key regulators of actin reorganization, cell
motility, cell-cell and cell-extracellular matrix (ECM) adhesion, whose activities
are found closely correlated with tumor expansion and malignant progression.
Despite a predicted benefit, targeting Cdc42 and Rac1 GTPases has not yet
been translated to clinical practice. Through high throughput screening and
computational shape homology approaches, we established the R-enantiomers
of selected NSAIDs (ketorolac and naproxen) as Cdc42 and Rac1 inhibitors;
distinct from the anti-inflammatory, cyclooxygenase inhibitory activity of Senantiomer. In this chapter, a bead-based flow cytometry assay was used to
establish that R-ketorolac and R-naproxen act as allosteric regulators of GTPase
nucleotide binding by Cdc42 and Rac1. Molecular docking analyses are
predicated on in vitro nucleotide binding assay results and GEF mediated
nucleotide exchange mechanisms. R-enantiomers are suggested to preferentially
interact with magnesium and exclude interaction with the guanine nucleotide
phosphate residue. A preliminary structure-activity relationship study of ketorolac
demonstrates that substituents on the phenyl ring are critical in modulating
ketorolac inhibition of nucleotide binding by the GTPase, offering guidance for
20

generating more selective chemical entities. Taken together, the studies in
Chapter 2 demonstrate that the R-enantiomers of selected NSAIDs (ketorolac
and naproxen) act as Cdc42 and Rac1 inhibitors, which may have potential
benefits for cancer therapy.
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Introduction
The Rho-family (Ras homolog) GTPases are central to dynamic actin
cytoskeleton assembly and rearrangement that are the underpinnings of normal
cell-cell adhesion, cell migration and even transformation (54, 125). Among the
Rho-family GTPases, Cdc42 and Rac1 are of particular interest due to their
frequent overexpression or hyperactivation in epithelial cancers including ovarian
cancer (73, 77, 86, 126, 127).
The conformational GTPase switch is regulated by the bound nucleotide
(GTP or GDP) and determines the GTPase activation status. The conserved
domain of Rho GTPases consists of a six-stranded β-sheet surrounded by five αhelices, known as the switch 1 and switch 2 regions (Figure 4) (58, 128). This
domain includes the guanine nucleotide binding site that recognizes the guanine
base as well as the β-phosphate and the Mg2+. This domain is involved in the
coordination of the β-phosphate and hydrolysis of GTP. For example, in Cdc42
nucleotide exchange (Figure 5), which is mediated by DOCK9 (a GEF for Cdc42),
the nucleotide-binding site is first exposed via a conformational transition of
switch 1. The movement of switch 1 triggered by DOCK9 (for Cdc42) and
DOCK2 (for Rac1) GEFs facilitates release of GDP via rotation of P-loop Cys18C
and disrupts interaction with GDP by excluding Mg2+ (129, 130). Mg2+ is regarded
as enhancing nucleotide affinity by neutralizing the negatively charged phosphate
groups (128). During GTP hydrolysis, crystal structure analyses showed that
Rich - a Rho GAP, hydrolyzes GTP by interacting with Cdc42 through the switch
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1 and switch 2 regions. Specifically, Arg85 of Rho GAP contacts the β-γ oxygens
and catalyzes the GTP hydrolysis by interacting with P-loop (131, 132).
Since Cdc42 and Rac1 are potential high value, therapeutic targets in
ovarian and other cancers, several GTPase targeted inhibitors have been
identified with various modes of action. Irrespective of whether they affect
GTPase membrane association by inhibiting protein prenylation (e.g. statins),
GTPase regulator activity (e.g. NSC23766, secramine) or nucleotide binding
ability (e.g. CID2950007), none have as yet been translated to human use (99,
103-105).
To investigate small molecules targeting Cdc42 and Rac1 which could be
rapidly translated to clinical application, high-throughput screening and
computational simulation of the 2007 Prestwick Chemical Library® of off-patent
and FDA approved drug-like small molecules were conducted and identified Renantiomers of selected NSAIDs, R-naproxen and R-ketorolac, as potential
Cdc42 and Rac1 inhibitors; while S-enantiomers, which are identified as COX
inhibitors, displayed little or no activity against GTPases.
In this chapter, a flow cytometry based in vitro nucleotide binding assay
was used to establish the mechanism of inhibition of the R-enantiomer of
selected NSAIDs on Cdc42 and Rac1. This approach enables distinction of
allosteric or competitive inhibition of nucleotide binding.
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Figure 4. Structure of Rho GTPase. α-helix, β-sheet, switch 1, switch 2, and
magnesium are indicated. (Vetter, IR et al., Science, 2001,294;1299-1304)
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Figure 5. DOCK9 mediates the conformational changes in Cdc42 to
facilitate nucleotide exchange. Cdc42 is colored orange/gold with switch 1(red)
and 2 (magenta) and P loop (blue). DOCK9 is colored in light blue/purple. GTP
and magnesium are colored in green. DOCK9 interacts with Cdc42 and triggers
the conformational change of switch 1, which facilitates Mg2+ exclusion and
nucleotide exchange of GDP for GTP. The conformational change of DOCK9
includes α6 and α10C helices (indicated by arrows) and β3/β4 and β5/β6 loops.
(Kulkarni, K. et al., The Journal of Biological Chemistry, 2011; 286:25341-51)
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Materials and Methods
Reagents
Superdex peptide beads (13 µm with an exclusion limit of 7kDa) were from
Amersham Biosciences (custom-order). GST (glutathione S-transferase)-tagged
GTPases (Cdc42/Rac1) were purified as described previously (133). Compounds
for dose response assays were obtained as follows: R-ketorolac (K235600,
Toronto Research Chemical Inc), S-ketorolac (K235605, Toronto Research
Chemical Inc), R-naproxen (Acme Bioscience #A5026, Palo Alto, CA), Snaproxen sodium (N5160, Sigma-Aldrich), 6-methoxy-2-napthalene acetic acid
(6-MNA) (70620, Cayman Chemical, Ann Arbor, MI, USA), NSC23766 (204823,
Santa Cruz, CA), CID2950007 (71203-35-5, Tocris). GST-PAK1 protein was from
Millipore (14-864). BODIPY-GTP ((4,4-difluoro-4-bora-3a,4a-diaza-s-indacene or
dipyrromethene boron difluoride) nucleotide analogue) was from Invitrogen
Molecular Probes (Cat #: G22360). Ketorolac analogs (Screening Center Vial
Barcode Number: SKCM101436, 101439, 100846, 104309, 104402, 104352,
100538, 100897, 102026, 100621, 101671, 103977, 103793, 103959) were
synthesized by Dr. Jennifer Golden (Associate Director Medicinal Chemistry
Center, Pharmaceutical Sciences Division, University of Wisconsin). CID2950007
analogs (44216842-CCCH2CH2NGtBoc(RS-II-16P), 44216842-Iodide(AG-II-106),
44216842-CCCH2CH2NH2(RS-II-24C),

44216842-Heptynoic-Dioxy-HPY(490))

were synthesized by Dr. Jeffery Arterburn (Department of Chemistry, New
Mexico State University). All compounds were dissolved in dimethyl sulfoxide
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(DMSO) at 100 mM stock concentrations. Stocks should be aliquoted and
multiple freeze-thaw cycles avoided.
Expression and Purification of GST-Cdc42/Rac1
GST-Cdc42/Rac1 protein was expressed in E. coli BL21 (DE3). Cultures
were grown at 37ºC to a bacterial density of 0.6-0.8 absorbance units at λ=595
nm. Bacteria were chilled on ice for 20 min and then induced by transfer to room
temperature and addition of 0.2 mM isopropyl-beta-D-1-thiogalactopyrano- side
(IPTG) for 16-18 h to maximize yield of properly folded active fusion protein.
Purification of GST-Cdc42/Rac1 was used for the flow cytometry based in vitro
nucleotide binding assay according to standard procedures (133).
Synthesis of Glutathione (GSH) Beads for Flow Cytometry Assay
High density glutathione (GSH) conjugated beads were synthesized for flow
cytometry assays by loading Superdex peptide beads with GSH as previously
reported (134). Typical site occupancies of the beads at saturation are in the
range of 1 to 4 ×106 ligand sites/bead (determined by the characteristic kinetic
and equilibrium binding of GST fused green fluorescent protein (GFP) (135).
Immobilization of Cdc42/Rac1 on GSH Beads for Flow Cytometry
All in vitro nucleotide binding to GTPases and measurements were
performed in HPS buffer (30 mM Hepes, pH 7.5, 20 mM NaCl and 100 mM KCl)
containing 1 mM EDTA, 0.1% BSA (w/v) and 0.01% NP40 (v/v). A Becton
Dickinson FACScan flow cytometer with a 488 nm excitation laser and standard
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detection optics was used for all assays (133). Purified GST-tagged Cdc42/Rac1
protein was incubated in a 1.5 ml Eppendorf tube at 4ºC overnight with 2×105
GSH beads in a total volume of 100 µl of HPS buffer containing 1 mM EDTA, 1
mM dithiothreitol (DTT) added fresh and 0.1% BSA (w/v). Unbound protein was
removed by centrifugation and washes by spinning GTPase bound beads twice
at 800 g followed by resuspension of washed beads in fresh HPS buffer with 1
mM EDTA, 1 mM DTT added fresh and 0.1% BSA (w/v).
Flow Cytometric BODIPY-GTP Binding Assay
The nucleotide binding assays were carried out according to the protocols
described previously (134). In order to measure BODIPY-GTP binding to Cdc42
and Rac1 GTPases, the in vitro nucleotide binding assay was performed in HPS
buffer containing 1 mM EDTA in order to chelate the magnesium and facilitate
GTPase nucleotide exchange. Briefly, individual GST-GTPases were allowed to
bind to their respective GSH beads and combined. In the equilibrium assay, 2
×103 GSH beads loaded with GST-GTPase were pre-incubated with either
DMSO or a fixed compound concentration for 15 min followed by incubation with
varying concentrations of BODIPY-GTP for 30 min at room temperature. A stock
solution of ketorolac was prepared by dissolving to 10 mM concentration in
DMSO. A three-fold serial dilution was made from the 10 mM stock in DMSO. In
dose-response assays, 2 ×103 GSH beads loaded with GST-GTPase were preincubated with DMSO or increasing concentrations of the compounds for 15 min
followed by incubation with a fixed concentration of BODIPY-GTP for 30 min at
room temperature. Final DMSO concentrations were held constant in each
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sample at 1%. For measurement, samples were diluted at least 10-fold and
delivered and analyzed on a BD FACScan flow cytometer.
To measure the effect of a fluorescent CID2950007 analog (RS-II-79,
synthesized by Dr. Arterburn and colleagues) on Cdc42 nucleotide binding, a
single-plex dose-response assay was conducted. Diluted samples were
measured on a BD FACScan flow cytometer. The fluorescence intensity of
BODIPY-GTP was detected by FL-1 (λex=488 nm, λem = 530/30 nm). FL-2
(λex=488 nm, λem = 585/42 nm) was used to measure the fluorescence intensity
of the fluorophore (HPY490) (136), which quantifies the bound RS-II-79 on
GTPase. The non-specific binding of the RS-II-79 was measured by incubating
GST-GSH beads with the fluorescent compound. The intensity of the bona fide
bound RS-II-79 was calculated as: Mean Channel Fluorescence

(Cdc42-GSH beads)

–

Mean Channel Fluorescence (GST-GSH beads).
Live Cell Imaging
GFP-actin-expressing MDCK cells were cultured on coverslips to 70-80%
in DMEM media containing 10% FBS overnight. The next day the coverslip was
transferred to NuncTM glass bottom dish (Thermo Scientific, Cat #: 150682) in
DMEM-No Phenol Red (Gibco, Cat #: 31053-028) media with 10% FBS and
loaded with 10 µM RS-II-79. Confocal images were obtained using a Zeiss
Axiovert 200M microscope and a 60x oil immersion objective. RS-II-79 (HPY-490)
fluorescence was monitored with excitation at 480 nm and emission above
530±30 nm. GFP fluorescence was determined with excitation at 490 nm and
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emission above 510±10 nm. The fluorescence intensity of RS-II-79 was analyzed
by Slidebook 5 software.
HPY490 Labeled RS-II-79 Penetration into MCA
For multicellular aggregate (MCA) assays, 2,000 SKOV3ip-GFP cells were
seeded into each well of a Lipidure-coated 96 well plate (NOF America
Corporation, White Plains, NY) and incubated for 48 hours to allow for the
formation of MCA. MCAs were transferred to a Nunc Lab-Tek Chambered
Coverglass 8-well imaging chamber (Thermo Scientific) and treated with
fluorescently-labeled RS-II-79 (10 µM) to determine drug penetration. Confocal
images through the center of the spheroid were captured at time points up to 66
minutes of treatment on a Zeiss Axiovert 200 M inverted confocal microscope
equipped with a warming chamber to maintain the temperature at 37ºC. Images
were analyzed with Zeiss Zen software.
Statistical Analyses
Prism 5 software (GraphPad) was used to analyze all data to determine
statistical significance. One-way ANOVA (Analysis of Variance) with Dunnett’s
test for multiple comparisons was performed to compare differences between the
means of each group relative to the control group for all assays. P-values less
than 0.05 were considered statistically significant. ANOVA was performed on
these standardized values.
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Results
R-ketorolac and R-naproxen Inhibit Cdc42 and Rac1 GTPase Nucleotide
Binding as Allosteric Inhibitors
To test the capacity of ketorolac (Figure 6A) to inhibit GTPase nucleotide
binding activity and determine the mechanism of inhibition, a bead based flow
cytometry assay – which measures the in vitro GTPase nucleotide binding
activity – was used. First, equilibrium nucleotide binding assays were performed
under conditions where the tested compound concentration was held fixed
against increasing concentrations of fluorescent nucleotide. In the presence of Rketorolac, both the maximum fluorescence (Bmax) and the apparent dissociation
constant (Kd) of BODIPY-GTP for Cdc42 and Rac1 changed, which suggests a
noncompetitive mechanism of action (Figure 6B, 6D, Table 1). S-ketorolac did
not change the Bmax and the Kd for Cdc42 (Figure 6C, Table 1) and exhibited a
minor inhibition of Rac1 only at the maximum concentration of 100 µM (Figure
6E). Single-plex dose-response measurements were used to verify the
enantiomer selectivity of ketorolac for inhibiting nucleotide binding by Cdc42 and
Rac1. The nucleotide concentrations in the assay were fixed at the determined
dissociation constants (Kd ≈ 300 nM). Increasing R-ketorolac concentrations
reduced BODIPY-GTP binding, with respective EC50 (half-maximal effective
concentration) values of 1.89×10-5 M for Cdc42 and 2.31×10-5 M for Rac1 (Figure
6F, 6G). The maximal inhibitory response was ~20% for both GTPases. Sketorolac did not exhibit an inhibitory activity against either GTPase under the
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tested conditions. Together, these findings suggest an enantiomer-selective,
inhibitory activity of R-ketorolac against the nucleotide binding activity of Cdc42
and Rac1. Mechanistically, R-ketorolac action is consistent with an allosteric
inhibition of GTPase nucleotide binding.
Moreover, single-plex dose-response measurements were used to test the
effect of R-naproxen on Cdc42 and Rac1 nucleotide binding. The nucleotide
concentration in this assay was fixed at the determined dissociation constant of
300 nM. As shown in Figure 7, nucleotide binding to the Cdc42 and Rac1
GTPases was inhibited by R-naproxen with an EC50 of 18 µM. The maximal
inhibitory response was ~30% for both GTPases. However, EC50 for the inhibition
of Rac1 by S-naproxen was higher than 200 µM. S-naproxen exhibited a similar
EC50 for inhibition of Cdc42 but failed to reach the threshold of 20%. Together,
these findings demonstrate R-naproxen, but not S-naproxen inhibits Cdc42 and
Rac1 nucleotide binding, which is consistent with the enantiomer-selectivity of Rketorolac.
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Figure 6. R-ketorolac acts as an allosteric inhibitor to selectively inhibit
BODIPY-GTP binding to Cdc42 and Rac1 GTPases. (A) Chemical structure of
R- and S-ketorolac with chiral center noted. (B-C) The presence of R-ketorolac
changed both the Bmax and the Kd (values are tabulated in Table 1) of BODIPYGTP binding to Cdc42 measured under equilibrium binding conditions, while S33

ketorolac did not affect BODIPY-GTP binding. (D-E) R-ketorolac changed the
Bmax and the Kd of BODIPY-GTP binding to Rac1 measured under equilibrium
binding conditions, while S-ketorolac did not affect BODIPY-GTP binding except
at 100 µM. The equilibrium binding of BODIPY-GTP to the GTPases was
measured in the presence of 0.1% DMSO or various concentrations of R- or Sketorolac (1~100 µM). BODIPY-GTP binding curves were fitted to a hyperbolic
one-site binding equation from GraphPad Prism 5. (F-G) R-ketorolac in contrast
to S-ketorolac inhibited BODIPY-GTP binding to Cdc42 and Rac1 GTPases in a
dose-dependent manner. BODIPY-GTP concentration was fixed at 300 nM for
these experiments. The inhibition curves were fitted to the sigmoidal doseresponse equation from GraphPad Prism5. In all experiments, GST-Cdc42 or
Rac1 were immobilized on GSH beads and used to measure BODIPY-GTP
binding. Bead-associated fluorescence intensity was quantified by flow cytometry
and used to monitor drug treatment induced changes in nucleotide binding.
Fluorescence attributed to nonspecific nucleotide binding was subtracted
accordingly. Quantification of three independent measurements is plotted ± SEM.
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Table 1

Biochemical properties of Cdc42 and Rac1 nucleotide binding

(BODIPY-GTP) with R- or S-ketorolac treatment
Cdc42

Bmax

Kd

Rac1

R-ketorolac

S-ketorolac

R-ketorolac

S-ketorolac

0.1% DMSO

1303 ± 38.45

1429 ± 49.49

1594 ± 28.08

1595 ± 23.75

1 µM

1243 ± 22.98

1436 ± 48.54

1428 ± 21.17

1509 ± 19.02

10µM

1134 ± 29.46

1426 ± 52.29

1355 ± 26.64

1471 ± 25.36

100µM

1009 ± 13.20

1388 ± 38.97

1249 ± 23.76

1444 ± 27.02

0.1% DMSO

303.6 ± 26.56

219.6 ± 24.47

206.2 ± 13.66

230.7 ± 10.93

1 µM

288.7 ± 16.03

195.8 ± 21.98

185.9 ± 10.59

204.4 ± 8.433

10µM

226.6 ± 12.42

197.5 ± 23.90

176.1 ± 13.43

193.4 ± 11.06

100µM

195.6 ± 8.465

186.7 ± 17.54

169.8 ± 11.94

180.6 ± 11.39

The Bmax and Kd for the nucleotide binding (BODIPY-GTP) values were derived
from data shown in Figure 6B-6E using Prism 5 software (GraphPad).
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22% inhibition
-5
EC50=1.84×10 M

30% inhibition
-5
EC50=1.82×10 M

13% inhibition
-4
EC50=2.01×10 M

25% inhibition
-6
EC50=4.2×10 M

<10% inhibition

Figure 7.

<10% inhibition

R-naproxen selectively inhibits BODIPY-GTP binding by Rac1

and Cdc42 in vitro. R-naproxen in contrast to S-naproxen and 6-methoxy
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naphthalene acid (6MNA) inhibited BODIPY-GTP binding to GSH bead
immobilized GST-Rac1 (A) and GST-Cdc42 (B) GTPase in a dose-dependent
manner. BODIPY-GTP concentration was held constant at 100 nM for these
experiments and drug concentrations varied from 10 nM to 100 µM. Beadassociated fluorescence intensity was quantified by flow cytometry and used to
monitor drug treatment induced changes in nucleotide binding. The inhibition
curves were fitted to the sigmoidal dose-response equition using GraphPad
Prism 5. Quantification of three independent measurements is plotted ± SEM.
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Molecular Docking of ketorolac and naproxen on Cdc42 and Rac1 GTP
Bound Shows Enantiomer Selectivity of R-ketorolac-Magnesium Interaction
A recent structural study of guanine nucleotide exchange factor (GEF)mediated nucleotide exchange on Cdc42 by Yang et al. demonstrated the
importance of a valine residue (1951) in the nucleotide sensing domain of the
DOCK9 GEF (129). The insertion of the sensing domain valine occludes the
critical coordination of Mg2+ by the nucleotide and the consequent reduced
charge shielding significantly decreases nucleotide affinity and leads to its
release from the GTPase. The mechanism of Mg2+ exclusion to promote
nucleotide release is distinct from that of other GEF proteins and is suggested to
enhance DOCK GEF activity against a broader range of GTPases (129).
Therefore, Mg2+ exclusion was considered as a possible mechanism for
destabilization of nucleotide binding by R-ketorolac and R-naproxen through
docking analyses. The carboxyl moiety has the potential to neutralize or displace
Mg2+ from interacting with the nucleotide by forming a competing complex with
the Mg2+. In Figure 8, docking models based on Mg2+ exclusion used by DOCK9
GEF to promote nucleotide exchange on Cdc42 and Rac1 support the observed
stereo-selectivity of R-ketorolac and R-naproxen, in which the carboxyl group is
more favorably positioned than S-enantiomers to participate in Mg2+ exclusion.
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Figure 8. Compound docking to Cdc42 based on a magnesium exclusion
model. The docking model is based on the work of Yang et al., 2009 (129)
wherein Val1951 in the sensing domain of DOCK9 (dark green ribbon) was
suggested to reduce nucleotide interaction with Mg2+ via steric hinderance or
‘exclusion’ and thereby destabilize nucleotide binding to cause release from the
GTPase active site. (A-B) The crystal structure of Cdc42-GDP in complex with
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the DOCK9 GEF (PDB ID 2WMN) was used to predict the active site docking of
(C-D) 6-MNA, (E-F) R-, S-naproxen and (G-H) R-, S-ketorolac. (B, D, F, H) The
carboxyl moiety in all compounds is proposed to interact with the Mg 2+, thereby
precluding interaction with GDP and reducing binding affinity analogous to
Val1951. R-naproxen and R-ketorolac are shown in green. 6-MNA, S-naproxen
and S-ketorolac are shown in rust color. R-enatiomers show more favorable
interaction with Mg2+ than S-enatiomers due to rotational constraints imposed on
the carboxylate by the stereocenter. Images provided courtesy of Drs. T.I. Oprea
and O. Ursu (Division of Translational Informatics, Department of Internal
Medicine, University of New Mexico).
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Structure-Activity

Relationship

(SAR)

Determination

Using

Modified

Ketorolac Analogs
The parent scaffold, represented by ketorolac, was modified on the phenyl
group to afford the initial analogue collection. Analogs bearing changes to the
phenyl ring moiety of the parent ketolorac were proposed since that functional
group occupies a lipophilic area in the binding model that would benefit from a
small appendage (e.g., Me, CF3, or halogen). These small extensions from the
phenyl ring were proposed to make key contacts within the binding site which
might alter binding affinity. The activities of derivatives were tested in single-plex
dose-response assays on Cdc42 and Rac1 GTPase nucleotide binding, and
EC50 values were determined (Figure 9 and Table 2). In comparison to the parent
compounds, most compounds exhibited similar magnitudes of inhibition and EC50
values on GTPase nucleotide binding. Interestingly, derivatives modified by
trifluoromethyl (SKCM 102026) and 3-thiophene (SKCM 103793) resulted in an
activation of nucleotide binding on Cdc42 with EC50 values of 2.43×10-8 M and
2.28×10-8 M respectively. SKCM -101439, modified with a fluorine atom resulted
in a 2.5-fold increased potency on Rac1 (EC50=5.28×10-6 M), while reducing
potency on Cdc42. 2-thiophene SKCM-103977 altered the compound activity
from inhibition to preferential activation of Rac1 nucleotide binding with an EC50
of 1.98×10-8 M. Similarly, 3-thiophene SKCM 103793 switched the activity from
inhibition to preferential activation of Cdc42 nucleotide binding with an EC50 value
of 2.28×10-8 M. Notably, the potency of SKCM 103977 and SKCM 103793 were
dramatically increased (~100-fold) as activators. The structure of the ketorolac

41

analogs are shown in Table 2 along with a tabulation of their efficacies and
potencies against Cdc42 and Rac1 nucleotide binding activity. Although
enantiomeric identity of each pair of compounds is unknown and it is difficult to
conclude the relationship of enantiomeric selectivity observed between the
analogs and the parent compound, the structural modification in the phenyl group
is confirmed to have an effect on the overall GTPase nucleotide binding activity.
Trifluoromethyl (SKCM 102026) and 3-thiophene (SKCM 103793) resulted in an
activation of Cdc42 nucleotide binding. This finding supports that lipophilic areas
play a key role in modulating GTPase activity, possibly by affecting property of
carboxyl group at the chiral center.
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Figure 9. The impact of ketorolac analogs on Cdc42 and Rac1 nucleotide
binding. Parent compounds – ketorolac (A) were modified on the phenyl with a
fluorine atom (B), a chlorine atom (C), a methyl group (D), or a trifluoromethyl
group (E). Alternatively, the phenyl ring was replaced by 2-thiophene (F) or 3thiophene (G) rings. These analogs were tested by a single-plex dose-response
assay to evaluate their activities of nucleotide binding on Cdc42 and Rac1
GTPases. BODIPY-GTP concentration was fixed at 300 nM. The inhibition
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curves were fitted to the sigmoidal dose-response equation from GraphPad
Prism5. In all experiments, GST-Cdc42 or Rac1 were immobilized on GSH beads
and used to measure BODIPY-GTP binding. Bead-associated fluorescence
intensity was quantified by flow cytometry and used to monitor drug treatment
induced changes in nucleotide binding. Quantification of two independent
measurements is plotted ± SEM,
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Table 2 Impact of ketorolac analogs on in vitro Cdc42 and Rac1 nucleotide
binding

Structure

Screening
Center Vial
Barcode
Number

Cdc42

Rac1

Inhibition(-)
/Activation(+
) magnitude

EC50

Inhibition(-)
/Activation(+
) magnitude

EC50

R-ketorolac

~ 20% (-)

1.89×10

~ 20% (-)

2.31×10

S-ketorolac

<10% (-)

<10% (-)

-

SKCM 101436

< 10% (-)

-

< 10% (-)

-

SKCM 101439

~ 30% (-)

1.42×10

-4

~ 20% (-)

5.28×10

SKCM 100846

~ 20% (-)

9.38×10

-6

~ 25% (-)

8.17×10

SKCM 104309

< 10% (-)

-

< 10% (-)

-

SKCM 104402

~ 20% (-)

5.46×10

-5

< 10% (-)

-

SKCM 104352

~ 20% (-)

6.75×10

-6

~ 20% (-)

4.99×10

SKCM 102026

~ 25% (+)

2.43×10

-8

< 10% (-)

-

SKCM 100621

< 10% (-)

-

< 10% (-)

-

SKCM 101671

~ 31% (-)

1.72×10

~ 20% (-)

3.21×10

SKCM 103977

< 10% (-)

-

< 10% (+)

1.97×10

SKCM 103793

~ 15% (+)

2.28×10

-8

< 10% (-)

-

SKCM 103959

~ 32% (-)

6.75×10

-4

~ 20% (-)

1.03×10
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-5

-4

-5

-6

-5

-5

-4

-8

-4

The Effect of Ketorolac Analogs on Cdc42 and Rac1 Activation in SKOV3ip
Cells
A flow-based GTPase effector binding assay (G-trap, detects and quantifies
GTPases in the GTP-bound conformation) (135) was performed to test the
impact of ketorolac analogs on Cdc42 and Rac1 activation in SKOV3ip cells.
Cells were starved for 2 h, treated with each compound for 2 h, and finally
stimulated with EGF (10 ng/ml). As shown in Figure 10, in comparison to the
parent compounds, most derivatives did not alter ketorolac activity, which
showed similar inhibition efficacies and EC50 values on Cdc42 and Rac1 GTPase
activation. Notably, the 2-thiophene modified analog (SKCM 101671 and SKCM
103977) exhibited less enantiomer selectivity on the inhibition of Cdc42. The
trifluoromethyl (SKCM 102026 and SKCM 100621) resulted in loss of inhibition
against Rac1 for both enantiomers. SKCM 102026 behaved as an inhibitor in
cells, having been clarified as an activator in vitro (Figure 9E); behavior is similar
to screening studies that identified R-naproxen as an activator, while cell based
studies demonstrated inhibitory activity against Rac1 and Cdc42 (Ref PLoS One).
The different observed behaviors of SKCM 102026 under different assay
conditions may be due to the experimental context such as the local
concentration of Mg2+, nucleotide, and other regulatory proteins (e.g. GEFs,
GAPs). Thus, compounds identified as activators only through in vitro nucleotide
binding assays, warrant further study in cell-based assays (137). Importantly, 3thiophene (SKCM 103793 and SKCM 103959) exhibited more enantiomeric
selectivity in the inhibition of both Cdc42 and Rac1 GTPases and the active
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enantiomer retained the inhibition efficacy (~50%) and similar EC50 values
compared to the parent compound. Taken together, these results suggest
trifluoromethyl and 2-thiophene alter ketorolac activity, which may be due to
changed properties of the carboxyl group at the chiral center. One possibility is
that the trifluoromethyl group, as a strong electron-withdrawing group, may
enhance the interaction between the -COOH and Mg2+ by decreasing the
electron density of the carboxyl group. 3-thiophene, as a strong electron-donating
group, may reduce the interaction between -COOH and Mg2+ by decreasing the
acidity of the -COOH. The other possibility is that the trifluoromethyl group might
actually improve lipophilic stabilization of the parent compound and decrease
carboxyl magnesium interaction through an electron donating activity, which
induces the observed increased nucleotide binding on GTPase. In addition,
thiophene may also interact with Mg2+ directly through the cation-π interaction.
According to the results of the GTPase nucleotide binding assay and the G-trap
assay, 3-thiophene modification in the phenyl ring was tolerated and provides
guidance for developing improved ketorolac derivatives with higher affinity,
efficacy and enantiomeric selectivity.

48

-continued
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Figure 10. Ketorolac derivatives exhibit different inhibitory effects on
Cdc42 and Rac1 activation in SKOV3ip cells. Parent compound – ketorolac (A)
was modified on the phenyl with a fluorine atom (B), a chlorine atom (C), a
methyl group (D), or a trifluoromethyl group (E). Alternatively, the phenyl ring was
replaced by 2-thiophene (F) or 3-thiophene (G) rings. These analogs were tested
by a GTPase effector binding (G-trap) assay to evaluate their activities on
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epidermal growth factor mediated Cdc42 and Rac1 activation in SKOV3ip cells.
In all experiments, SKOV3ip cells were starved in 0% FBS media for 2 h and
pretreated with individual drugs for 2 h prior to EGF (10 ng/ml) stimulation.
Activated Cdc42 and Rac1 levels in cell lysates were measured using a flow
cytometry based GTPase effector binding assay. Flow intensities were
normalized

to

untreated

controls.

Quantification

measurements is plotted ± SEM.
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of

two

independent

Table 3

Impact of ketorolac analogs on Cdc42 and Rac1 activation in cell-

based assay

Structure

Screening
Center Vial
Barcode
Number

Cdc42

Rac1

Inhibition(-)
/Activation(+
) magnitude

EC50

Inhibition(-)
/Activation(+
) magnitude

EC50

R-ketorolac

~ 50% (-)

2.58×10

~ 50% (-)

5.87×10

S-ketorolac

<10% (-)

-

<10% (-)

-

SKCM 101436

~ 20% (-)

1.42×10

-5

< 10% (-)

-

SKCM 101439

~ 50% (-)

2.15×10

-5

~ 50% (-)

2.71×10

SKCM 100846

~ 50% (-)

1.13×10

-6

~ 50% (-)

2.03×10

SKCM 104309

~ 20% (-)

1.54×10

-5

< 10% (-)

-

SKCM 104402

< 10% (-)

-

< 10% (-)

-

SKCM 104352

~ 50% (-)

2.02×10

-6

~ 50% (-)

1.32×10

SKCM 102026

< 10% (-)

9.25×10

-6

~ 20% (-)

7.10×10

SKCM 100621

< 10% (-)

-

< 10% (-)

-

SKCM 101671

~ 30% (-)

1.41×10

~ 50% (-)

1.52×10

SKCM 103977

< 10% (-)

-

< 10% (-)

-

SKCM 103793

< 10% (-)

-

< 10% (-)

-

SKCM 103959

~ 50% (-)

1.04×10

~ 50% (-)

5.48×10
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-6

-6

-6

-7

-6

-5

-5

-5

-6

-7

CID2950007 Analogs Inhibit GTP Binding to Cdc42
CID2950007 has been identified as a noncompetitive allosteric Cdc42
inhibitor (Avg EC50 2.6 µM), which binds to guanine nucleotide-bound Cdc42,
induces dissociation of nucleotide, and locks the protein in an inactive
conformation (104, 138). The related structural analog CID44216842 differs by
the replacement of phenyl and and 4-methoxyphenyl groups of CID2950007 with
3-methoxyphenyl and 4-bromophenyl substituents at the 3- and 5-positions of the
4,5-dihydro-1H-pyrazole core, respectively. CID44216842 exhibited a slightly
improved EC50 (0.4 µM) although the aqueous solubility was decreased (104,
138). In preparation for fluorescent modification, three analogs were synthesized
with modifications to the phenyl ring in the pyrazole 5-position as shown in Figure
11. The 4-bromophenyl substituent of CID44216842 was selected as the site for
the introduction of a linking alkylamine moiety that could be conjugated to aminereactive fluorophores. The 4-iodophenyl analog AG-II-106 was synthesized as a
more reactive substrate for the palladium catalyzed carbon-carbon coupling
chemistry that was envisioned for the installation of a linkage, The latent
chemical linkage was installed using a Sonogashira coupling reaction with tertbutyl but-3-yn-1-ylcarbamate to give RS-II-16P. The tert-butylcarbamate
protecting group was removed using trifluoroacetic acid to give the free amine
RS-II-24C. The effect of each of these new analogs on the binding of BODIPYGTP to Cdc42 was assessed in a bead based flow cytometry assay. In this assay,
the concentration of BODIPY-GTP was fixed at the Kd concentration of Cdc42 (Kd
=100 nM). Compared to the parent compound (CID2950007, EC50=1.04×10-6 M),
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AG-II106 and RS-II-16P showed improved EC50 values of 2.90×10-7 M and
1.06×10-7 M, respectively, and RS-II-24C exhibited a similar EC50 of 1.23×10-6 M.
Taken together, all three analogs retained inhibitory activity toward Cdc42
nucleotide binding with either improved or similar EC50 values and similar
inhibition efficacies.
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EC50=1.03×10-6

EC50=2.90×10-7

EC50=1.28×10-6

EC50=1.06×10-7

Figure 11. CID2950007 analogs inhibit BODIPY-linked nucleotide binding to
Cdc42. All analogs - AG-II-106 (B), RS-II-24C (C) and RS-II-16P (D) exhibited
similar potencies and efficacies against Cdc42 nucleotide binding in comparison
to the parent compound-CID2950007 (A).
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Fluorescent Analog of CID2950007 (RS-II-79) Inhibits Cdc42 Nucleotide
Binding
A fluorescent analog of CID2950007 and CID44216842 - RS-II-79 was
synthesized by modifying AG-II-106 with a linkage connected to a fluorescent
dye. The amine-reactive N-hydroxysuccinimide ester of a hydrazinylpyridine
based

fluorescent

HPY-dye

was

first

reacted

with

N-(2-(2-(2-

aminoethoxy)ethoxy)ethyl)hept-6-ynamide to give 2-(9H-fluoren-9-ylidene)-3,3difluoro-6-((2-(2-(2-(hept-6-ynamido)ethoxy)ethoxy)ethyl)carbamoyl)-2,3-dihydro[1,2,4,3]triazaborolo[4,5-a]pyridin-2-ium-3-uide. This hept-6-ynamido compound
was coupled with the iodophenyl analog AG-II-106 using the Sonogashira
coupling procedure to give the desired product RS-II-79 in good yield. This onestep coupling approach for introduction of a fluorescent label was analogous to
the synthesis of RS-II-16P described in the previous section. RS-II-79 exhibits
absorption spectra with λabs = 472-490 nm and emission spectra with λemi = 551563 nm with characteristically large Strokes shifts (136). Based on the efficacy of
the model compounds RS-II-16p and RS-II-24C possessing alkynyl linkages in
that position, RS-II-79 was expected to be a functional probe. RS-II-79 was
tested for efficacy as a probe for inhibiting guanine nucleotide binding and as well
for comparatively measuring small molecule interaction and affinity for the Cdc42
GTPase. Using a single-plex dose response assay, RS-II-79 inhibited BODIPYGTP nucleotide binding in a dose-dependent manner with EC50 of 1.07×10-6 M
and maximum inhibition of ~80% (Figure 12). In comparison to the parent
CID2950007, the inhibitory activity of RS-II-79 against nucleotide binding to
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Cdc42 was unchanged, though was slightly reduced compared to CID44216842.
Additionally, the direct binding of RS-II-79 to Cdc42 was tested by following the
HPY-dye fluorescence intensity bound to GTPase, which showed an Kd of
1.90×10-7 M and maximum binding efficacy of 80%. Taken together, these results
suggest that the fluorescent analog, RS-II-79 retains a similar inhibitory effect on
the nucleotide binding to Cdc42 in comparison to the parent compound,
CID29500007. The binding curve of the RS-II-79 demonstrates that the
compound reduces nucleotide binding by direct binding to Cdc42. These data are
consistent with CID2950007 being identified as an allosteric inhibitor of Cdc42
(104, 139).
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EC50=1.07×10-6

Kd=1.90×10-7

Figure 12. Fluorescent analog of CID2950007 - RS-II-79 (44216842Hyptanoic-Dioxy-HPY(490)) inhibits BODIPY-linked nucleotide binding to
Cdc42. (A) Structure of RS-II-79. (B) RS-II-79 reduced BODIPY-GTP nucleotide
binding to Cdc42 in a dose-dependent manner with an EC50 of 1.07×10-6 M. (C)
Fluorescent RS-II-79 specifically interacted with Cdc42 in a dose-dependent
manner. Based on the one-site binding curve, the Kd was determined as 1.90×107

M. In the flow cytometry assay, the fluorescent intensity of BODIPY-GTP was

detected by FL-1 (λex=488 nm, λem = 530/30 nm), which quantified the nucleotide
binding. The fluorescent intensity of the fluorophore (HPY) was detected by FL-2
(λex=488 nm, λem = 585/42 nm) (136), which quantified bound RS-II-79 on
GTPase. GST-GSH beads were used in the control experiment and represented
non-specific binding of the compound. The intensity of the bona fide bound RS-II79 was calculated as: Mean Channel Fluorescence(Cdc42-GSH
Channel Fluorescence (GST-GSH beads).
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beads)

– Mean

Penetration of Multicellular Aggregates (MCA) by RS-II-79
Since the fluorescent analog RS-II-79 was identified as a Cdc42 specific
inhibitor interacting at an allosteric binding site of GTPase, a live cell imaging
study was conducted to test the cellular permeability of RS-II-79. In order to
investigate the rate of RS-II-79 uptaken by the cell, 2 µl of 10 mM stock
(dissolved in DMSO) was added to 2 ml of the media. Figure 13 shows GFPactin-expressing MDCK cells before and after the addition of RS-II-79 with
excitation at 488 nm and emission detection in the range 530±30 nm. These cells
started to take up the RS-II-79 within 2-3 min and continue to rise steadily over
10 min. Therefore, RS-II-79 was found to have good permeability in cultured cells.
However, due to the diffuse distribution and low signal-to-noise ratio of the
fluorescent compound, the exact subcellular localization needs to be further
confirmed.
Moreover, the penetration of RS-II-79 into MCA was investigated to
evaluate

the

drug

diffusion

processes

that

mimic

the

extracellular

microenvironment in actual solid tumors. The MCA was formed by 2000
SKOV3ip cells. Appendix A shows representative images of penetration of an
MCA by RS-II-79, observed by confocal microscopy. A steady increase in
penetration depth within the MCA was observed from the periphery toward the
core of the MCA over time. In addition, the MCA penetration assay was also
conducted in Doxorubicin at 6 µM and Doxil (liposome-encapsulated doxorubicin)
at 6 µM. The result (data not shown) shows the penetration ability of RS-II-79 is
similar to Doxil, but not as good as Doxorubicin. These observations suggest that
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the fluorescent analog of CID2950007, RS-II-79 penetrates within the MCA in a
time-dependent manner. A gradually diffused and decreased fluorescence
pattern from the periphery to center region of the MCA was evident. Penetration
experiments with longer incubation time (up to 24 h) will need to be performed to
test whether the RS-II-79 could fully penetrate into the MCA.
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Figure 13. Distribution of fluorescent RS-II-79 in living cells in a timedependent manner. GFP-actin expressing MDCK cells were treated with
fluorescent RS-II-79 at 10 µM final concentration. (A) Representative images of
GFP-actin expressing MDCK cell in 10 µM RS-II-79 at 0, 7, and 14 min after
loading the RS-II-79. (B) Quantification of the uptake of RS-II-79 in MDCK cell
over time.
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Conclusion and Discussion
In this chapter, R-ketorolac and R-naproxen identified from high throughput
screening and computational simulation are shown to inhibit in vitro BODIPYGTP nucleotide binding to Cdc42 and Rac1. Equilibrium binding and single-plex
dose-response studies demonstrated that the R-enantiomers, but not the Senantiomers of selected NSAIDs (ketorolac and naproxen) act as allosteric, noncompetitive inhibitors. A computational simulation was conducted and confirmed
the enantiomer-selective activity of these NSAIDs. We suggest that [R] α-Me
carboxylates preferentially interact with magnesium and reduce stabilization and
promote nucleotide release.

Using ketorolac analogs, an SAR analysis was

initially conducted, which suggests that the phenyl ring plays a key role in
modulating ketorolac activity on GTPase nucleotide binding, possibly by affecting
the properties of the carboxyl group at the chiral center. In addition, CID2950007
derivatives with modifications on the phenyl ring were well tolerated and enabled
the synthesis of a fluorescent derivative. The fluorescent analog, RS-II-79 has
similar properties as CID2950007 and is able to permeabilize into single cells
and penetrate into 3-D tumor MCA.
The biochemical basis for GTPase inhibition by R-ketorolac and R-naproxen
is provided by computational and experimental approaches. The model is
enantiomer-selective, with S-ketorolac being poorly positioned to exert the same
magnesium exclusion and therefore could explain the observed differences in
EC50 values measured for R- and S-ketorolac in the in vitro nucleotide binding
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assay. The model is further supported by X-ray crystallography data, which
identified the preferential binding of S-naproxen to COX-2 (111). R-naproxen, like
R-ketorolac, exhibits Cdc42 and Rac1 inhibitory activity, albeit with less potency.
Naproxen, like ketorolac has a constrained alpha methyl carboxyl that may
account for the stereo-selective activities of the R- and S-enantiomers (140).
In preliminary SAR studies, ketorolac analogs were synthesized with
modifications to the phenyl ring of the parent compound; including additions of a
methyl group (Me), halogens (F, Cl), trifluoromethyl (CF3) and replacement of
phenyl with a thiophene. The analogs were tested in vitro using a GTPase
nucleotide binding assay and in cells using GTPase effector binding assay.
Because the enantiomeric identity is unknown and the initial compound set was
fairly limited with modification in a lipophilic area (the phenyl ring), we are unable
to define a clear SAR trend that improves the activity profile of the parent
compound in this preliminary study. The fluorine derivatives showed interesting
trends toward increased Rac1 selectivity over Cdc42 and provide a very sensitive
nucleus that can be effectively exploited in 1D NMR experiments to probe direct
binding of small molecule inhibitors to unlabeled GTPase samples and assess
stoichiometry. However, the 3-thiophene analog shows the most promising
results with improved affinity, efficacy and enantiomeric selectivity on both Cdc42
and Rac1 GTPases. This finding indicates that 3-thiophene modification could be
a good starting point for further analog syntheses and screening. Further SAR
work is required to evaluate the substitutons on the adjacent carbon of the phenyl
ring, modifications to the ketone, or alterations to the fused ring system in order
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to identify the key structures and improved chemical entities for developing
effective GTPase regulators.
The identification of R-ketorolac and R-naproxen as allosteric regulators of
Cdc42 and Rac1 presents a novel mechanism of action based on stabilization of
the GDP-bound GTPase that may in part be promoted through interference with
GEF-mediated activation or by making nucleotide exchange independent of
regulatory proteins. This potential mechanism is distinct from the currently known
inhibitors that interfere directly with GEF, GAP or GDI interaction or block
GTPase membrane association, e.g. farnesyl-transferase (FTI), geranylgeranyltransferase (GGTI) and prenyl-transferase inhibitors, which display poor
selectivity for individual Rho GTPases (141-143). The identified R-ketorolac and
R-naproxen have been shown to specifically inhibit Cdc42 and Rac1 activation,
but have no effect on RhoA in cell based GTPase effector binding (G-trap)
assays (See Chapter 4, Figure 35) (138, 140). Naproxen is clinically only
available as the S-enantiomer. In contrast, ketorolac is an FDA-approved drug
and is in active clinical use as the racemic mixture. Thus, R-ketorolac is an ideal
candidate for drug repurposing and development for cancer therapy. In the
following chapters, the anti-tumor effect of ketorolac was investigated in cellbased assays and clinical trials, which confirm Cdc42 and Rac1 as novel targets
of R-ketorolac and demonstrate benefit in patient outcomes in ovarian cancer
therapy.
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CHAPTER 3
R-KETOROLAC TARGETS CDC42 AND RAC1 AND ALTERS
OVARIAN CANCER CELL BEHAVIORS CRITICAL FOR INVASION
AND METASTASIS
Abstract
Cdc42 and Rac1 are attractive therapeutic targets in ovarian cancer based
on established importance in tumor cell migration, adhesion and invasion.
Despite a predicted benefit, targeting GTPases has not yet been translated to
clinical practice. R-ketorolac is an established allosteric inhibitor of Cdc42 and
Rac1. In this chapter, cell-based assays were utilized to determine R-ketorolac
activity against Cdc42 and Rac1 activation and subsequent biological functions.
Studies on immortalized human ovarian adenocarcinoma cells (SKOV3ip), and
primary, patient-derived ovarian cancer cells show R-ketorolac is a robust
inhibitor of growth factor or serum dependent Cdc42 and Rac1 activation with a
potency and cellular efficacy similar to small molecule inhibitors of Cdc42
(CID2950007/ML141) and Rac1 (NSC23766). Furthermore, GTPase inhibition by
R-ketorolac reduces downstream p21-activated kinases (PAK1/PAK2) effector
activation by >80%. Multiple assays of cell behavior using SKOV3ip and primary
patient-derived ovarian cancer cells show that R-ketorolac significantly inhibits
cell adhesion, migration and invasion. In sum, the evidence demonstrate Rketorolac is a direct inhibitor of Cdc42 and Rac1 that is capable of modulating
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downstream GTPase-dependent, physiological responses, which are critical to
tumor metastasis. The findings demonstrate the selective inhibition of Cdc42 and
Rac1 GTPases by an FDA approved drug-racemic ketorolac that can be used in
humans.
All the work in this chapter are published: Guo, Y, et al., 2015 Oct;14(10):2215-27.
doi: 10.1158/1535-7163.MCT-15-0419. Epub 2015 Jul 23.
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Introduction
PAK1- Effector of Cdc42 and Rac1
Serving as molecular switches, Cdc42 and Rac1 control a variety of
signaling pathways that are central to dynamic actin cytoskeletal assemblies and
rearrangements that are the underpinnings of cell-cell adhesion, cell migration
and even transformation (62). P21 activated kinases (PAKs) are well known
downstream effector proteins of Cdc42 and Rac GTPases. As shown in Figure
14, inactive PAKs form dimers, where the auto-inhibitory domain (AID) binds to
the kinase domain which prevents auto-phosphorylation. Cdc42 and Rac interact
with PAK at the Cdc42/Rac interacting binding motif (CRIB) to disrupt the
interaction between the AID and the dimer PAK, which in turn leads to a
conformational change of PAK to an activated monomer and causes autophosphorylation of PAK (144). Activated Group A PAK (PAK1, 2, 3) proteins
phosphorylate regulatory myosin light chain (MLC) or LIM Kinase (LIMK1) which
leads to formation of polymerized actin structure, such as focal adhesion
complex, lamellipodia and filopodia (64, 145). However, other types of PAK (e.g.
PAK4) lead to the dissolution of stress fiber by decreasing myosin light-chain
kinase (MLC) phosphorylation (63).
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Inactive PAK

Active PAK

Figure 14. A model for PAK1 activation. Based on the published structure
(145),

PAK1 contains a N-terminal regulatory domain, including Cdc42/Rac1

interaction/binding (CRIB) and auto-inhibitory domain (AID), a PAK-interacting
exchange factor (PIX) and a kinase domain. In inactive state, the PAK is autoinhibited through the formation of dimers between the AID and the kinase domain
to prevent auto-phosphorylation. In the present of GTP-Cdc42/Rac1, the GTPase
CRIB complex catalyzes phosphorylation of Serine144 at AID, which disables the
AID-kinase domain interaction and activates the monomeric PAK autophosphorylation kinase domain at Threonine 423. The phosphorylation of Serine
199 is activated by a PAK-interacting exchange factor (PIX).
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Rho GTPases Mediated Cell Motility
Extracellular matrix (ECM) is composed of multiple fibrous protein,
including collagen, fibronectin, and laminin, providing structural support and the
biochemical and biomechanical environment for cell division, growth and
development (146). Cdc42 and Rac1 are involved in cellular signaling pathways
that transduce extracellular signals to the assembly of integrin-mediated focal
adhesion complexes (147). In early adhesion events, integrins through G-protein
coupled signaling mediate focal adhesion kinase (FAK)-Src kinase complex to
activate Rac for nascent adhesion to the ECM. Later, activated Rac coordinates
extensive crosstalk between integrin (particularly α5β1), Src kinases and other
Rho GTPases, which leads to formation of mature focal adhesions involved in
cell spreading (60, 148-150) (Figure 15). Downstream effectors of Rho GTPases,
such as PAK1 and IQGAP are responsible for cadherin-mediated cell-cell
adhesion, which are significant for the formation of MCA, cell migration and EMT
(151, 152). Cell-matrix and cell-cell adhesion play critical roles during cancer
metastasis which is required for the anchoring of malignant MCA to the ECM of
target abdominal organs (19).
During tumor metastasis, cell migration is another critical step of cell
movement that is controlled by Rho GTPases (Figure 15). Activated by
extracellular

stimuli,

Rho

GTPases

stimulate

actin

polymerization

for

lamellipodium extension and filopodia formation. Lamellipodia are thin, sheet-like
membrane protrusions at the leading edge. Filoopodia are finger-like protrusions
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that extend from lamellipodium (153). Both are regulated by Cd42 and Rac1
through Rho GTPase-PAK-LIM kinase (LIMK) and Rho GTPase-WASP/WAVEArp2/3 signaling pathways for actin reorganization and serve to establish cell-cell
and cell-matrix contact (125, 154). Once the lamellipodia and filopodia contact
the ECM, focal adhesions form to stably anchor cells to the matrix. At the same
time, when cells migrate in a 3-D ECM, activated Rho GTPases and Src kinase
are involved in the formation of invadopodia which are membrane protrusions
that concentrate matrix metalloproteinases (MMP), e.g. MMP2 and MMP-9, at
their tips and based on their matrix degradative properties enable cell invasive
behaviors (149, 155, 156).
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Figure 15. Cell migration model. Cell migration on 2-D and in 3-D ECM is
schematized in five steps: (1) Lamellipodium extension at the leading edge –
actin polymerization at the leading edge of cell. Rac, Cdc42 and Arp2/3 involved.
(2) Formation of new focal adhesion complex – integrins interact with ECM
ligands and mediate focal adhesion complex formation. Rac involved. (3)
Secretion of surface proteases at sites of ECM contact leads to focal proteolysis
and enables invasion of 3-D matrices; (4) Cell body contraction by actomysin
complexes; (5) Tail detachment. (Parri, M., Cell Communication and Signaling.
2010;8:23)
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Materials and Methods
Cell and Reagents
Compounds for dose response assays were obtained as follows: Rketorolac (K235600, Toronto Research Chemical Inc), S-ketorolac (K235605,
Toronto Research Chemical Inc), R-naproxen (Acme Bioscience #A5026, Palo
Alto, CA), S-naproxen sodium (N5160, Sigma-Aldrich), 6-methoxy-2-napthalene
acetic acid (6-MNA) (70620, Cayman Chemical, Ann Arbor, MI, USA),
NSC23766 (204823, Santa Cruz, CA), CID2950007 (71203-35-5, Tocris). GSTPAK1 protein was from Millipore (14-864). Rat tail type I collagen was obtained
from BD Biosciences (Cat #: 354265). A polyclonal antibody directed against
Tks5 (Src tyrosine kinase substrate 5) was obtained from Dr. Rytis Prekeris
(University of Colorado, Denver) (157). The following commercial antibodies
were used: mouse mAb (monoclonal antibody) directed against Rac1 from BD
Transduction Laboratories (Cat #: 610651), mouse mAb directed against Cdc42
from Santa Cruz (Cat #: sc-8401), FITC (fluorescein isothiocyanate)-conjugated
mouse mAb directed against EpCAM (epithelial cell adhesion molecule) (clone
Ber-EP4) from Dako (Cat #: F0860); rabbit polyclonal Cy5-conjucated antiCA125 (cancer antigen 125) from Bioss Inc.(Cat #: bs-0091R-Cy5), mouse mAb
PE (Phycoerythrin)-conjugated anti-CD45 (lymphocyte common antigen 45) from
eBioscience (Cat #: 12-9459), rabbit polyclonal antibodies directed against
phospho-PAK1

(Ser144)/PAK2(Ser141)

PAK1(Ser199/204)/PAK2(Ser192/197)

(Cat
(Cat
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#:
#:

2606),
2605),

phosphophospho-

PAK1(Thr423)/PAK2(Thr402) (Cat #: 2601) and PAK1 (Cat #: 2602) from Cell
Signaling Technology. Alexa 488 goat anti-mouse antibody (Cat #: A-11029) and
Alexa 647 goat anti-rabbit antibody (Cat #: A-21235) from Life Technology, all
used per manufacturers’ instructions.
Patient Information
A Phase 0 trial investigating the use of postoperative ketorolac

was

reviewed and approved by the University of New Mexico Health Sciences Center
Human Research Review Committee (NCT01670799 clinicaltrials.gov) (158).
Informed patient consent was obtained prior to surgery. Eligible patients having
suspected advanced stage ovarian, fallopian tube or primary peritoneal cancer
underwent planned optimal cytoreductive surgery. Upon surgical entry into the
abdomen, ascites fluid was retrieved and residual material was recovered and
sent fresh to the investigators for processing. Ascites material used for this study
was from patients confirmed to have stage III or IV at final pathologic diagnosis.
Nine patient samples were included in the study (Table 4).
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Table 4

Patient Information

Assay application

Patient
number

Tumor
stage

INST111524

IIIC



INST111529

IIIC





INST111530

IV





INST111531

IV*





INST111535

IIIC





INST111536

IIIC





INST111542

Cdc42
activity

Rac1
activity

Filopodia
formation

Cell
adhesion

Gelatin
degradation

IIIC







INST111543

IIIC







INST111544

Unstaged*
*





INST111549

IIIC



All except for two patients had ovarian serous carcinoma.
* Patient #30 had stage IV uterine serous carcinoma.
** Patient #44 had mucinous ovarian cancer.
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Isolation and Cell Culture of Ascites-Derived Primary Ovarian Cancer Cells
Peritoneal ascites were obtained at the time of debulking surgery with an
average volume of 200 ml. Cells were collected by centrifugation at 300g for 5
min. The Ficoll-Paque (1.073 ± 0.001 g/ml) PREMIUM density gradient media
(GE

Healthcare)

was

used

to

pellet

and

remove

erythrocytes

and

polymorphonuclear cells. The mononuclear white cells and tumor cells found at
the top of the Ficoll interface were transferred to a sterile tube and washed with
RPMI 1640 media with 5% FBS. To deplete leukocytes and further enrich tumor
cells, samples were incubated with CD45-coated Dynabeads® (Life technologies,
Cat #: 11350D) for 1.5 h at 4 °C, washed and collected by centrifugation
according to the manufacturer’s protocol. Isolated tumor cells were cultured as
described by T. Shepherd et. al (159). Briefly, enriched ovarian cancer cells were
cultured on collagen-coated (20 µg/cm2) tissue culture dishes. After 3-4 d, when
most of the tumor cells had adhered, the media was replaced and continued to
be changed every 2-3 d until cells grew to confluence. The expanded cells were
used for filopodia formation, cell adhesion, migration and extracellular matrix
degradation assays.
Flow Cytometric GTPase Effector Binding Assay for Quantification of
Cellular, Active GTPase Levels
The assay was carried out according to the protocols described previously
(135). Ketorolac treated and vehicle-control cells were lysed in RIPA (high
stringency cell lysis buffer) buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA,
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0.25% (w/v) Na-deoxycholate, 1 mM Na3VO4, 1 mM NaF, 1% (v/v) NP-40 (nonyl
phenoxypolyethoxylethanol), 1 mM PMSF (phenylmethylsulfonyl fluoride) and
protease inhibitors consisting 10 µg/ml each of chymostatin, leupeptin, pepstatin
and antipain). Insoluble debris was removed by centrifugation and the
supernatants were incubated with GTPase effector coated beads (PAK1-PBD for
Cdc42 and Rac1) for 1 h. Primary antibodies directed against Cdc42 or Rac1 and
secondary antibody Alexa 488 were incubated with the beads for 1 h.
Fluorescence intensity MCF (mean channel fluorescence) was used to measure
the amount of active intracellular GTPase. MCF was measured by flow cytometry
(Accuri C6, BD Biosciences). GTPase activity was calculated as (MCFsample group –
MCFunstimulated negative control) / MCFstimulated positive control.
Quantification of Filopodia Formation
The assay was conducted as described previously (104). Cells were
cultured on coverslips to 50% confluence and serum-starved for 2 h, treated with
individual drugs and stimulated with 10 ng/ml EGF for 20 min. Cells were gently
rinsed 3x with ice cold PBS and fixed with 3% paraformaldehyde. Rhodamine
phalloidin (ThermoFisher Scientific, Cat #: R415) was used to label the actin.
Images were collected using a Zeiss LSM (laser scanning microscope) 510
confocal microscope equipped with a 63× oil immersion lens. For each
experiment, a battlement pattern was used to select 30 images at random.
Length and number of filopodia per cell were quantified using Slidebook 5.5
software.
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Cell Adhesion Assay
The adhesion assay was modified from the method described by M.J.
Humphrie (160). Cells were cultured at least 48 h and disassociated with 0.05%
trypsin/EDTA. Suspended cells were rested in 0% FBS RPMI media for 1 h and
treated with individual drugs. Cells stimulated with 5% serum were seeded on a
96-well plate (5×104 cells/well) coated with 0.5 µg/cm2 fibronectin or collagen and
permitted to attach for 1 h. The 96-well plate was gently washed with PBS and
cells were fixed with 3% paraformaldehyde. Samples were stained with crystal
violet and lysed with 10% acetic acid and absorbance (λ=595 nm) quantified
using on a plate reader.
Cell Migration Assay
SKOV3ip cells were plated at 1x105 cells/well in 24-well Boyden chambers
and allowed to attach for 4 h. Ketorolac enantiomers were added from 10 mM
DMSO stocks to growth media at final concentrations ranging from 1 to 300 µM.
After 48 h, inserts were removed and stained with DAPI (4’,6-diamidino-2phenylindole). Final DMSO concentration should be no higher than 0.1%.
Membrane filters were imaged on a Zeiss inverted microscope using a 20x
objective. Three representative fields were counted from each treatment group.
Gelatin Degradation Assay
The commercial gelatin degradation kit (Millipore, Cat #: ECM671) was used
per manufacturer’s instructions and modified to incorporate drug treatment and

77

EGF stimulation as follows. Briefly, according to the manufacturer’s instruction,
poly-L-lysine was diluted for coating pre-cleaned (e.g. acid washed with 15 min
sonication in waterbath) 12 mm diameter round coverslips (50 µl/coverslip) for 20
min. 50 µl diluted glutaraldehyde was next placed on coverslips for 15 min. Cy3gelatin and unlabeled gelatin were mixed and 25 µl/coverslip was placed on
parafilm and glutaraldehyde coated coverslip placed carefully face down on top
of the drop – taking care to avoid trapping air bubbles – and allowed to set for 10
min in a humidified chamber. Coated coverslips were lifted gently by adding 500
µl PBS underneath and then incubated with 70% ethanol for 30 min to sterilize,
protected from light. To quench residual free aldehydes, 500 µl growth media per
well was added and incubated for 30 min. Cells were seeded on fluorescent
coverslip and allowed to adhere for 6 h and then treated with individual drugs for
24 h. Cells were fixed with 3% paraformaldehyde, permeabilized with 0.1% Triton
X-100 and immunostained for Tks5. Actin was visualized with FITC-phalloidin.
Fifteen fields per coverslip were imaged on a Zeiss LSM 510 META with a 63x oil
immersion objective. Gelatin degradation by invadopodia was analyzed using
Slidebook 5.5 software. Percent degradation was quantified as: (degradation
area)/(total cell area) for each image.
Western Blot
SKOV3ip cells were serum-starved for 2 h and treated with individual drugs
for 1 h. After simulation with 10 ng/ml EGF for 20 min, cells were washed with ice
cold PBS and lysed with RIPA buffer. Cell lysates were processed for SDS-
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PAGE, transferred to polyvinylidene fluoride membranes and individual proteins
were detected with specific antibodies directed against PAK and phospho-PAK.
Statistical Analyses
Prism 5 software (GraphPad) was used to analyze all data to determine
statistical significance. One-way ANOVA (Analysis of Variance) with Dunnett’s
test for multiple comparisons was performed to compare differences between the
means of each group relative to the control group for all assays. P-values less
than 0.05 were considered statistically significant. For some assays conducted
on primary ovarian patient samples (GTPase activity measurements and gelatin
degradation assays), standard z-scores of the values were calculated for each
patient to minimize large ranges of values and to compare across groups on a
uniform scale. ANOVA was performed on these standardized values.
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Results
R-ketorolac Inhibits Cdc42 and Rac1 Activation in Immortalized and
Primary Human Ovarian Cancer Cells
A flow cytometry based assay for quantitatively assessing the levels of
active GTPases in cell lysates was developed in the Wandinger-Ness and
Buranda laboratories (135). The assay was used to test the cellular impact of
ketorolac isoforms on GTPase activation. Maximal Cdc42 and Rac1 activation in
SKOV3ip cells treated with 10 ng/ml EGF occurred at different times; 20 min for
Cdc42 and 5 min for Rac1 (Figure 16). Growth factor stimulated activation of
Cdc42 and Rac1 was differentially inhibited in an enantiomer-selective manner
(Figure 17). R-ketorolac substantially inhibited growth factor dependent activation
of Cdc42 and Rac1 in a dose-dependent manner with an EC50 value of 2.577 µM
for Cdc42 and 0.587 µM for Rac1 (Figure 17, circles). In contrast, even at the
highest dose of 100 µM, S-ketorolac exhibited limited inhibition (less than 30% of
maximum by R-ketorolac) of Cdc42 and Rac1 (Figure 17, squares). Enantiomerselective inhibition was also found in HeLa cells treated with R-ketorolac (140).
Control cytotoxicity measurements in three different cell lines (SKOV3ip, OVCA
429, and OVCA 433) showed <10% inhibition of cell proliferation induced by
either enantiomer of ketorolac at the highest tested dose and treatment (300
µmol/L for 96 hours) (data not shown).

80

Figure 16. Time course of maximal Cdc42 and Rac1 activation in SKOV3ip
cells upon growth factor stimulation. SKOV3ip cells were cultured overnight to
reach ~80% confluence, then stimulated with 10 ng/ml EGF for different time
length (0 - 40 min). The activation was terminated by washing with ice cold PBS.
Cells were lysed with RIPA buffer and the activated GTPase levels were
measured using a flow cytometry based GTPase effector binding assay.
Normalized activities are expressed relative to unstimulated controls.
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A

B

Figure 17. R-ketorolac preferentially inhibits Cdc42 and Rac1 activities in
SKOV3ip cells. R-ketorolac causes a dose-dependent, enantiomer selective
inhibition of growth factor stimulated Cdc42 and Rac1 activation in SKOV3ip cells.
SKOV3ip cells were starved in 0% FBS media for 2 h and pretreated with
individual drugs for 2 h prior to EGF (10 ng/ml) stimulation. Activated Cdc42 and
Rac1 levels in cell lysates were measured using a flow cytometry based GTPase
effector binding assay. Flow intensities were normalized to untreated controls. All
experiments were repeated three times independently. Results are normalized as
[(sample MCF—negative control MCF)/positive control MCF], where the negative
control is the MCF reading obtained using lysates from unstimulated cells, and
the positive control is the MCF reading obtained from the stimulated cells treated
with DMSO. Values below zero represent inhibition of GTPase activity in cells to
below the basal levels (resting cells without EGF stimulation).
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The effect of ketorolac was also examined in primary ovarian cancer cells
purified from patient ascites. Surgery samples were obtained and analyzed as
part of an approved clinical study (see Materials and Methods and Table 4).
Primary human ovarian cancer cells were enriched via Ficoll gradient
centrifugation and depletion of lymphocytes using CD45 Dynabeads. Purified
primary human ovarian cancer cells were positive for CA125 and EpCAM, which
are commonly overexpressed in epithelial ovarian carcinomas (Figure 18) (161,
162). Isolated tumor cells were treated with individual ketorolac isoforms or
specific Cdc42 and Rac1 inhibitors and the endogenous Cdc42 and Rac1
activities were tested. Because of the heterogeneity in activity levels of the
GTPases for individual patient samples, z-scores were used to comparatively
evaluate the impact of ketorolac on tumor cell GTPase activities from different
patients. Treatment with 10 µM R-ketorolac reproducibly inhibited both Cdc42
and Rac1 in a statistically significant manner (Figure 19). The magnitude of Rketorolac inhibition of Cdc42 or Rac1 was similar to the inhibition observed in
positive controls treated with CID2950007, an allosteric Cdc42 inhibitor, or
NSC23766, a Rac1 inhibitor that interferes with GEF-mediated GTPase
activation (104, 105). S-ketorolac exhibited limited inhibition and was not
statistically significant (Figure 19). Taken together, the results demonstrate that
R-ketorolac is a potent, enantiomer-selective inhibitor of Cdc42 and Rac1 in
primary human ovarian cancer cells.
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Figure 18. Characterization of primary ovarian cancer cell marker
expression by immunofluorescence. (A) Cells were purified via Ficoll gradient
and negative selection using CD45-Dynabeads. Cells were stained for CA125
and EpCAM (clone Ber-EP4). (B) Isolated cells were expanded by brief cell
culture and stained for CA125 and EpCAM (clone Ber-EP4).
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Figure 19. R-ketorolac preferentially inhibits Cdc42 and Rac1 activities in
ascites derived primary human ovarian cancer cells. R-ketorolac causes a
dose-dependent, enantiomer-selective inhibition of endogenous Cdc42 and Rac1
activities in primary ovarian cancer cells. Isolated primary ovarian cancer cells
from three independent patients were treated with drugs for 1 h and processed
for flow cytometry GTPase effector binding assays to measure the GTPase
activity. Six patient samples were tested for Cdc42 activity and five patient
samples were tested for Rac1 activity in response (Table 4). CID2950007 and
NSC23766 served as Cdc42 and Rac1 specific inhibitors respectively. Plotted
are z-scores. For individual patient sample, z-score is defined as z=(X - μ)/σ,
where X is MCF, μ is the mean of X, and σ is the standard deviation of X.
Quantification of three independent measurements is plotted ± SEM. Statistically
significant

differences

are

indicated:
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*p<0.05,

**p<0.01,

***p<0.001.

Inhibition of Cdc42 and Rac1 by R-ketorolac Decreases Activation of
Downstream p21 Activated Kinases (PAK1/PAK2)
The impact of R-ketorolac on PAK1/PAK2 effector signaling directly
downstream of the Cdc42 and Rac1 GTPases was examined (Figure 20). Cells
stimulated with 10 ng/ml EGF exhibited robust phosphorylation of the Ser144/141
residues compared to unstimulated control cells. In contrast, there was a dosedependent suppression of p-PAK1/PAK2 following R-ketorolac treatment that
was similar to positive controls treated with Cdc42 or Rac1 specific inhibitors. Sketorolac on the other hand had limited effect on p-PAK1/PAK2 levels at either 1
µM or 10 µM (Figure 20). The expression of total PAK1 was not affected by
either R- or S-ketorolac treatment (Figure 20). These results demonstrate the
suppression of p-PAK1/PAK2 paralleled the inhibition of Cdc42 and Rac1 in a
dose-dependent manner following R-ketorolac treatment; and S-ketorolac
exhibited no significant inhibition of p-PAK1/PAK2.
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Figure

20.

R-ketorolac

decreases

the

phosphorylation

of

PAK1(Ser144)/PAK2(Ser141) without affecting total PAK levels. (A) SKOV3ip
cells were cultured overnight, then starved in 0% FBS media for 2 h and
pretreated with individual drugs for 2 h followed by EGF stimulation (10 ng/ml) for
20 min. Representative blots from one of three independent experiments are
shown. Equal amounts of cell lysate protein were resolved by SDS-PAGE and
immunoblotted for p-PAK1(Ser144)/PAK2(Ser141). GAPDH served as the
loading control. Cdc42 inhibitor, CID2950007 and Rac1 inhibitor, NSC232766
87

were used as positive controls. (B-C) Films from three independent experiments
were quantified by ImageJ analysis. p-PAK1/PAK2 levels were normalized to
unstimulated controls. Quantification of three independent measurements is
plotted ±SEM. Statistically significant differences are indicated: *p<0.05, **p<0.01,
***p<0.001.
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Phosphorylation of PAK1/PAK2 on two further residues (Thr423/402 or
Ser199/204 / Ser192/197) that are downstream of other signaling pathways were
also

examined.

Interestingly,

p-PAK1(Thr423)/PAK2(Thr402)

and

p-

PAK1(Ser199/204)/PAK2(Ser192/197) were reduced by R and S-ketorolac with
greater variability and less pronounced enantiomeric selectivity (Figure 21). For
example, R-ketorolac consistently inhibited the phosphorylation at pPAK1/PAK2
(Thr423) with statistical significance at 1 µM though more variably at 10 µM. Sketorolac exhibited statistically significant inhibitory effects at 10 µM against
Thr432/402,

but

not

against

Ser199/204

/

Ser192/197.

Inhibition

of

phosphorylation by the Rac1 inhibitor NSC23766 and the Cdc42 inhibitor
CID2950007 was also more modest and failed to reach statistical significance in
some instances. The explanation for the differences in responsiveness of
individual phosphorylation sites is likely due to the fact that Ser144/141 is
localized in an N-terminal regulatory domain and directly interacts with Cdc42
and Rac1 (Figure 14). While Thr423/402 residues in the catalytic kinase domain
and Ser199/204/ Ser192/197 adjacent to auto-inhibitory domain are targeted by
other regulatory molecules in a GTPase-independent manner (145, 163). For
example, S-ketorolac may inhibit phosphorylation on these sites by affecting
lipid-dependent stimulation of PAK1/PAK2 (e.g. sphingosine) or through crosstalk
between COX-1/COX-2 and PI3K signaling and the GTPase-PAK1/PAK2
pathway (164, 165).
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Figure 21. Ketorolac inhibition of p-PAK1 (Thr423)/PAK2(Thr402) and pPAK1(Ser199)/PAK2(Ser192).

(A-D)

Quantification

of

three

independent

measurements of the expression of p-PAK1(Thr423)/PAK2(Thr402) and pPAK1(Ser199)/PAK2(Ser192) levels in SKOV3ip cells +/- drug treatments as
indicated. p-PAK1/PAK2 levels were normalized to unstimulated controls.
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R-ketorolac Inhibits Cdc42-Dependent Flopodia Formation in SKOV3ip
Cells and Primary Ovarian Cancer Cells
Filopodia are membrane protrusions that are constructed of bundled actin
filaments and directly regulated by Cdc42 (166). Therefore, we tested filopodia
formation, including numbers and length of filopodia to evaluate the effect of
ketorolac on cell behaviors. When resting cells were stimulated with 10 ng/ml
EGF, both numbers and length of filopodia increased with the most striking
activation seen 20 min post-stimulation. Two concentrations of R-, and Sketorolac were tested to take into consideration differential sensitivities of Cdc42
to the two enantiomers. In comparison to the vehicle treatment group, Rketorolac (at both 1 µM and 10 µM concentrations) decreased numbers length of
filopodia to basal levels and similar to CID2950007; while S-ketorolac only
showed a significant inhibition on filopodia length at 10µM and did not
significantly inhibit filopodia numbers at either 1 µM or 10 µM. (Figure 22). These
results demonstrate that R-ketorolac impedes filopodia formation, which depends
on the upstream activation of Cdc42.
Filopodia formation assays performed using primary ovarian cancer cells
yielded similar results and reinforced the finding of the enantiomer-selective
effect. R-ketorolac treated primary ovarian cancer cells exhibited significantly
decreased filopodia numbers and length; while S-ketorolac exerted no inhibitory
effect (Figure 23).
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Figure 22. R-ketorolac decreases Cdc42 dependent filopodia formation in
SKOV3ip cells following EGF stimulation.

(A) Representative confocal

images of filopodia formation for each treatment group in SKOV3ip cells are
shown. Lower panels are magnified images of the boxed regions. (B-C)
Quantification of numbers and length of filopodia on each cell. For all
experiments, cells were plated on coverslips and cultured overnight, then starved
in 0% FBS media for 2 h and pretreated with drug or 0.1% DMSO vehicle for 2 h,
followed by EGF (10 ng/ml) stimulation for 20 min. Cells were permeabilized and
stained with rhodamine-phalloidin. Confocal images were taken on a Zeiss LSM
510 META confocal microscope. All quantification is based on three independent
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trials with 30 cells imaged in a battlement pattern and analyzed using Slidebook
5.5 software. Mean lengths or numbers of filopodia are plotted ±SEM.
Statistically significant differences are indicated: *p<0.05, **p<0.01, ***p<0.001.
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A

B

C

Figure 23. R-ketorolac decreases Cdc42 dependent filopodia formation in
primary human ovarian cancer cells following EGF stimulation.

(A)

Representative confocal images of filopodia formation for each treatment group
in primary human ovarian cancer cells are shown. Lower panels are magnified
images of the boxed regions. (B-C) Quantification of numbers and length of
filopodia per cell in primary human ovarian cancer cells. For all experiments, cells
were plated on coverslips and cultured overnight, then starved in 0% FBS media
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for 2 h and pretreated with drug or 0.1% DMSO vehicle for 2 h, followed by EGF
(10 ng/ml) stimulation for 20 min. Cells were permeabilized and stained with
rhodamine-phalloidin. Confocal images were taken on a Zeiss LSM 510 META
confocal microscope. All quantification is based on three independent trials with
30 cells imaged in a battlement pattern and analyzed using Slidebook 5.5
software. Mean lengths or numbers of filopodia are plotted ±SEM. Statistically
significant differences are indicated: *p<0.05, **p<0.01, ***p<0.001.

95

R-ketorolac Inhibits Cdc42- and Rac1-Mediated Cell Adhesion, Migration
and Invasion
Cell Adhesion - A cell attachment assay was used to test the effect of ketorolac
on cell adhesion. Stimulated cells were allowed to adhere to matrix-coated
substrates. R-ketorolac reduced SKOV3ip cell adherence to both fibronectin and
collagen, and S-ketorolac had no significant effect (Figure 24A-B). R-ketorolac
also inhibited human primary ovarian cancer cell adhesion to collagen; while Sketorolac had no significant effect (Figure 24C). This observation suggests that
the R-enantiomer of ketorolac inhibits cell-substrate adhesion likely as a
biological consequence of its inhibitory effect on upstream Cdc42 and Rac1
activation.
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B

A

C

Figure 24. R-ketorolac inhibits cell-substrate adhesion in SKOV3ip cells
and primary human ovarian cancer cells. (A-B) R-ketorolac significantly
inhibits cell adhesion in SKOV3ip cells compared to S-ketorolac. SKOV3ip cells
were trypsinized, starved in 0% FBS media for 1 h, pretreated with drug for 1 h,

97

followed by serum stimulation (5% (v/v) final concentration) and seeded on
matrix pre-coated 96-well plate for 1 h. Cells were fixed and stained with crystal
violet and finally lysed with acetic acid. Cell substrate adhesion was quantified
based on absorbance of cell lysates at 595 nm and normalized to unstimulated
controls. (C) Similar to SKOV3ip cells, R-ketorolac significantly inhibits cell
substrate adhesion in primary human ovarian cancer cells as well. Primary
ovarian cancer cells were purified, cultured and used for the cell attachment
assays to test the effect of drugs on cell substrate adhesion. CID2950007 and
NSC23766 served as positive controls. Each group was normalized to
unstimulated controls as [(sample absorbance—negative control absorbance) /
positive control absorbance], where the negative control is the absorbance
reading obtained using lysates from unstimulated cells, and the positive control is
the absorbance reading obtained from the stimulated cells treated with DMSO.
Value zero represents the basal level (resting cells without serum stimulation) of
adhesion. Data represented three independent trials. Each data point represents
the mean of measured values ±SEM. Statistically significant differences are
indicated: *p<0.05, **p<0.01, ***p<0.001.
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Cell Migration - Activated by extracellular stimuli and dependent on GTPase
activation, cell migration is initiated by the formation of membrane protrusions,
including Cdc42-dependent filopodia and Rac1-mediated lamellipodia (125).
SKOV3ip cell migration in the presence of R- or S-ketorolac was tested in a
Boyden chamber assay. Migration was inhibited in a dose-dependent manner
with R-ketorolac beginning to impinge on cell migration at 1 µM. The inhibitory
effect increased in a dose-dependent manner with maximum inhibition of 80% at
300 µM R-ketorolac (Figure 25). Modest inhibition by S-ketorolac was detected at
about 50 µM with a maximum inhibition less than 50% at 300 µM. The results
demonstrate that cell migration was inhibited as a direct biological consequence
mediated by Cdc42 and Rac1 inhibition by R-ketorolac, whereas S-ketorolac was
50-fold less potent.
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Figure 25. R-ketorolac seletively inhibits cell migration in a dose-dependent
manner. SKOV3ip cells were seeded in Boyden chambers in the presence of
drug for 48 h. Cell migration was normalized to no treatment controls. Three
fields of view were counted for each treatment group. Data represented three
independent trials. Each data point represents the mean of measured values
±SEM. Statistically significant differences are indicated: *p<0.05, **p<0.01,
***p<0.001. Data provided courtesy of Dr. S.R. Kenney (Department of
Pharmaceutical Sciences, University of New Mexico).
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Cell Invasion - Invadopodia are membrane protrusions that are dependent on
activated

Cdc42

and

Src

kinase.

Invadopodia

concentrate

matrix

metalloproteinases at their tips and based on their matrix degradative properties
serve as surrogates for cell invasive behaviors (155). To study the effect of
ketorolac on invadopodia formation, the invadopodia-mediated degradation of
gelatin matrices was quantified. In Skov3ip cells, invadopodia were observed as
puncta of F-actin and Tks5-positive structures, which colocalized with the
degradation sites on the gelatin matrix (Figure 26A). R-ketorolac treatment also
resulted in reduced gelatin degradation in a dose-dependent manner with 70 to
80% inhibition at 1 and 10 µM. However, S-ketorolac did not exert any obvious
inhibition of gelatin degradation at 1 µM and the reduction of gelatin degradation
with 10 µM S-ketorolac treatment was ~50% but failed to reach the statistical
significance (Figure 26 B, C). Tks5 is an early marker of invadopodia formation
that precedes matrix metalloprotease localization to the tips of mature structures.
To

distinguish

whether

R-ketorolac

had

a

direct

inhibitory

effect

on

metalloprotease activity or whether the observed effect on gelatin degradation
was primarily due to inhibition of invadopodia formation, the impact on
metalloproteinase activity secreted into the culture medium was also measured
and found to be similar ± ketorolac. Therefore, we conclude that the primary
effect of R-ketorolac is to prevent Cdc42-dependent invadopodia formation.
When the gelatin degradation assay was conducted in primary ovarian cancer
cells, the standardized z-scores showed the degradation of matrix by tumor cells
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was also significantly decreased in a dose-dependent manner by R-ketorolac
treatment, while the inhibition by S-ketorolac was less and reached significance
only at the highest dose (Figure 27). Z-scores were used to account for large
differences in absolute GTPase activity levels observed for individual patient
samples

(Figure

19),

likely related

to

known

differences in

GTPase

overexpression seen in ovarian cancer (77, 86). The inhibitory effect of Rketorolac in primary ovarian cancer cells is consistent with the observations in
SKOV3ip cells.
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C

Figure

26.

R-ketorolac

inhibits invadopodia

formation and gelatin

degradation in SKOV3ip. (A) Colocalization of gelatin degradation, actin and
Tks5 antibody in SKOV3ip cells. Insets are magnified images of the boxed
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regions. Arrowheads denote points of invadopodia formation that are coincident
with gelatin degradation. (B) Representative confocal images of gelatin
degradation for each treatment group in SKOV3ip cells are shown. Lower panels
are magnified images of the boxed regions. Arrowheads denote the gelatin
degradation sites. (C) Quantification of the gelatin degradation area in SKOV3ip
cells. For all experiments, SKOV3ip cells were seeded on Cy3-gelatin labeled
coverslips for 24 h in the presence of different drugs, including two enantiomers
of ketorolac, and Cdc42 and Rac1 specific inhibitors (CID2950007 and
NSC23766, respectively) as positive controls. DMSO (0.1%) served as the
vehicle control treatment. Results are normalized as [(sample degraded area—
negative degraded area) / positive control degraded area], where the negative
control is the degradation of unstimulated cells, and the positive control is the
degradation of the stimulated cells treated with DMSO. Value zero represents the
basal level (resting cells without EGF stimulation) of gelatin degradatiion. All
quantification is based on three independent trials with 15 representative fields
counted for each treatment. Each data point represents the mean of measured
values ±SEM. Statistically significant differences are indicated: *p<0.05, **p<0.01,
***p<0.001.
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A

B

Figure 27.

R-ketorolac inhibits invadopodia formation and gelatin

degradation in primary human ovarian cancer cells. (A)

Representative

confocal images of gelatin degradation for each treatment group in primary
ovarian cancer cells are shown. Lower panels are magnified images of the boxed
regions. Arrowheads denote the gelatin degradation sites. (B) Quantification of
the gelatin degradation area in primary ovarian cancer cells. Due to the variability
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of the extent of gelatin degradation observed with primary human ovarian cancer
cells, z-scores are plotted. For all experiments, primary ovarian cancer cells were
seeded on Cy3-gelatin labeled coverslips for 24 h in the presence of different
drugs, including two enantiomers of ketorolac, and Cdc42 and Rac1 specific
inhibitors (CID2950007 and NSC23766, respectively) as positive controls. DMSO
(0.1%) served as the vehicle control treatment. Plotted are z-scores. For
individual patient sample, z-score is defined as z=(X - μ)/σ, where X is the gelatin
degraded area for each treatment, μ is the mean of X, and σ is the standard
deviation of X. All quantification is based on three independent trials with 15
representative fields counted for each treatment. Each data point represents the
mean of measured values ±SEM. Statistically significant differences are indicated:
*p<0.05, **p<0.01, ***p<0.001.
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Conclusion and Discussion
In this chapter, R-ketorolac is shown to inhibit Cdc42 and Rac1 activation
and associated cell functions, including adhesion, migration and invasion in both
SKOV3ip cell and primary human ovarian tumor cells. In its clinical application,
ketorolac is given for its potent analgesic activity. It is administered as a racemic
mixture via diverse routes (intravenous, injectable, oral, intranasal) and is known
as ToradolTM. The pain relieving activity is ascribed primarily to the S-enantiomer,
which is a known non-selective cyclooxygenase (COX-1/COX-2) inhibitor (122,
167). The R-enantiomer lacks significant activity against cyclooxygenases (e.g.
IC50 >100 µM against COX1 and COX2 and ~3 orders of magnitude greater than
the IC50 of S-ketorolac) and has until now been considered inert (122, 167). The
previously unrecognized and novel mechanism of action for the R-enantiomer
has important ramifications when considering the efficacy and novel activities of
clinically administered ketorolac. For example, breast cancer patients treated
with ketorolac perioperatively had a decreased rate of early breast cancer
relapse

(53).

Collaborative

studies

from

Hudson

and Wandinger-Ness

laboratories with collogue Muller and Cook demonstrate ovarian cancer patients
receiving ketorolac exhibit an enrichment of R-ketorolac in the peritoneum, a
reduction in GTPases activation of residual tumor cells, and improved 5-year
survival (86). The cell based studies using human immortalized and primary
human ovarian cancer cells presented here, demonstrate that R-ketorolac
treatment alters tumor cell adhesion, migration and invasion—all behaviors that
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are central to ovarian cancer metastasis. The findings offer unprecedented
mechanistic insights regarding the R-ketorolac activity against GTPases, which
may explain the clinically observed survival benefit in patients treated
perioperatively with racemic ketorolac.
In ovarian cancer, cyclooxygenases are upregulated and have been
considered as potential targets, however, clinical trials have been mixed and do
not support significant benefit in combinatorial treatment with chemotherapy and
a cyclooxygenase inhibitor versus treatment with chemotherapy alone (168).
Although the survival benefit of ketorolac use in breast cancer was postulated to
be due to possible inhibitory roles in anti-angiogenesis, inhibition of prostaglandin
synthesis and decreased immune suppression as compared to opioids and other
analgesics (169, 170), there was previously no precedence for other
pharmacologic activities associated with R- or S-ketorolac. A recent structural
study identifies a new hydrophobic ligand binding site on intestinal fatty acid
binding protein that can interact with ketorolac (all deposited structures show
protein complexed to R-ketorolac though not explicitly stated in publication –
Ursu and Oprea, unpublished observation), though functional consequences are
unknown (170). We speculate that the slight inhibitory effects of S-ketorolac on
GTPase activation and actin dependent cell behaviors may arise from crosstalk
between COX-2 and PI3K and integrin regulated pathways. COX-2 dependent
crosstalk has been shown through knockout and pharmacologic means to
regulate Cdc42 and Rac1 activation, and adhesion and migration of
macrophages and endothelia (165, 171). Because R-ketorolac is a much less
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potent COX inhibitor than S-ketorolac, its more pronounced effect on GTPase
activation and downstream cell behaviors indicates that it is primarily targeting
Cdc42 and Rac1 through a direct mechanism. Furthermore, pharmacokinetic
analyses show that S-ketorolac is more rapidly excreted, leading to an increased
prevalence of R-ketorolac in vivo (86, 122, 167). Taken together, our
identification of R-ketorolac as a GTPase inhibitor helps to explain the significant
benefits of racemic ketorolac in human breast and ovarian cancer patient survival,
and why other NSAIDs that preferentially target COX have not yielded similar
benefit (53, 86, 172).
Ketorolac is an FDA (Food and Drug Administration)-approved drug for
human use and is in active clinical use as the racemic mix. Therefore, Rketorolac has significant potential for rapid repurposing. Implementation of Rketorolac in human clinical trials would offer the first opportunity to directly test
the predicted benefit of a Cdc42 and Rac1 selective inhibitor for cancer patients.
Such an application could circumvent current renal and hematologic toxicities
that limit racemic ketorolac use to a maximum of 5 days. Analyses of Rac1
inhibition in cancer cell lines and animal models with NSC23766 treatment
suggests benefit for inhibiting metastasis and angiogenesis (173). Additionally,
Rac1 inhibition may mitigate Trastuzumab resistance in breast cancer cell lines,
thus suggesting that the availability of a clinically accessible selective Cdc42 and
Rac1 inhibitors could offer new paradigms for combinatorial therapies (173). We
envision that the use of R-ketorolac in the perioperative window and thereafter
presents a unique opportunity to block tumor reseeding and spread, as well as
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angiogenesis, which may enhance the efficacy of combined chemotherapies or
targeted therapies.
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CHAPTER 4
A NOVEL PHARMACOLOGIC ACTIVITY OF KETOROLAC FOR
THERAPEUTIC BENEFIT IN OVARIAN CANCER PATIENTS
Abstract
Previous studies identified the R-enantiomer of ketorolac as an inhibitor of
the Rho family GTPases Cdc42 and Rac1. Cdc42 and Rac1 regulate cancerrelevant functions including cytoskeleton remodeling necessary for tumor cell
adhesion and migration. In this chapter, elevated expression and activity of
Cdc42 and Rac1 are reported in ovarian cancer patient tissues, confirming target
relevance. A clinical trial is performed in eligible patients to measure the
bioavailability of R- and S-ketorolac in serum and peritoneal fluid, and GTPase
activity in peritoneal cells. The results show ketorolac in peritoneal fluids is
enriched in the R-enantiomer and GTPase activity is inhibited in ascites-derived
primary ovarian tumor cells after ketorolac administration when R-ketorolac is at
peak levels.

In addition, a retrospective study suggest that women given

perioperative ketorolac have a lower hazard of death (Hazard Ratio=0.30
[95%CI 0.11-0.88]). Thus, ketorolac has a novel pharmacologic activity conferred
by the R-enantiomer and R-ketorolac achieves sufficient levels in the peritoneal
cavity to inhibit Rac1 and Cdc42, potentially contributing to the observed survival
benefit in women who received ketorolac.
All the work in chapter 4 are published Guo, Y and Kenney SR, et al.,Clin Cancer
Res. 2015 Jun 12. [Epub ahead of print] PMID: 26071482
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Introduction
Ovarian cancer is the leading cause of death from gynecologic
malignancies and the second most common gynecologic cancer (174). Five year
patient survival remains less than 50% and the mortality rate hasn’t changed
appreciably in two decades (174). The majority of women are diagnosed with
metastatic disease, and although a substantial proportion of women respond to
initial treatment, recurrence is common (16). Despite concerted efforts,
identification of effective targeted therapies has remained elusive in this disease
(6). There remains a great need to identify new strategies to treat and manage
ovarian cancer.
The Rho family of small GTPases (Cdc42, Rac and Rho) are key
regulators of cancer-relevant cellular functions including actin reorganization, cell
motility, cell-cell and cell-ECM adhesion and invasion (54, 149, 153). In many
human tumors (including colon and breast), there is clinical and experimental
evidence that aberrant Rho-family signaling contributes to tumor growth, survival,
invasion and metastasis (54, 68, 175-177). On the basis of these functions,
Cdc42 and Rac1 have been recognized as attractive therapeutic targets (173,
178) and inhibitors are effective in experimental systems (104, 107-110, 179,
180), but specific inhibitors of Cdc42 or Rac1 have not been translated to clinical
use.
A Cdc42 selective inhibitor effectively blocked migration of two ovarian
tumor cell lines (104, 181), suggesting that Rho-family GTPases may be potential
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therapeutic targets in ovarian cancer. Using findings obtained from a high
throughput screen of the Prestwick library of off patent, FDA-approved drugs and
cheminformatics approaches, we identified the R-enantiomers of a limited
number of NSAIDs as inhibitors of Cdc42 and Rac1. The corresponding Senantiomers are considered the active component in racemic drug formulations
acting as NSAIDs with selective activity against cyclooxygenases (COX). One
candidate, R-ketorolac, inhibited ovarian tumor cell migration and adhesion
without causing cytotoxicity (182, 183). Our data indicate that the clinically
administered racemic ketorolac (Toradol®) has two distinct pharmacologic
activities; the well-established inhibition of COX 1 and 2 by S-ketorolac serving
as the basis of the FDA-approved indication for pain management, and a
previously unrecognized property of Cdc42 and Rac1 inhibition conferred by the
R-enantiomer. Cell based measurement of GTPase activity demonstrated that Rketorolac specifically inhibits EGF-stimulated Cdc42 and Rac1 activation at low
micromolar concentrations. The GTPase inhibitory effects of R-ketorolac in cells
mimic those of established Cdc42 (CID2950007/ML141) and Rac1 (NSC23766)specific inhibitors (104, 183).
In this chapter, R-ketorolac is shown to achieve an effective concentration
in peritoneal fluids and inhibited Cdc42 and Rac1 activity in cells retrieved from
the peritoneal compartment of post-surgical ovarian cancer patients following
administration of the racemic drug for postoperative pain management. A
medical record review to compare the ovarian cancer-specific survival of ovarian
cancer patients who did or did not receive ketorolac for post-operative analgesia
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revealed increased survival of patients receiving ketorolac. This observation is in
keeping with reports for improved clinical outcomes associated with ketorolac
usage, as compared with other NSAIDs, in breast cancer patients (53, 169, 184).
Although it has been long recognized that R-enantiomers of NSAIDs are poor
inhibitors of COX activity (167, 185, 186), potential pharmacologic activities or
benefits of the R-enantiomers have remained largely unexplored. The findings
show that Cdc42 and Rac1 are unrealized therapeutic targets in ovarian cancer
and use of ketorolac may benefit ovarian cancer patients.
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Materials and Methods
Immunohistochemical Analyses of GTPase Targets
Immunohistochemical staining was performed using standard procedures.
Rac1 was stained with mAb (clone 102, BD Biosciences, 10155-1-AP) and
Cdc42 was stained with rabbit pAb (Protein Tech Group). A Vectastain Ready-toUse (RTU) ABC-peroxidase kit and ImmPact DAB (SK-4105) were used to
visualize primary antibody labeling with hematoxylin nuclear counterstain (H3401) for tissue staining and samples were mounted in VectaMount (H-5000); (all
from Vector Laboratories).
For large scale ovarian tumor profiling, tissue microarrays were purchased
from US BioMax, Inc. (Rockville, MD, cat# OV1005 061 and OV8010 009). In
total180 unique tissue samples were included in the evaluation; ranging from
stage I-IV and grades 1-3 (Appendix A). All tumor types were validated and
staining was scored by a pathologist with gynecologic pathology specialty (Dr.
Lomo) and evaluated for location (nuclear and cytoplasmic), as well as intensity
of positive staining. Scoring was based on the product of the percentage of cells
stained and the intensity of the staining in each localization (3+: strong, 2+:
intermediate, 1+: weak and 0: no staining), resulting in a minimum of 0 (100%
cells x 0) and a maximum of 300 (100% cells x 3+).
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qPCR of Ovarian Cancer cDNA Arrays
qPCR was performed using Origene SYBR Green I master mix solution
diluted to a final concentration of 1X with primers at a concentration of 0.33μM.
PCR mix was added to each well of the microarray plate and incubated on ice for
15m to dissolve the cDNA. qPCR was conducted using a Bio-Rad iCycler
(Hercules, CA) under the following conditions; 95° for 5m, 30 cycles of (95° for
15s, 60° for 30s, 72° for 1m), followed by melt curve analysis, hold at 4°. Rac1b
levels were measured using custom primers synthesized by Invitrogen. Rac1b
forward primer, 5’-TCCGCAAACAGTTGGAGA-3’, was coupled with Rac1
reverse primer, 5’-CTACATGTTTGCGGATAGGATAGGG-3’. The identity of the
PCR product as Rac1b was confirmed by sequence analysis.
qPCR of Ovarian Cancer cDNA Arrays
Rac1b levels were measured using custom primers synthesized by
Invitrogen.

Rac1b

forward

primer,

5’-TCCGCAAACAGTTGGAGA-3’,

was

coupled with Rac1 reverse primer, 5’-CTACATGTTTGCGGATAGGATAGGG-3’.
The identity of the PCR product as Rac1b was confirmed by sequence analysis.
Quantitative PCR (qPCR) of Ovarian Cancer cDNA Arrays
qPCR analysis of Rho family GTPases was performed using Tissuescan
Ovarian Cancer cDNA microarrays (Appendix B) from Origene (Rockville, MD,
cat#

HORT301,

HORT302,HORT303)

and

standard

techniques.

qPCR

amplification utilized Qiagen Quantitect primers for Cdc42 (Valencia, CA,
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QT01674442), Rac1 (QT00065856), and RhoA (QT00044723), and β-actin
(Origene), and custom Rac1b primers from Invitrogen (Carlsbad, CA). Primer
information for Rac1b, additional information on the Ovarian Cancer cDNA arrays
is presented in Appendix B. Analysis of serous cancer only is shown in Figure 32.
CT values obtained using iCycler software. Relative expression levels were
determined using ΔΔCT values.
Patients, Study Design and Treatment
A Phase 0 trial investigating the use of postoperative ketorolac was
reviewed and approved by the University of New Mexico Health Sciences Center
Human Research Review Committee (clinicaltrials.gov -NCT01670799). Patients
presenting with a new diagnosis of ovarian, fallopian tube or primary peritoneal
cancer were screened for eligibility. Eligible women were at least 18 years old, an
ECOG Performance Status <2 and had consented to a planned debulking
surgery- Consent was obtained prior to surgery if primary eligibility was met.
Secondary eligibility after surgery included confirmed histologic diagnosis of
epithelial ovarian, fallopian tube or primary peritoneal cancer; optimal
cytoreduction and placement of an intraperitoneal port for planned chemotherapy;
adequate renal function and no postoperative complications prohibiting ketorolac
use. Patients with known bleeding disorders or other contraindications to NSAID
use were excluded.
Subjects received a single IV dose of Toradol® (15 or 30 mg based on the
patient age and creatinine clearance) within the first 72 h of surgery when all
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clinical safety parameters were met. Use of other NSAIDs during the trial was not
permitted; however narcotic regimens were allowed for postoperative pain
management. All study protocols were reviewed by an independent data and
safety monitoring board. Baseline ascites samples were obtained at surgery.
Subsequent peritoneal fluid samples were collected from the intraperitoneal port
prior to dosing and at 1, 6, and 24 h after single dose ketorolac administration.
Peripheral blood was collected at the same time points. Serum and peritoneal
fluid were separated from cellular material via low speed centrifugation. Tumor
cells were further purified on Ficoll gradients to red blood cells and negative
selection with anti-CD45 beads to remove lymphocytes. The resulting tumor cell
fractions were analyzed by flow cytometry for EpCAM and MUC16/CA125 (see
Figure 28 for representative purity).
Analysis of Patient Derived Cells
To purify ovarian cancer cells from ascites, cells were recovered from
ascites samples by low speed centrifugation at 1000 rpm. The cell pellets were
gently resuspended and overlaid on a Ficoll (density 1.077±0.001 g/ml; GE
Healthcare 17-5442-02) to separate red blood cells from lymphocytes and tumor
cells per manufacturer's instructions. Anti-CD45 beads (ThermoFisher Scientific,
11153D) were used to deplete lymphocytes and the resulting tumor cell fraction
was analyzed visually and by flow cytometry. For flow cytometric analysis, cells
suspended in phosphate buffered saline (PBS) were fixed with formaldehyde (2-4%
final concentration) for 10 min, chilled for 20 min and then processed for
immunostaining

as

described

by
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Cell

Signaling

Technology

(http://www.cellsignal.com/contents/resources-protocols/flow-cytometry-protocol(flow)/flow; webpage Accessed July 22, 2014). Briefly, non-specific mAb binding
to human Fc receptor was blocked by pretreatment for 10 min at room
temperature with human Fc receptor binding inhibitor (14-916, Affymetrix
eBioscience).

Conjugated primary antibody staining was performed in PBS

containing 0.5% BSA using 0.5-1 x106 cells / assay for 1 h at room temperature.
Cells were washed with 500 µM PBS containing 0.5% BSA once and
resuspended in 500 µl PBS for flow cytometry measurement (BD FACSCalibur)
Tumor cell fractions were positive for EpCAM (detected with mAb against
EpCAM clone Ber-EP4, Dako) and MUC16/CA125 (detected with a Cy5-labeled
rabbit pAb directed against human MUC16/CA125; bs-0091R-Cy5, Bioss
Antibodies) and negative for CD45 (detected with a PE-labeled rabbit pAb
directed against human CD45/LCA, 12-9459, Affymetrix eBioscience) (Figure 28).
For analysis of GTPase activity in patient-derived cells, active RhoA was
quantified based on binding to GST-Rhotekin (RT01, Cytoskeleton, Inc.).
Antibodies specific for Cdc42 (sc-8401, Santa Cruz Biotechnology, Inc.), Rac1
(610650, BD Transduction Labs) or RhoA (26C4, sc-418, Santa Cruz
Biotechnology, Inc.) and Alexa Fluor 488 donkey anti-mouse lgG (A21202, Life
Technologies) were also used.
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Figure 28. Purified ovarian tumor cells express EpCAM and MUC16/CA125.
Ovarian tumor cell identification by flow cytometry using patient ascites samples
from three individuals (designated 29, 30, and 35). Tumor cells were purified
from ascites using Ficoll gradients to remove red blood cells and CD45
Dynabeads negative selection to remove leukocytes. The resulting cells (gated
as R3) were negative for CD45 and positive for EpCAM and MUC16/CA125.
Markers were tracked by flow cytometry on a Becton Dickinson FACSCalibur
Flow Cytometer.
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High Performance Liquid Chromatography
R- and S-enantiomers of ketorolac were analyzed by high performance
liquid chromatography (HPLC) using published procedures (186, 187). See
Appendex C for additional information. The R-value for the standard curve of
total ketorolac was 0.9997 and represented a concentration range that spanned
established human serum concentrations (0.092 μg / ml to 6.0 μg / ml).
Analysis of GTPase Activity
Two methods were used to assess GTPase activity in cells based on
effector binding. Commercial GLISA kits from Cytoskeleton, Inc., analyzed Rac1
(Denver, CO, cat# BK-128), Cdc42 (BK-127) or RhoA (BK-124) per
manufacturer’s instructions. Alternatively, Rac1, Cdc42 and RhoA activities were
measured using a flow cytometric effector binding assay (G-trap) (135, 140).
Briefly, ~105 purified primary tumor cells were lysed in 200 µl RIPA buffer for
each assay. GST-PAK1 protein (Millipore, 14-864) was immobilized to the GSHbeads according to the methods reported in previous work (180). Cell lysates
were normalized to the same concentration and incubated with pre-labeled
beads for 1 h at 4ºC. Primary antibody and conjugated secondary antibody
staining were performed in HPS buffer containing 1% BSA for 1 h at 4ºC. Stained
beads were resuspended in 500 µl HPS buffer. Fluorescence intensity (mean
channel fluorescence, MCF) was measured by flow cytometry (Accuri C6).
GTPase activity was calculated by (MCF of sample group – MCF of unstimulated
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group) / MCF of stimulated group. Equal amounts of protein were used for each
assay.
Retrospective Patient Outcomes Review
A medical record review was conducted under institutional review board
approval with a waiver of patient consent. Ovarian cancer patients were identified
from the New Mexico Tumor Registry [NMTR] a member of the population-based
Surveillance, Epidemiology, and End Results [SEER] Program of the National
Cancer Institute (34). Inclusion criteria were as follows: invasive, epithelial
ovarian cancer (any histology), age 40-79 years at diagnosis, years of diagnosis
2004–2006, and receipt of surgery at an Albuquerque, NM hospital (only three
hospitals in the metropolitan area provide this level of surgery). Diagnosis years
of 2004-2006 ensured at least 6 years follow-up (mortality followed through Dec
31, 2012) for each patient. We abstracted the surgical medical records for all
analgesics and anesthesia medications used before hospital admission, during
surgery and hospital stay, and given at discharge. Of the 138 potential cases, 6
women did not undergo surgery because of advanced disease/severe
comorbidities or desired palliative care only, 1 woman had her surgery in another
state, 2 women died before surgery, and medical records were not located for
6women, leaving 123 women in the final analysis.
Statistical Analysis
qPCR findings for GTPase expression levels were analyzed using oneway ANOVA followed by Dunnett’s Multiple comparisons test to determine
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differences between ovarian cancer grade. IHC data was analyzed using oneway ANOVA followed by Tukey's post test to determine significant differences
between groups. Data obtained from patient fluid and cell samples was analyzed
as a repeated measure ANOVA followed by Dunnett’s multiple comparisons test
to determine significant differences between groups. For the retrospective
medical record review, information from the medical record was merged with
information from the NMTR for final analysis. Clinical and treatment
characteristics of patients who did and did not receive peri-operative ketorolac
were compared with chi-square tests and t-tests. In a preliminary, crude analysis
the Kaplan-Meier method was used to estimate the survival probabilities. The
difference in survival based on receipt of peri-operative ketorolac was examined
using the stratified log-rank test to adjust the effect of a single categorical factor
such as age group, AJCC stage, etc. Because this was an observational study
and not a randomized controlled trial, the final analysis was based on a Cox
proportional hazards model to adjust for clinical and treatment characteristics that
may have differed between those who did and did not receive peri-operative
ketorolac. We estimated the hazard ratio (HR) for ovarian cancer-specific
mortality comparing those who did and did not receive peri-operative ketorolac
while adjusting for age at diagnosis (<50, 50-64, >65) AJCC stage (I, II, III, IV),
completion of chemotherapy as planned (yes, no), and receipt of neoadjuvant
chemotherapy (yes, no). Based on the Cox proportional hazards regression, an
example survival plot is presented in Figure 36. Additional survival plots are
presented in Appendix C-F.
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Results
Expression of Rac1 and Cdc42 in Ovarian Cancer
On the basis of the established functions of Rho-family GTPases, ovarian
cancer metastasis is predicted to be strongly dependent on Rac1/Cdc42regulated pathways for exfoliation, formation of multicellular aggregates,
mesothelial adhesion, and localized invasion into the interstitial collagen-rich
submesothelial matrix (6, 16, 188). To test whether these GTPases are
dysregulated in ovarian cancer, we examined grade-dependent expression of
Cdc42and Rac1 protein by immunohistochemical staining of human tumor
samples (Figure 29) and GTPase mRNA using quantitative PCR analysis of
ovarian cancer tissue cDNA arrays (Figure 30 and Figure 31). Cdc42 protein
overexpression levels were highly significant for malignant, high grade tumors
(p<0.001) compared to lower grade tumors without an apparent increase in
mRNA levels. In contrast, there was little evidence of increased expression of
Rac1 protein with increasing grade (Figure 29). However, significantly elevated
expression of a constitutively active splice variant Rac1b (36-38) was detected in
ovarian tumors (Figure 30). These findings provide evidence for aberrant
expression of Rac1 and Cdc42 in ovarian cancer and suggest that they may
represent therapeutic targets for this disease.
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Figure 29. Overexpression of Rac1 and Cdc42 protein in ovarian cancer
specimens. (A-C) Representative images of ovarian serous cancer tissue are
shown. Clinical characteristics of the samples in the array are provided in Figure
32. Magnification 200X. Scale bar 20µm. (A) Hematoxylin/Eosin staining (H&E).
(B-C) Samples were stained with antibodies against Rac1 or Cdc42 and
avidin/biotin horse radish peroxidase enzyme complex. Controls and tissue
samples were developed for identical times. (D-E) Tissue pathology and staining
evaluated by board certified pathologist with gynecologic pathology specialization
(Lesley Lomo, MD) and statistical analyses by statistician (Ed Bedrick, PhD,
University of Colorado Denver, Anshutz Medical Campus). For Rac1 one way
non-parametric ANOVA (p=0.0087) and Tukey post-test shows normal stroma vs.
intermediate to high grade carcinoma (p<0.05) with all other comparisons non-
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significant. For Cdc42 one way non-parametric ANOVA (p=0.0001) and Tukey
post-test shows normal stroma and benign to borderline tumor vesus
intermediate to high-grade carcinoma p<0.05 with all other comparisons nonsignificant. Images provided courtesy of Dr. L. Lomo and Ms. E. Romero
(Department of Pathology, University of New Mexico)

126

Figure 30. Expression of constitutively active Rac1b mRNA is elevated in
ovarian cancer specimens. Tissuescan ovarian cancer cDNA microarrays
(Origene) were amplified using primers against Rac1, Rac1b, Cdc42, RhoA, and
β-actin as described in Patients and Methods. As per the manufacturer's
description, patients with endometriosis, leiomyoma of myometrium, follicular
cysts, abscesses, or secretory endometrium, but otherwise healthy ovarian tissue,
were considered normal (n=19). Tissues defined as low grade have a FIGO
score of 1 (n=19) or 2 (n=32). Tissues considered high grade have a FIGO score
of 3 (n=60) or 4 (n=9). The cDNAs of 10 patients were excluded due to a lack of
grade information. Clinical characteristics of the samples in the array are
provided in Appendix B. Groups were compared to normal using a two-tailed t-
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test, and significant increase in Rac1b was detected. * indicates significance is
p<0.05. Serous only, analysis by grade is reported in Figure 31. Data provided
courtesy of Dr. S.R. Kenney (Department of Pharmaceutical Sciences, University
of New Mexico)
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Figure 31.

Overexpression of Rac1, Rac1b, Cdc42 and RhoA mRNA is

dependent on ovarian cancer grade. This analysis does not include
endometrioid tissue.
leiomyoma

of

As per the manufacturer description, patients with

myometrium,

follicular

cysts,

abscesses,

or

secretory

endometrium, but otherwise healthy ovarian tissue, were considered normal
(n=11). Data from two normal patients were not included due to Grade 3
carcinomas of adjacent tissues. Tissues considered low grade have a FIGO
score of 1 (n=19) or 2 (n=32). Tissues considered high grade have a FIGO
score of 3 (n=60) or 4 (n=9). The cDNA of 10 patients was removed because
they had no grade information. Groups were compared to normal using a twotailed t-test, * indicates significance is p<0.05. Data provided courtesy of Dr. S.R.
Kenney (Department of Pharmaceutical Sciences, University of New Mexico)
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Study Design and Patient Population
In previous work, R-ketorolac was identified as an inhibitor of Rac1 and
Cdc42 at low micromolar concentrations (183, 189). R-ketorolac is inactive
against the enzyme targets of S-ketorolac, COX-1 and COX-2 (122, 167, 185),
and the inhibitory concentration (IC50) values for inhibition of Rac1 and Cdc42 by
S-ketorolac were more than 100-fold greater than R-ketorolac (140). Thus, the
racemic (R,S) ketorolac possesses two distinct pharmacologic activities and our
findings identify R-ketorolac as a novel inhibitor of Rac1 and Cdc42.
In this “Phase 0” feasibility study, ketorolac was administered for its FDAapproved indication for post-operative pain management. Eligible patients had
suspected advanced-stage ovarian, fallopian tube or primary peritoneal cancer
with planned optimal cytoreductive efforts. Secondary eligibility was met if the
patient had confirmed ovarian cancer, was optimally cytoreduced and had an
intraperitoneal port placed for planned peritoneal chemotherapy. The patients
had no active postoperative bleeding, did not require therapeutic anticoagulation
and had good postoperative organ function. Forty-two patients met primary
eligibility, and considering secondary eligibility requirements, twenty patient
samples were collected at surgery. Samples of blood and peritoneal fluids after
ketorolac administration were obtained from 13 patients. Pathologic analysis of
the 20 surgical samples confirmed fifteen patients (75%) had stage III or IV
disease.

Histologically,

100%

had

high-grade

carcinoma;

one

was

a

carcinosarcoma, 16 of 19 were pure serous carcinomas, one was primary
peritoneal and one fallopian tube primary, and the rest ovarian primary tumors.
130

The average age was 60.8 (range 33-81), race and ethnic distribution was 85%
Caucasian (29.4% Hispanic), 5% American Indian and 10% Black or African
American. Ketorolac dosages administered on the basis of clinical indications
were 15 mg (33% of patients) or 30 mg (77% of patients). As illustrated in Figure
32A, blood and peritoneal fluid were obtained at T=0, 1 h, 6 h and 24 h after
administration of the recommended dose of ketorolac.
Distribution of R- and S-ketorolac in Peritoneal Fluids
Serum and peritoneal fluid samples were analyzed by HPLC to resolve
and quantify R- and S-ketorolac enantiomers in order to determine enantiomeric
ratios and distribution over time (Figure 32B, C). Clinical-grade ketorolac
tromethamine is a 1:1 mixture of R- and S-enantiomers (Figure 33); however, the
racemic distribution favors the R-form in both serum and peritoneal fluids at each
time point in keeping with the established shorter half-life of S-ketorolac in human
serum based on differences in pharmacokinetic parameters for each enantiomer
(122, 167, 185). Ketorolac distributes to the peritoneum within 1h after IV
administration, and ketorolac levels in the peritoneal fluids are nearly equivalent
to those present in the serum at 6 h and decline dramatically by 24 h in both
serum and peritoneal fluids. Our results represent the first evidence of ketorolac
distribution to peritoneal fluids.
The IC50 values for Rac1 and Cdc42 by R-ketorolac are 0.57 and 1.07 µM,
respectively, whereas the IC50 values for S-ketorolac for these targets was >100
µM (183). The concentrations of R- and S-ketorolac in the peritoneal fluids were
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0.98 µM and 0.32 µM, respectively, 6 h after IV ketorolac administration. Thus,
R-ketorolac achieved concentrations in the peritoneal fluids at or above the IC 50
values for Rac1 and Cdc42 and is predicted to inhibit these GTPase targets in
cells obtained from this compartment.
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Figure 32. Ketorolac distributes to peritoneal fluids and is enriched in the
R-enantiomer. (A) Ascites samples were obtained at cytoreductive surgery and
1 to 3 days after surgery patients received a single dose of either 15 mg or 30 mg
of clinical grade racemic ketorolac. Blood and peritoneal fluid from patients were
collected before dosing (T=0), and at 1, 6, and 24 h after dosing as depicted by
the arrows. (B-C) Ketorolac enantiomers (R and S) were measured in blood and
peritoneal fluids using HPLC. (B) Total ketorolac levels in sera and peritoneal
fluids. (C) The levels of each ketorolac enantiomer (R or S) at each time point in
sera and peritoneal fluids were measured. Concentration conversion to
micromolar in serum and peritoneal fluids is provided in Table 5. Administered
drug is a 1:1 ratio of R to S (Figure 34), but S-ketorolac is eliminated more
rapidly than R-ketorolac leading to a ratio favoring the R-enantiomer in both
serum and peritoneal fluids. The R value for the standard curve used to calculate
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the ketorolac concentrations was 0.9997 and represented a concentration range
that spanned established human serum concentrations (0.092 μg/ml to 4.0 μg/ml;
3.0 μg/ml= 10 μM). Data (panel B, C) data provided courtesy of Dr. S.R. Kenney
(Department of Pharmaceutical Sciences, University of New Mexico)
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Analysis of Patient-Derived Cells
Tumor cell enriched fractions were prepared from ascites samples
obtained at the time of cytoreductive surgery from ovarian cancer patients and
post-surgery immediately prior and 1 h, 6 h, and 24 h post IV ketorolac
administration (Figure 33A). Both Rac1 and Cdc42 were highly activated in
freshly isolated tumor cells from ascites and the activity level declined within 48 h
in culture medium (Figure 34A) suggesting that the ovarian tumor environment
fosters Rac1 and Cdc42 GTPase activation. Post-surgery, we observed a
statistically significant decrease in Rac1 and Cdc42 activity with time after
ketorolac administration (Figure 34B, C). In contrast, RhoA activity was
insensitive to ketorolac (Figure 35), further affirming the selectivity of the drug. Rketorolac predominates in the peritoneal fluids at the S-enantiomer is virtually
undetectable at 24 h (Figure 33C) indicating that the R-enantiomer is bioactive
and accounts for the observed inhibition of the GTPases in vivo.
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Figure 33.

Enantiomer analyses of clinical drug. To confirm that this

apparent shift in racemic ratio was not due to either 1) unequal distribution of the
racemates in the administered drug or 2) differential extraction of each racemate
from serum proteins, we conducted control experiments. (A)

Racemic

distribution of ketorolac enantiomers of the clinically administered drug was
confirmed by HPLC. (B) Clinical grade ketorolac incubated with human serum
(shown) and ascites fluid (not shown, but identical results) at 37°C for 1 h and the
samples were then processed as for samples obtained from patients. The equal
distribution of R- and S-ketorolac in the extracted control sample indicates that
the difference in enantiomer composition in patient samples is not due to
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differential extraction from serum proteins during sample processing and more
likely represents a pharmacokinetic parameter such as preferential binding of Sketorolac to tissue proteins. Data provided courtesy of Dr. S.R. Kenney
(Department of Pharmaceutical Sciences, University of New Mexico)
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Table 5. Ketorolac enantiomer concentration in serum or peritoneal fluids.

Sample

[R] μM

[S] μM

Serum 1h

3.97

1.65

Serum 6h

1.44

0.33

Serum 24h

0.40

0.02

Ascites 1h

0.5

0.33

Ascites 6h

0.98

0.32

Ascites 24h

0.27

0.03

Table provided courtesy of Dr. S.R. Kenney (Department of Pharmaceutical
Sciences, University of New Mexico)
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Figure 34.

GTPases are activated in patient ascites and inhibited by

ketorolac administration in vivo. (A) GTPase activity and target inhibition in
patient-derived cells. GLISA PAK-effector binding was used to individually detect
activated Rac1-GTP or Cdc42-GTP in tumor cells isolated from ovarian cancer
patient ascites. Purified GTP-loaded GTPases were used to calculate ng GTPbound GTPase in the patient sample. Unpaired two-tailed t tests showed
samples in culture for 48 h were statistically different from fresh ascites samples
for both Rac1 and Cdc42 (p=0.0109). The levels of active GTPase declined
sharply with 48 h in culture, indicating that soluble factors in the ascites serve to
upregulate Rac1 and Cdc42 GTPase activities. (B-C) Rac1 GTPase target
inhibition following administration of racemic ketorolac to ovarian cancer patients
post-surgery. Cells isolated from patient ascites samples post-surgery were
assayed for active Rac1 orCdc42 using a flow based effector-binding assay.
Patient diagnoses were all stage III, high grade ovarian serous or papillary
serous carcinoma, with one mixed serous endometrioid carcinoma and one
suspected primary peritoneal carcinoma (Pt 20, 24, 35, 39, 43). Fluorescence
readings were normalized to the 0-h time point drawn immediately before
ketorolac administration. For Rac1, one way non-parametric ANOVA (p=0.0009)
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and Bonferroni multiple comparison test, * indicates p<0.05, ** indicates p<0.01:
0 h versus 6 h (**); 0 h versus 24 h (**); 1 h versus 6 h (*); 1 h versus 24 h (**).
Differences between 0 h versus 1 h and 6 h versus 24 h were non-significant. For
Cdc42, one way non-parametric ANOVA (p=0.0250) and Bonferroni multiple
comparison test, * indicates p<0.05: p<0.05 for 0 h versus 24 h (*) was significant
and all others were non-significant. RhoA was not responsive to ketorolac (Figure
35).
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Figure 35. RhoA activity is insensitive to ketorolac treatment. (A-B) RhoA
GTPase target inhibition assayed by quantification of active RhoA using a flow
based Rhotekin effector binding assay. (A) Patient derived tumor cells purified
from ascites fluids at the time of debulking surgery were treated in vitro for 1 h
with 10 µM R-ketorolac, S-ketorolac or CID2950007– a Cdc42 selective inhibitor
(104, 139, 180). Tumor cells incubated with 0.1% DMSO served as a negative
control. (B) Results of administration of racemic ketorolac to ovarian cancer
patients post-surgery. Cells isolated from patient ascites samples post-surgery
were assayed as in (A). Patient diagnoses were stage II-III, high grade ovarian
serous or papillary serous carcinoma, with one suspected primary peritoneal
carcinoma (Pt 20, 21, 43). Fluorescence readings were normalized to 0.1%
DMSO control or the 0 h time point drawn immediately prior to ketorolac
administration. One way non-parametric ANOVA and Bonferroni multiple
comparison test showed no statistically significant differences between either the
ex vivo or the in vivo samples.
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Retrospective Patient Outcomes Review
Peri-operative ketorolac was used in 14% of the 123 women in the study.
Younger women (<50 years) were more likely than older women to receive perioperative ketorolac (p<0.05); all other clinical and treatment characteristics were
similar between the two groups. At 60 months of follow-up, 3 of 17 ketorolactreated patients (18%) and 40 of 92 nontreated patients (43%) had died of
ovarian cancer. Stratified log-rank tests for categorical factors such as age group,
AJCC stage, completion of chemotherapy as planned, and receipt of neoadjuvant
chemotherapy as coded in Table 6, showed a consistent ketorolac survival
benefit in each strata (Appendix C-F). The better survival in women treated with
ketorolac consistently found in the stratified analysis was also evident in the
proportional hazards analysis when we adjusted for age at diagnosis, AJCC
stage, completion of chemotherapy as planned, and receipt of neoadjuvant
chemotherapy. The adjusted HR for ovarian cancer-specific mortality associated
with perioperative ketorolac (yes vs. no) was 0.30 [95% confidence interval (CI),
0.11-0.88, Table 6]. On the basis of the proportional hazards model, an example
survival plot is shown in Figure 36 for women who had AJCC stage III cancer,
were 50 to 60 years at diagnosis, did not receive neoadjuvant therapy, and
completed post-surgery chemotherapy as planned. Other survival plots are
shown in Appendix C-F, and although these plots highlight the results for women
who completed their post-surgery chemotherapy as planned, all combinations of
women defined by stage of disease, age at diagnosis, neoadjuvant therapy, and
post-surgery chemotherapy showed a consistently better survival with ketorolac
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versus without. These preliminary findings suggest that perioperative ketorolac
reduces ovarian cancer-specific mortality.
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Table 6.

Hazard ratios for ovarian cancer specific mortality for each

characteristic adjusted for the other characteristics in the table.

Data provided courtesy by Dr. L. Cook (Division of Epidemiology, Biostatistics
and Preventive Medicine, Department of Internal Medicine, University of New
Mexico School of Medicine).
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Figure 36. Retrospective survival analyses among ovarian cancer patients
with and without peri-operative ketorolac. Cox proportional hazards
regression was used to estimate ovarian cancer specific survival probabilities for
women who did (dashed line,17 women) and did not (solid line, 92 women)
receive ketorolac among ovarian cancer cases with AJCC Stage III cancer, 50-60
years of age at diagnosis, no neo-adjuvant chemotherapy and completed
chemotherapy as planned (overall adjusted Hazard Ratio = 0.30, 95%CI = 0.11 –
0.88, likelihood ratio test p-value = 0.013). Data provided courtesy by Dr. L. Cook
(Division of Epidemiology, Biostatistics and Preventive Medicine, Department of
Internal Medicine, University of New Mexico School of Medicine).
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Conclusion and Discussion
In many human cancers, aberrant Rho-family GTPase activity or
downstream signaling pathways are associated with increased aggressiveness
and poor patient prognosis (54, 153, 173, 175, 176, 178). The specific
mechanisms by which Rho-family GTPases modulate tumor development and
progression remain under investigation (54, 68, 107, 153, 175, 176); however,
experimental evidence places Rac1 and Cdc42 within the metastatic cascade.
Little is known regarding Rac1 and Cdc42 expression in ovarian cancer. We
demonstrated elevated expression of Rac1 and Cdc42 in human ovarian cancer
specimens and high activity of these GTPases in freshly isolated tumor cells from
ascites obtained at surgery (Figure 30 and 34). In a recent study, high Rac1
protein expression in ovarian cancer was associated with early recurrence and
poor prognosis (77). Furthermore, partial silencing of Rac1 by shRNA decreased
tumor cell proliferation, migration and invasion in culture, and decreased growth
of subcutaneous ovarian cancer xenografts in vivo (77). We find that R-ketorolac
inhibits adhesion and invasion of primary human ovarian tumor cells from patient
ascites (183) thereby indicating that pharmacologic inhibition of Rac1 and Cdc42
also blocks these tumor-relevant functions. These observations in conjunction
with inhibition of ovarian tumor cell migration by a Cdc42-specific inhibitor (180)
indicate the potential value of targeting Rac1 and Cdc42 in ovarian cancer.
The present chapter presents evidence that Rac1 and Cdc42 inhibition
can be achieved in ovarian cancer patients following administration of racemic
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ketorolac (Toradol®). Ketorolac is a 1:1 racemic mix of the R- and S-enantiomers.
The S-form inhibits COX enzymes which confers the drug’s anti-inflammatory
activities. The COX inhibitory action of S-ketorolac supports its indication for
postoperative pain management, but also limits its long term use due to COXrelated toxicity (122, 167, 185). R-ketorolac has little activity against COX (122,
167, 185) and therefore is not functional as an NSAID, but is bioactive and
inhibits Rac1 and Cdc42 (183). Importantly, the levels of R-ketorolac within the
peritoneal fluids were sufficient to inhibit Rac1 and Cdc42 activity in cells
obtained from the peritoneal cavity following ketorolac administration. The
innovative Phase 0 clinical trial design enabled real-time sampling of fluids and
cells from the peritoneal cavity. Direct demonstration of the difference in racemic
distribution of ketorolac enantiomers illustrates the value of a study design that
allows direct testing of drug and cell activities within peritoneal fluids rather than
extrapolation from serum drug levels.
Furthermore, the peritoneal bioactivity of ketorolac is shown to have
benefit for ovarian cancer patient outcomes. Perioperative use of ketorolac was
found to reduce ovarian cancer specific mortality (Figure 36). There is
precedence in the literature that ketorolac usage in the perioperative period is
associated with improved cancer outcomes. The first observation was made for
breast cancer patients in 2010 (169). In this study, ketorolac use was associated
with a decreased risk of breast cancer relapse (HR=0.37, 95%CI=0.0-0.79).
Follow-up papers noted that this relapse reduction was most pronounced in the
first 24 months post-surgery (53, 184). No change in breast cancer recurrence
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was noted in patients who received sufentanil, clonidine, ketamine, or other
intraoperative analgesics. Lung cancer patients receiving ketorolac displayed
improved overall survival as well (190). The authors hypothesize that the benefit
is due to the anti-inflammatory actions of ketorolac, particularly on the
extravasation of circulating tumor cells in the transient inflammatory environment
stimulated by surgery (172). Ketorolac appears to have more pronounced
positive outcomes than other NSAIDs (172), and this may be based on the
combined impact of anti-inflammatory activity by the S-enantiomer and Renantiomer effects on Rac1 and Cdc42 leading to decreased adhesion and
implantation of circulating or residual tumor cells. Ketorolac is not cytotoxic to
ovarian tumor cells (183), but predicted decreases in establishment or further
development of micrometastases due to Rac1 and Cdc42 inhibition would be
expected to improve response to subsequent chemotherapy, which cannot be
initiated until patients have recovered from cytoreductive surgery. Therefore,
administration of ketorolac during a key therapeutic window may offer a
particularly efficacious benefit against later relapse.
Collectively, the findings support the potential repositioning of ketorolac as
an addition to current ovarian cancer therapy. The work demonstrates that the Renantiomer of ketorolac acts as a first-in-class drug for inhibition of the cancerrelevant targets Rac1 and Cdc42 (182, 183) and provides the first evidence that
these therapeutic targets can be inhibited in humans using an approved drug.
There is precedence for pharmacologic activities dictated by R-enantiomers of
specific NSAIDs against novel (non-COX) targets (191-193). For example, R148

etodolac and its analogs SDX-301 and SDX-308 display antitumor activity in
chronic lymphocytic leukemia and activity against multiple myeloma in cell and
animal models (192, 194-197). R-etodolac also significantly suppressed tumors
in a colitis-related mouse model colon cancer (191) and retarded tumor
development and metastasis in a transgenic mouse model of prostate cancer
(193). These examples and others demonstrate that R-enantiomers of NSAIDs
can possess unanticipated anticancer activities based on interactions with nonCOX targets. Further evidence that targeting Rac1 may provide therapeutic
benefit in ovarian cancer was recently reported (198). Zoledronic acid is a
nitrogen containing bisphosphonate that inhibits prenylation of small GTPases.
Administration of this drug decreased growth of ovarian cancer peritoneal
xenografts through inhibition of angiogenesis driven by a Rac1-mediated
pathway (198). Collectively, the results suggest that racemic ketorolac may
provide a survival benefit to ovarian cancer patients through inhibition of COX
enzymes by the S-enantiomer and inhibition of the small GTPases Rac1 and
Cdc42 by the R-enantiomer. Additional studies to determine whether clinical
benefit can be observed in ovarian cancer patients through perioperative
administration of ketorolac in a placebo-controlled clinical trial are in process.
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CHAPTER 5
FUTURE PERSPECTIVES
In this thesis work, R-ketorolac is established as a potential anti-tumor drug
with previously unrecognized pharmacological property. R-ketorolac is identified
as an allosteric inhibitor of Cdc42 and Rac1 using an in vitro nucleotide binding
assay. To validate the anti-tumor impact of R-ketorolac, a human patient
immortalized ovarian cancer cell line (SKOV3ip) and primary ascites-derived
ovarian cancer cells were used to demonstrate that R-ketorolac inhibits the
activation of Cdc42 and Rac1 and their downstream PAK signaling axis. As a
consequence of the inhibition there is a reduction in ovarian cancer cell adhesion,
migration and invasion. In a phase 0 clinical trial, R-ketorolac is found to achieve
an effective concentration and persistence in peritoneal fluids for 24 hours. Rac1
and Cdc42 activities in cells retrieved from the peritoneal compartment of postsurgical ovarian cancer patients were substantially reduced in a time-dependent
manner following a single IV ketorolac dose for post-operative pain management.
A medical record review to compare the ovarian cancer-specific survival of
ovarian cancer patients who did or did not receive ketorolac revealed an
improved survival with perioperative use of ketorolac. We speculate that
ketorolac benefits ovarian cancer patient outcomes through targeted inhibition of
Cdc42 and Rac1 GTPases, which in turn decreases adhesion and implantation
of circulating or residual tumor cells and/or tumor stem cells.
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Docking studies predict R-ketorolac inhibits Cdc42 and Rac1 GTPase
activity by excluding magnesium, which is induced by the carboxyl moiety at the
chiral center. Follow-on SAR studies support the docking in that trifluoromethyl
and 2-thiophene alter ketorolac activity possibly through impact on the carboxyl
group at the chiral center. Derivatives modified by trifluoromethyl on the phenyl
ring or substitution of the phenyl ring with the heterocyclic, aromatic 3-thiophene
selectively switched the activity of ketorolac from inhibition to activation on
GTPase activity with increased potencies, indicating that an aromatic ring may
increase lipophilic binding to the GTPases, while still accommodating bound
nucleotide. To further elucidate the mechanism, SAR analysis will need to be
extended by making additional variants of these promising parent compounds.
The 3-thiophene is of particular interest because of a potential for increased
Rac1 selectivity. The modified analogs with enhanced activity would provide
guidance to develop more effective inhibitors. On the other hand, to further verify
the magnesium exclusion mechanism of R-ketorolac inhibition against Cdc42
and Rac1, nucleotide binding assays should be performed on GTPase mutants
targeting putative amino acid contact points with the docked compound. For
example, the methyl group of alanine 59 within Cdc42 or equivalent in Rac1 has
been shown to impinge upon magnesium binding within the GEF-GTPase
complexes. Introduction of A59G point mutant, which significantly cripples GEF
binding and exchange, should be constructed as one way to validate if
magnesium exclusion is essential for R-ketorolac activity (199, 200).
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Malignant ascites is the accumulation of peritoneal fluid, and is frequently
found in high-grade ovarian cancer patients. Ascites is composed of soluble
factors such as growth factors, cytokines, and cellular components such as tumor
cells, associated stromal cells (mesothelial and fibroblast cells) and inflammatory
cells, which provide a pro-inflammatory and tumor-promoting microenvironment
(21, 23, 201). Tumor cells in ovarian cancer ascites trigger disease recurrence
(202). In the current study, ascites-derived tumor cells are used for the cell-based
studies. Compared to immortalized tumor cells, the use of ascites-derived tumor
cells represents a more experimentally accurate model to evaluate the impact of
ketorolac on ovarian tumor growth and metastasis (18, 21, 23, 201-204). For the
initial analyses, the cell adhesion, migration and invasion assays were performed
in a 2-D environment, which lack the architectural and cellular complexity of
tumors in vivo. To mimic the in vivo human microenvironment, further study will
require testing the impact of ketorolac on ovarian tumor adhesion and invasion in
a three-dimensional (3-D) organotypic system or using omental explants (205);
the omentum is a preferred seeding site for ovarian tumor metastases in vivo
(206). In the 3-D organotypic model, primary human ovarian tumor cells or
immortalized tumor cell lines are cultured with primary human mesothelial cells
isolated from patient omentum, primary human fibroblast and patient-derived
ECM which mimic the superficial layer of the peritoneum (204, 207). This ex vivo
model or omental explants could help establish structural and functional
environment of the ovarian tumor tissue for tumor metastasis including adhesion,
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migration and invasion, which will provide a more accurate system for drug
screening (204, 208).
The retrospective study shows racemic ketorolac has pronounced benefits
on patient survival outcomes. The findings that R-ketorolac targets Rac1 and
Cdc42, but not RhoA and reduces cell adhesion, migration and invasion of tumor
cells suggests that the drug may reduce relapse by making the remaining tumor
cells more vulnerable to chemotherapy post-debulking surgery. Accumulating
evidence show that cancer stem cells are enriched after first-line chemotherapy
for advanced stage ovarian cancer patients, leading to tumor relapse with
chemoresistance. The cancer stem cell model could also explain the
heterogeneity of phenotypic and functional features in epithelial ovarian cancer,
contributing

to

the

poor

diagnosis

and

prognosis

(209,

210).

Rac1

overexpression is also implicated in quiescence, stemness and cancer cell
adhesion to the bone marrow niche (211-213). Therefore, it is also conceivable
that through an impact on cancer stem cell Rac1 activity R-ketorolac could
increase cell cycling and reduce sequestration of tumor cells or cancer stem cells
in a protected niche. Both mechanisms would increase chemotherapy sensitivity
and account for the observed improved survival. Thus, targeting of cancer stem
cells by ketorolac to suppress proliferation and metastasis would be another
explanation for the observed benefits. Further studies of niche adhesion and
quiescence in preclinical animal models are needed to evaluate ovarian tumor
cell homing to the bone marrow or peritoneal niches. Immortalized ovarian cell
lines have been reported to be heterogeneous with highest fractions of stem-like
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cells detected in the most aggressive lines (214). NSAIDs have been reported to
suppress stem cells proliferation, metastasis and differentiation through a COXdependent (e.g. PGE2 – NF - κB) or a COX - independent manner (e.g. cell cycle
regulators) (215-217). Future work will require investigation of the impact of
ketorolac on the proliferation, differentiation and metastasis of ovarian cancer
stem cells by using patient-derived ovarian tumor stem cells (e.g. CD133 positive
selection) (218, 219). Identifying molecular targets of ketorolac in cancer stem
cells and developing ketorolac as an adjuvant anti-tumor therapy could
potentially increase tumor sensitivity to chemotherapy, reduce recurrence, and
improve ovarian cancer patient outcomes (209, 210).
There are other possibilities for the reduced mortality observed in
retrospective analyses of patients receiving post-operative ketorolac as
compared to patients who had surgery only or received opiod pain relievers. For
example, surgery induced inflammation is known to increase stimulation and
proliferation of residual tumor cells. S-ketorolac present in the racemic clinical
drug is a powerful anti-inflammatory and has been suggested to provide benefit
in breast cancer patients on account of this anti-inflammatory activity (53, 220).
However, a purely anti-inflammatory role mediated by COX inhibition by Sketorolac has been challenged (221). It is also inconsistent with the specificity of
ketorolac in reducing tumor relapse in ovarian cancer as demonstrated here, and
also reported while the studies were in progress in breast, kidney and other
cancers (190, 220). Addressing this question will require further testing in
preclinical animal models, e.g. surgery +/- drug administration +/- tumor cells.
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To more directly compare if the inhibition of GTPase activity is purely drugmediated or due to other changes in the post-operative peritoneal cavity, a
prospective clinical trial is needed in which patients will be given placebo after
surgery and their primary tumor cells will be processed for GTPase activity
assays and related measures of GTPase activation. A small placebo trial will
further confirm that the observed inhibition of GTPase activity is dependent on
ketorolac administration. Through longer term tracking of patients in the trial,
GTPase inhibition can be evaluated as a surrogate for time to relapse,
progression free survival, and overall survival. Only through continued systematic
study can the therapeutic benefits of patient outcomes be specifically attributed
to ketorolac administered during perioperative period.
Overall, future studies will focus on 1) identifying critical determinants for
Rho GTPase inhibition and developing more effective and selective Cdc42/Rac1
inhibitors; 2) establishing 3-D organotypic models for testing GTPase inhibitors
alone or in combination; 3) investigating the impact of ketorolac on stem cells in
ovarian cancer and other epithelial cancers; 4) conducting a placebo-controlled
clinical trial to confirm the clinical benefit of ketorolac. These studies will offer a
rapid translational and clinical study to repurpose FDA-approved drug-ketorolac
as an anti-tumor drug for ovarian cancer therapy.
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APPENDICES

Appendix A.

Time lapse imaging of HPY (490) labeled fluorescent

compound RS-II-79 penetration into MCA. In the experiment, 2000
multicellular aggregates (SKOV3ip cells) were incubated with 10 µM RS-II-79.
The images were captured at 9, 22, 40, 42, 54 and 66 min by Zeiss Axiovert 200
M inverted confocal microscope. Images provided courtesy of Dr. M. Steinkamp
(Department of Pathology, University of New Mexico).
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Appendix B. Patient Characteristics for IHC Microarrays OV1005 and
OV8010

Age#
Stage I#

Stage II#

Stage III#

46.6 +/- 13.7 (std. dev)
12
A
5
B
5
C
4
21
A
13
B
6
C
3
1
C
31
11
51
20
25
13

Stage IV#
Stage undetermined#
Normal stroma
Benign/borderline
Grade - Low* (1#)
Grade - Intermediate* (1-2,
2#)
7
#
Grade - High* (2, 2-3, 3 )
98
*Diagnoses by board certified pathologist with gynecologic pathology
specialization were as follows: Clear cell carcinoma (4); endometrioid
carcinoma (13); endometrioid neoplasm (5); mucinous carcinoma (4);
mucinous neoplasm (9); mucinous cystadenoma (5); normal stroma
only-no epithelia (20); papillary serous carcinoma (78); serous
neoplasm (5); serous cystadenoma (4); undifferentiated carcinoma
(16). There was 77% agreement with #BioMax specification sheet,
differences were confined to ID of rarer subtypes (endometrioid, clear
cell, mucinous, transitional and serous). Samples included in analysis:
163 of 180 total (9% were excluded due to poor staining at edge of
slide or no neoplasm in the section).
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Appendix C. Patient Characteristics for cDNA Microarray
Age

57.26 -/+ 14.85 (st. dev)

Stage I

A

20

B

8

C

10

A

4

B

9

C

4

A

15

B

17

C

26

A

10

Stage II

Stage III

Stage IV
Grade Not Reported

10

Grade I

9

Grade II

32

Grade III

60

Grade IV

9

Diagnoses were as follows: Carcinoma of Ovary (2); Carcinoma of ovary, endometrioid
(6); Carcinoma of ovary, papillary serous (8);
Carcinoma of ovary, clear cell (1); Adenocarcinoma of ovary, endometrioid (23);
Adenocarcinoma of ovary, papillary serous (32); Adenocarcinoma of ovary, serous (28);
Adenocarcinoma of ovary, metastatic (2); Adenocarcinoma of ovary, mucinous (4);
Adenocarcinoma of ovary, clear cell (5); Tumor of ovary, borderline (2); Tumor of ovary,
papillary serous, borderline (2); Tumor of ovary, serous, borderline (5)
These microarray plates consisted of 19 normal, 9 Grade I, 32 Grade II, 60 Grade III, 9
Grade IV, and 10 grade not reported patients. Patients with grade not reported were not
included in grade analysis.
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Appendix D. Survival estimates based on Cox-regression for Stage I (AJCC)
with completion of chemotherapy. Cox proportional hazards regression was
used to estimate ovarian cancer specific survival probabilities for women who did
(dashed line) and did not (solid line) receive ketorolac among ovarian cancer
cases with AJCC Stage I cancer, sorted by age group and -/+ neoadjuvant
chemotherapy. Data provided courtesy of Dr. L. Cook (Division of Epidemiology,
Biostatistics and Preventive Medicine, Department of Internal Medicine,
University of New Mexico School of Medicine).
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Appendix E.

Survival estimates based on Cox-regression for Stage II

(AJCC) with completion of chemotherapy. Cox proportional hazards
regression was used to estimate ovarian cancer specific survival probabilities for
women who did (dashed line) and did not (solid line) receive ketorolac among
ovarian cancer cases with AJCC Stage II cancer, sorted by age group and -/+
neoadjuvant chemotherapy. Data provided courtesy of Dr. L. Cook (Division of
Epidemiology, Biostatistics and Preventive Medicine, Department of Internal
Medicine, University of New Mexico School of Medicine).
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Appendix F. Survival estimates based on Cox-regression for Stage III
(AJCC) with completion of chemotherapy. Cox proportional hazards
regression was used to estimate ovarian cancer specific survival probabilities for
women who did (dashed line) and did not (solid line) receive ketorolac among
ovarian cancer cases with AJCC Stage III cancer, sorted by age group and -/+
neoadjuvant chemotherapy. Data provided courtesy of Dr. L. Cook (Division of
Epidemiology, Biostatistics and Preventive Medicine, Department of Internal
Medicine, University of New Mexico School of Medicine).
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Appendix G. Survival estimates based on Cox-regression for Stage IV
(AJCC) with completion of chemotherapy. Cox proportional hazards
regression was used to estimate ovarian cancer specific survival probabilities for
women who did (dashed line) and did not (solid line) receive ketorolac among
ovarian cancer cases with AJCC Stage IV cancer, sorted by age group and -/+
neoadjuvant chemotherapy. Data provided courtesy of Dr. L. Cook (Division of
Epidemiology, Biostatistics and Preventive Medicine, Department of Internal
Medicine, University of New Mexico School of Medicine).
162

REFERENCES
1.
Howlader N NA, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL,
Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Chronin
KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute
http://seer.cancer.gov/csr/1975-2011/Dec. 2014.
2.
Soslow RA. Histologic subtypes of ovarian carcinoma: an overview.
International journal of gynecological pathology : official journal of the
International Society of Gynecological Pathologists. 2008 Apr;27(2):161-74.
PubMed PMID: 18317227.
3.
Bell DA. Origins and molecular pathology of ovarian cancer. Modern
pathology : an official journal of the United States and Canadian Academy of
Pathology, Inc. 2005 Feb;18 Suppl 2:S19-32. PubMed PMID: 15761464.
4.
Erickson BK, Conner MG, Landen CN, Jr. The role of the fallopian tube in
the origin of ovarian cancer. American journal of obstetrics and gynecology. 2013
Nov;209(5):409-14. PubMed PMID: 23583217. Pubmed Central PMCID:
3937451.
5.
Dietl J. Revisiting the pathogenesis of ovarian cancer: the central role of
the fallopian tube. Archives of gynecology and obstetrics. 2014 Feb;289(2):241-6.
PubMed PMID: 24100801.
6.
Vaughan S, Coward JI, Bast RC, Jr., Berchuck A, Berek JS, Brenton JD,
Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H,
Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB,
Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill
FR. Rethinking ovarian cancer: recommendations for improving outcomes.
Nature reviews Cancer. 2011 Oct;11(10):719-25. PubMed PMID: 21941283.
Pubmed Central PMCID: 3380637.
7.
Nezhat FR, Apostol R, Nezhat C, Pejovic T. New insights in the
pathophysiology of ovarian cancer and implications for screening and prevention.
American journal of obstetrics and gynecology. 2015 Mar 25. PubMed PMID:
25818671.
8.
Berns EM, Bowtell DD. The changing view of high-grade serous ovarian
cancer. Cancer research. 2012 Jun 1;72(11):2701-4. PubMed PMID: 22593197.
9.
Zhang Y, Guo B, Bi R. Ovarian cancer: biomarker proteomic diagnosis in
progress. Applied biochemistry and biotechnology. 2012 Oct;168(4):910-6.
PubMed PMID: 22945560.
10.
Davidson B, Trope CG. Ovarian cancer: diagnostic, biological and
prognostic aspects. Women's health. 2014 Sep;10(5):519-33. PubMed PMID:
25335543.
163

11.
Blagden SP. Harnessing Pandemonium: The Clinical Implications of
Tumor Heterogeneity in Ovarian Cancer. Frontiers in oncology. 2015;5:149.
PubMed PMID: 26175968. Pubmed Central PMCID: 4485078.
12.
Luvero D, Milani A, Ledermann JA. Treatment options in recurrent ovarian
cancer: latest evidence and clinical potential. Therapeutic advances in medical
oncology. 2014 Sep;6(5):229-39. PubMed PMID: 25342990. Pubmed Central
PMCID: 4206613.
13.
Hall M, Rustin G. Recurrent ovarian cancer: when and how to treat.
Current oncology reports. 2011 Dec;13(6):459-71. PubMed PMID: 22045509.
14.
McGuire WP. Maintenance therapy for ovarian cancer: of Helsinki and
Hippocrates. Journal of clinical oncology : official journal of the American Society
of Clinical Oncology. 2009 Oct 1;27(28):4633-4. PubMed PMID: 19704055.
15.
Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, Nur U,
Tracey E, Coory M, Hatcher J, McGahan CE, Turner D, Marrett L, Gjerstorff ML,
Johannesen TB, Adolfsson J, Lambe M, Lawrence G, Meechan D, Morris EJ,
Middleton R, Steward J, Richards MA, Group IMW. Cancer survival in Australia,
Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International
Cancer Benchmarking Partnership): an analysis of population-based cancer
registry data. Lancet. 2011 Jan 8;377(9760):127-38. PubMed PMID: 21183212.
Pubmed Central PMCID: 3018568.
16.
Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer.
Lancet. 2014 Apr 17. PubMed PMID: 24767708.
17.
Coleman RL, Monk BJ, Sood AK, Herzog TJ. Latest research and
treatment of advanced-stage epithelial ovarian cancer. Nature reviews Clinical
oncology. 2013 Apr;10(4):211-24. PubMed PMID: 23381004. Pubmed Central
PMCID: 3786558.
18.
Ahmed N, Stenvers KL. Getting to Know Ovarian Cancer Ascites:
Opportunities for Targeted Therapy-Based Translational Research. Frontiers in
oncology. 2013;3:256. PubMed PMID: 24093089. Pubmed Central PMCID:
3782691.
19.
Hudson LG, Zeineldin R, Stack MS. Phenotypic plasticity of neoplastic
ovarian epithelium: unique cadherin profiles in tumor progression. Clinical &
experimental metastasis. 2008;25(6):643-55. PubMed PMID: 18398687. Pubmed
Central PMCID: 2836537.
20.
Shield K, Ackland ML, Ahmed N, Rice GE. Multicellular spheroids in
ovarian cancer metastases: Biology and pathology. Gynecologic oncology. 2009
Apr;113(1):143-8. PubMed PMID: 19135710.

164

21.
Thibault B, Castells M, Delord JP, Couderc B. Ovarian cancer
microenvironment: implications for cancer dissemination and chemoresistance
acquisition. Cancer metastasis reviews. 2014 Mar;33(1):17-39. PubMed PMID:
24357056.
22.
Naora H. Heterotypic cellular interactions in the ovarian tumor
microenvironment: biological significance and therapeutic implications. Frontiers
in oncology. 2014;4:18. PubMed PMID: 24567915. Pubmed Central PMCID:
3915179.
23.
Davidson B, Trope CG, Reich R. The role of the tumor stroma in ovarian
cancer. Frontiers in oncology. 2014;4:104. PubMed PMID: 24860785. Pubmed
Central PMCID: 4026708.
24.
Mutsaers SE. The mesothelial cell. The international journal of
biochemistry & cell biology. 2004 Jan;36(1):9-16. PubMed PMID: 14592528.
25.
Mutsaers SE, Wilkosz S. Structure and function of mesothelial cells.
Cancer treatment and research. 2007;134:1-19. PubMed PMID: 17633044.
26.
Zeillemaker AM, Verbrugh HA, Hoynck van Papendrecht AA, Leguit P. CA
125 secretion by peritoneal mesothelial cells. Journal of clinical pathology. 1994
Mar;47(3):263-5. PubMed PMID: 8163699. Pubmed Central PMCID: 501908.
27.
Ween MP, Oehler MK, Ricciardelli C. Role of versican, hyaluronan and
CD44 in ovarian cancer metastasis. International journal of molecular sciences.
2011;12(2):1009-29. PubMed PMID: 21541039. Pubmed Central PMCID:
3083686.
28.
Moreno-Bueno G, Peinado H, Molina P, Olmeda D, Cubillo E, Santos V,
Palacios J, Portillo F, Cano A. The morphological and molecular features of the
epithelial-to-mesenchymal transition. Nature protocols. 2009;4(11):1591-613.
PubMed PMID: 19834475.
29.
Carduner L, Leroy-Dudal J, Picot CR, Gallet O, Carreiras F, Kellouche S.
Ascites-induced shift along epithelial-mesenchymal spectrum in ovarian cancer
cells: enhancement of their invasive behavior partly dependant on alphav
integrins. Clinical & experimental metastasis. 2014 Aug;31(6):675-88. PubMed
PMID: 24946950.
30.
Shaw D, Clamp A, Jayson GC. Angiogenesis as a target for the treatment
of ovarian cancer. Current opinion in oncology. 2013 Sep;25(5):558-65. PubMed
PMID: 23942301.
31.
Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt
MR, Romero IL, Carey MS, Mills GB, Hotamisligil GS, Yamada SD, Peter ME,
Gwin K, Lengyel E. Adipocytes promote ovarian cancer metastasis and provide
165

energy for rapid tumor growth. Nature medicine. 2011;17(11):1498-503. PubMed
PMID: 22037646. Pubmed Central PMCID: 4157349.
32.
Chen C, Chang YC, Lan MS, Breslin M. Leptin stimulates ovarian cancer
cell growth and inhibits apoptosis by increasing cyclin D1 and Mcl-1 expression
via the activation of the MEK/ERK1/2 and PI3K/Akt signaling pathways.
International journal of oncology. 2013 Mar;42(3):1113-9. PubMed PMID:
23354006.
33.
Yigit R, Massuger LF, Figdor CG, Torensma R. Ovarian cancer creates a
suppressive microenvironment to escape immune elimination. Gynecologic
oncology. 2010 May;117(2):366-72. PubMed PMID: 20144842.
34.
Preston CC, Goode EL, Hartmann LC, Kalli KR, Knutson KL. Immunity
and immune suppression in human ovarian cancer. Immunotherapy. 2011
Apr;3(4):539-56. PubMed PMID: 21463194. Pubmed Central PMCID: 3147144.
35.
Ko SY, Barengo N, Ladanyi A, Lee JS, Marini F, Lengyel E, Naora H.
HOXA9 promotes ovarian cancer growth by stimulating cancer-associated
fibroblasts. The Journal of clinical investigation. 2012 Oct;122(10):3603-17.
PubMed PMID: 22945634. Pubmed Central PMCID: 3461910.
36.
Raja FA, Chopra N, Ledermann JA. Optimal first-line treatment in ovarian
cancer. Annals of oncology : official journal of the European Society for Medical
Oncology / ESMO. 2012 Sep;23 Suppl 10:x118-27. PubMed PMID: 22987945.
37.
Ramirez I, Chon HS, Apte SM. The role of surgery in the management of
epithelial ovarian cancer. Cancer control : journal of the Moffitt Cancer Center.
2011 Jan;18(1):22-30. PubMed PMID: 21273977.
38.
Wakabayashi MT, Lin PS, Hakim AA. The role of cytoreductive/debulking
surgery in ovarian cancer. Journal of the National Comprehensive Cancer
Network : JNCCN. 2008 Sep;6(8):803-10; quiz 11. PubMed PMID: 18926091.
39. Schwartz PE. Cytoreductive surgery in the management of ovarian cancer.
Oncology. 2008 Aug;22(9):1025-33; discussion 33-8, 41, 45. PubMed PMID:
18777954.
40.
Markman M. Current standards of care for chemotherapy of optimally
cytoreduced advanced epithelial ovarian cancer. Gynecologic oncology. 2013
Oct;131(1):241-5. PubMed PMID: 23726888.
41.
Grosso G, Rossetti D, Coccolini F, Bogani G, Ansaloni L, Frigerio L.
Intraperitoneal chemotherapy in advanced epithelial ovarian cancer: a survey.
Archives of gynecology and obstetrics. 2014 Sep;290(3):425-34. PubMed PMID:
24845970.

166

42.
Dedrick RL, Flessner MF. Pharmacokinetic problems in peritoneal drug
administration: tissue penetration and surface exposure. Journal of the National
Cancer Institute. 1997 Apr 2;89(7):480-7. PubMed PMID: 9086004.
43.
Horowitz M, Neeman E, Sharon E, Ben-Eliyahu S. Exploiting the critical
perioperative period to improve long-term cancer outcomes. Nature reviews
Clinical oncology. 2015 Apr;12(4):213-26. PubMed PMID: 25601442.
44.
Pradeep S, Kim SW, Wu SY, Nishimura M, Chaluvally-Raghavan P,
Miyake T, Pecot CV, Kim SJ, Choi HJ, Bischoff FZ, Mayer JA, Huang L, Nick AM,
Hall CS, Rodriguez-Aguayo C, Zand B, Dalton HJ, Arumugam T, Lee HJ, Han
HD, Cho MS, Rupaimoole R, Mangala LS, Sehgal V, Oh SC, Liu J, Lee JS,
Coleman RL, Ram P, Lopez-Berestein G, Fidler IJ, Sood AK. Hematogenous
metastasis of ovarian cancer: rethinking mode of spread. Cancer cell. 2014 Jul
14;26(1):77-91. PubMed PMID: 25026212. Pubmed Central PMCID: 4100212.
45.
Romero-Laorden N, Olmos D, Fehm T, Garcia-Donas J, Diaz-Padilla I.
Circulating and disseminated tumor cells in ovarian cancer: a systematic review.
Gynecologic oncology. 2014 Jun;133(3):632-9. PubMed PMID: 24657303.
46.
Fisher B, Gunduz N, Coyle J, Rudock C, Saffer E. Presence of a growthstimulating factor in serum following primary tumor removal in mice. Cancer
research. 1989 Apr 15;49(8):1996-2001. PubMed PMID: 2702641.
47.
O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E,
Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of
angiogenesis and tumor growth. Cell. 1997 Jan 24;88(2):277-85. PubMed PMID:
9008168.
48.
Abramovitch R, Marikovsky M, Meir G, Neeman M. Stimulation of tumour
growth by wound-derived growth factors. British journal of cancer. 1999
Mar;79(9-10):1392-8. PubMed PMID: 10188881. Pubmed Central PMCID:
2362730.
49.
Gullino PM. Prostaglandins and gangliosides of tumor microenvironment:
their role in angiogenesis. Acta oncologica. 1995;34(3):439-41. PubMed PMID:
7540024.
50.
Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of
immunosuppressive networks during malignant progression. Cancer research.
2006 Jun 1;66(11):5527-36. PubMed PMID: 16740684.
51.
Liu MX, Chan DW, Ngan HY. Mechanisms of chemoresistance in human
ovarian cancer at a glance. Gynecologic oncology. 2012;2(3):1000e104.
52.
Steg AD, Katre AA, Bevis KS, Ziebarth A, Dobbin ZC, Shah MM, Alvarez
RD, Landen CN. Smoothened antagonists reverse taxane resistance in ovarian
167

cancer. Molecular cancer therapeutics. 2012 Jul;11(7):1587-97. PubMed PMID:
22553355. Pubmed Central PMCID: 3392529.
53.
Retsky M, Rogers R, Demicheli R, Hrushesky WJ, Gukas I, Vaidya JS,
Baum M, Forget P, Dekock M, Pachmann K. NSAID analgesic ketorolac used
perioperatively may suppress early breast cancer relapse: particular relevance to
triple negative subgroup. Breast cancer research and treatment. 2012
Jul;134(2):881-8. PubMed PMID: 22622810.
54.
Hall A. Rho family GTPases. Biochemical Society transactions. 2012 Dec
1;40(6):1378-82. PubMed PMID: 23176484.
55.
Madaule P, Axel R. A novel ras-related gene family. Cell. 1985
May;41(1):31-40. PubMed PMID: 3888408.
56.
Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. Annual review
of cell and developmental biology. 2005;21:247-69. PubMed PMID: 16212495.
57.
Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature. 2002
Dec 12;420(6916):629-35. PubMed PMID: 12478284.
58.
Cherfils J, Zeghouf M. Regulation of small GTPases by GEFs, GAPs, and
GDIs. Physiological reviews. 2013 Jan;93(1):269-309. PubMed PMID: 23303910.
59.
Whitehead IP, Zohn IE, Der CJ. Rho GTPase-dependent transformation
by G protein-coupled receptors. Oncogene. 2001 Mar 26;20(13):1547-55.
PubMed PMID: 11313901.
60. Huveneers S, Danen EH. Adhesion signaling - crosstalk between integrins,
Src and Rho. Journal of cell science. 2009 Apr 15;122(Pt 8):1059-69. PubMed
PMID: 19339545.
61.
Buchsbaum RJ. Rho activation at a glance. Journal of cell science. 2007
Apr 1;120(Pt 7):1149-52. PubMed PMID: 17376960.
62.
Hanna S, El-Sibai M. Signaling networks of Rho GTPases in cell motility.
Cellular signalling. 2013 Oct;25(10):1955-61. PubMed PMID: 23669310.
63.
Eswaran J, Soundararajan M, Knapp S. Targeting group II PAKs in cancer
and metastasis. Cancer metastasis reviews. 2009 Jun;28(1-2):209-17. PubMed
PMID: 19160016.
64.
Knaus UG, Bokoch GM. The p21Rac/Cdc42-activated kinases (PAKs).
The international journal of biochemistry & cell biology. 1998 Aug;30(8):857-62.
PubMed PMID: 9744077.

168

65.
Kurisu S, Takenawa T. The WASP and WAVE family proteins. Genome
biology. 2009;10(6):226. PubMed PMID: 19589182. Pubmed Central PMCID:
2718491.
66.
Casteel DE, Turner S, Schwappacher R, Rangaswami H, Su-Yuo J,
Zhuang S, Boss GR, Pilz RB. Rho isoform-specific interaction with IQGAP1
promotes breast cancer cell proliferation and migration. The Journal of biological
chemistry. 2012 Nov 2;287(45):38367-78. PubMed PMID: 22992742. Pubmed
Central PMCID: 3488105.
67. Wang XY, Gan MX, Li Y, Zhan WH, Han TY, Han XJ, Cheng JQ, Wang JB.
Cdc42 induces EGF receptor protein accumulation and promotes EGF receptor
nuclear transport and cellular transformation. FEBS letters. 2015 Jan
16;589(2):255-62. PubMed PMID: 25497016.
68.
Karlsson R, Pedersen ED, Wang Z, Brakebusch C. Rho GTPase function
in tumorigenesis. Biochimica et biophysica acta. 2009 Dec;1796(2):91-8.
PubMed PMID: 19327386.
69.
Arias-Romero LE, Villamar-Cruz O, Huang M, Hoeflich KP, Chernoff J.
Pak1 kinase links ErbB2 to beta-catenin in transformation of breast epithelial
cells. Cancer research. 2013 Jun 15;73(12):3671-82. PubMed PMID: 23576562.
Pubmed Central PMCID: 3687032.
70.
Gao L, Bai L, Nan Q. Activation of Rho GTPase Cdc42 promotes
adhesion and invasion in colorectal cancer cells. Medical science monitor basic
research. 2013;19:201-7. PubMed PMID: 23884297. Pubmed Central PMCID:
3735386.
71.
Wertheimer E, Gutierrez-Uzquiza A, Rosemblit C, Lopez-Haber C, Sosa
MS, Kazanietz MG. Rac signaling in breast cancer: a tale of GEFs and GAPs.
Cellular signalling. 2012 Feb;24(2):353-62. PubMed PMID: 21893191. Pubmed
Central PMCID: 3312797.
72.
Ebi H, Costa C, Faber AC, Nishtala M, Kotani H, Juric D, Della Pelle P,
Song Y, Yano S, Mino-Kenudson M, Benes CH, Engelman JA. PI3K regulates
MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1. Proceedings of
the National Academy of Sciences of the United States of America. 2013 Dec
24;110(52):21124-9. PubMed PMID: 24327733. Pubmed Central PMCID:
3876254.
73.
Ma J, Xue Y, Liu W, Yue C, Bi F, Xu J, Zhang J, Li Y, Zhong C, Chen Y.
Role of activated rac1/cdc42 in mediating endothelial cell proliferation and tumor
angiogenesis in breast cancer. PloS one. 2013;8(6):e66275. PubMed PMID:
23750283. Pubmed Central PMCID: 3672132.
74.
Friedland JC, Lakins JN, Kazanietz MG, Chernoff J, Boettiger D, Weaver
VM. alpha6beta4 integrin activates Rac-dependent p21-activated kinase 1 to
169

drive NF-kappaB-dependent resistance to apoptosis in 3D mammary acini.
Journal of cell science. 2007 Oct 15;120(Pt 20):3700-12. PubMed PMID:
17911169.
75.
Olson MF, Ashworth A, Hall A. An essential role for Rho, Rac, and Cdc42
GTPases in cell cycle progression through G1. Science. 1995 Sep
1;269(5228):1270-2. PubMed PMID: 7652575.
76.
Yang W, Lv S, Liu X, Liu H, Yang W, Hu F. Up-regulation of Tiam1 and
Rac1 correlates with poor prognosis in hepatocellular carcinoma. Japanese
journal of clinical oncology. 2010 Nov;40(11):1053-9. PubMed PMID: 20522449.
77.
Leng R, Liao G, Wang H, Kuang J, Tang L. Rac1 expression in epithelial
ovarian cancer: effect on cell EMT and clinical outcome. Medical oncology. 2015
Feb;32(2):329. PubMed PMID: 25585684.
78.
Singh A, Karnoub AE, Palmby TR, Lengyel E, Sondek J, Der CJ. Rac1b, a
tumor associated, constitutively active Rac1 splice variant, promotes cellular
transformation. Oncogene. 2004 Dec 16;23(58):9369-80. PubMed PMID:
15516977.
79.
Fiegen D, Haeusler LC, Blumenstein L, Herbrand U, Dvorsky R, Vetter IR,
Ahmadian MR. Alternative splicing of Rac1 generates Rac1b, a self-activating
GTPase. The Journal of biological chemistry. 2004 Feb 6;279(6):4743-9.
PubMed PMID: 14625275.
80. Radisky DC, Levy DD, Littlepage LE, Liu H, Nelson CM, Fata JE, Leake D,
Godden EL, Albertson DG, Nieto MA, Werb Z, Bissell MJ. Rac1b and reactive
oxygen species mediate MMP-3-induced EMT and genomic instability. Nature.
2005 Jul 7;436(7047):123-7. PubMed PMID: 16001073. Pubmed Central PMCID:
2784913.
81.
Zhou C, Licciulli S, Avila JL, Cho M, Troutman S, Jiang P, Kossenkov AV,
Showe LC, Liu Q, Vachani A, Albelda SM, Kissil JL. The Rac1 splice form Rac1b
promotes K-ras-induced lung tumorigenesis. Oncogene. 2013 Feb 14;32(7):9039. PubMed PMID: 22430205. Pubmed Central PMCID: 3384754.
82.
Schnelzer A, Prechtel D, Knaus U, Dehne K, Gerhard M, Graeff H,
Harbeck N, Schmitt M, Lengyel E. Rac1 in human breast cancer: overexpression,
mutation analysis, and characterization of a new isoform, Rac1b. Oncogene.
2000 Jun 15;19(26):3013-20. PubMed PMID: 10871853.
83.
Henriques AF, Barros P, Moyer MP, Matos P, Jordan P. Expression of
tumor-related Rac1b antagonizes B-Raf-induced senescence in colorectal cells.
Cancer letters. 2015 Dec 28;369(2):368-75. PubMed PMID: 26341689.

170

84.
Jordan P, Brazao R, Boavida MG, Gespach C, Chastre E. Cloning of a
novel human Rac1b splice variant with increased expression in colorectal tumors.
Oncogene. 1999 Nov 18;18(48):6835-9. PubMed PMID: 10597294.
85.
Alonso-Espinaco V, Cuatrecasas M, Alonso V, Escudero P, Marmol M,
Horndler C, Ortego J, Gallego R, Codony-Servat J, Garcia-Albeniz X, Jares P,
Castells A, Lozano JJ, Rosell R, Maurel J. RAC1b overexpression correlates with
poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated
with first-line FOLFOX/XELOX chemotherapy. European journal of cancer. 2014
Jul;50(11):1973-81. PubMed PMID: 24833563.
86.
Guo Y, Kenney SR, Cook L, Adams S, Rutledge T, Romero E, Oprea TI,
Bedrick E, Wiggins CL, Kang H, Lomo L, Muller CY, Wandinger-Ness A, Hudson
LG. A novel pharmacologic activity of ketorolac for therapeutic benefit in ovarian
cancer patients. Clinical Cancer Research. under revision.
87.
Ridley AJ. Rho GTPase signalling in cell migration. Current opinion in cell
biology. 2015 Sep 10;36:103-12. PubMed PMID: 26363959.
88.
Huang M, Prendergast GC. RhoB in cancer suppression. Histology and
histopathology. 2006 Feb;21(2):213-8. PubMed PMID: 16329046.
89.
Zhu Y, Zhou J, Xia H, Chen X, Qiu M, Huang J, Liu S, Tang Q, Lang N,
Liu Z, Liu M, Zheng Y, Bi F. The Rho GTPase RhoE is a p53-regulated candidate
tumor suppressor in cancer cells. International journal of oncology. 2014
Mar;44(3):896-904. PubMed PMID: 24399089.
90.
Goggs R, Harper MT, Pope RJ, Savage JS, Williams CM, Mundell SJ,
Heesom KJ, Bass M, Mellor H, Poole AW. RhoG protein regulates platelet
granule secretion and thrombus formation in mice. The Journal of biological
chemistry. 2013 Nov 22;288(47):34217-29. PubMed PMID: 24106270. Pubmed
Central PMCID: 3837162.
91.
Leszczynska K, Kaur S, Wilson E, Bicknell R, Heath VL. The role of RhoJ
in endothelial cell biology and angiogenesis. Biochemical Society transactions.
2011 Dec;39(6):1606-11. PubMed PMID: 22103495.
92.
Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP,
Cheng E, Davis MJ, Goh G, Choi M, Ariyan S, Narayan D, Dutton-Regester K,
Capatana A, Holman EC, Bosenberg M, Sznol M, Kluger HM, Brash DE, Stern
DF, Materin MA, Lo RS, Mane S, Ma S, Kidd KK, Hayward NK, Lifton RP,
Schlessinger J, Boggon TJ, Halaban R. Exome sequencing identifies recurrent
somatic RAC1 mutations in melanoma. Nature genetics. 2012 Sep;44(9):1006-14.
PubMed PMID: 22842228. Pubmed Central PMCID: 3432702.
93.
Kawazu M, Ueno T, Kontani K, Ogita Y, Ando M, Fukumura K, Yamato A,
Soda M, Takeuchi K, Miki Y, Yamaguchi H, Yasuda T, Naoe T, Yamashita Y,
Katada T, Choi YL, Mano H. Transforming mutations of RAC guanosine
171

triphosphatases in human cancers. Proceedings of the National Academy of
Sciences of the United States of America. 2013 Feb 19;110(8):3029-34. PubMed
PMID: 23382236. Pubmed Central PMCID: 3581941.
94.
Davis MJ, Ha BH, Holman EC, Halaban R, Schlessinger J, Boggon TJ.
RAC1P29S is a spontaneously activating cancer-associated GTPase.
Proceedings of the National Academy of Sciences of the United States of
America. 2013 Jan 15;110(3):912-7. PubMed PMID: 23284172. Pubmed Central
PMCID: 3549122.
95.
Li A, Machesky LM. Rac1 cycling fast in melanoma with P29S. Pigment
cell & melanoma research. 2013 Feb 8. PubMed PMID: 23530970.
96.
Alan JK, Lundquist EA. Mutationally activated Rho GTPases in cancer.
Small GTPases. 2013 Jul-Sep;4(3):159-63. PubMed PMID: 24088985. Pubmed
Central PMCID: 3976972.
97.
Adam O, Laufs U. Rac1-Mediated Effects of HMG-CoA Reductase
Inhibitors (Statins) in Cardiovascular Disease. Antioxidants & redox signaling.
2013 Sep 19. PubMed PMID: 23919665.
98.
Sendur MA, Aksoy S, Yazici O, Ozdemir NY, Zengin N, Altundag K. Statin
use may improve clinicopathological characteristics and recurrence risk of
invasive breast cancer. Medical oncology. 2014 Feb;31(2):835. PubMed PMID:
24381143.
99.
Cardwell CR, Hicks BM, Hughes C, Murray LJ. Statin use after colorectal
cancer diagnosis and survival: a population-based cohort study. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology.
2014 Oct 1;32(28):3177-83. PubMed PMID: 25092779.
100. Walker EJ, Ko AH, Holly EA, Bracci PM. Statin use and risk of pancreatic
cancer: Results from a large, clinic-based case-control study. Cancer. 2015 Apr
15;121(8):1287-94. PubMed PMID: 25649483. Pubmed Central PMCID:
4393339.
101. Berry JG, Hall DE, Kuo DZ, Cohen E, Agrawal R, Feudtner C, Hall M,
Kueser J, Kaplan W, Neff J. Hospital utilization and characteristics of patients
experiencing recurrent readmissions within children's hospitals. Jama. 2011 Feb
16;305(7):682-90. PubMed PMID: 21325184. Pubmed Central PMCID: 3118568.
102. Habis M, Wroblewski K, Bradaric M, Ismail N, Yamada SD, Litchfield L,
Lengyel E, Romero IL. Statin therapy is associated with improved survival in
patients with non-serous-papillary epithelial ovarian cancer: a retrospective
cohort analysis. PloS one. 2014;9(8):e104521. PubMed PMID: 25118694.
Pubmed Central PMCID: 4131884.

172

103. Pelish HE, Peterson JR, Salvarezza SB, Rodriguez-Boulan E, Chen JL,
Stamnes M, Macia E, Feng Y, Shair MD, Kirchhausen T. Secramine inhibits
Cdc42-dependent functions in cells and Cdc42 activation in vitro. Nature
chemical biology. 2006 Jan;2(1):39-46. PubMed PMID: 16408091.
104. Hong L, Kenney SR, Phillips GK, Simpson D, Schroeder CE, Noth J,
Romero E, Swanson S, Waller A, Strouse JJ, Carter M, Chigaev A, Ursu O,
Oprea T, Hjelle B, Golden JE, Aube J, Hudson LG, Buranda T, Sklar LA,
Wandinger-Ness A. Characterization of a Cdc42 protein inhibitor and its use as a
molecular probe. The Journal of biological chemistry. 2013 Mar 22;288(12):853143. PubMed PMID: 23382385. Pubmed Central PMCID: 3605667.
105. Gao Y, Dickerson JB, Guo F, Zheng J, Zheng Y. Rational design and
characterization of a Rac GTPase-specific small molecule inhibitor. Proceedings
of the National Academy of Sciences of the United States of America. 2004 May
18;101(20):7618-23. PubMed PMID: 15128949. Pubmed Central PMCID:
419655.
106. Akbar H, Cancelas J, Williams DA, Zheng J, Zheng Y. Rational design and
applications of a Rac GTPase-specific small molecule inhibitor. Methods in
enzymology. 2006;406:554-65. PubMed PMID: 16472687.
107. Zins K, Lucas T, Reichl P, Abraham D, Aharinejad S. A Rac1/Cdc42
GTPase-Specific Small Molecule Inhibitor Suppresses Growth of Primary Human
Prostate Cancer Xenografts and Prolongs Survival in Mice. PloS one.
2013;8(9):e74924. PubMed PMID: 24040362. Pubmed Central PMCID: 3770583.
108. Zins K, Gunawardhana S, Lucas T, Abraham D, Aharinejad S. Targeting
Cdc42 with the small molecule drug AZA197 suppresses primary colon cancer
growth and prolongs survival in a preclinical mouse xenograft model by
downregulation of PAK1 activity. Journal of translational medicine. 2013;11:295.
PubMed PMID: 24279335. Pubmed Central PMCID: 4222769.
109. Montalvo-Ortiz BL, Castillo-Pichardo L, Hernandez E, Humphries-Bickley
T, De la Mota-Peynado A, Cubano LA, Vlaar CP, Dharmawardhane S.
Characterization of EHop-016, novel small molecule inhibitor of Rac GTPase.
The Journal of biological chemistry. 2012 Apr 13;287(16):13228-38. PubMed
PMID: 22383527. Pubmed Central PMCID: 3339933.
110. Onesto C, Shutes A, Picard V, Schweighoffer F, Der CJ. Characterization
of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases.
Methods in enzymology. 2008;439:111-29. PubMed PMID: 18374160.
111. Duggan KC, Walters MJ, Musee J, Harp JM, Kiefer JR, Oates JA, Marnett
LJ. Molecular basis for cyclooxygenase inhibition by the non-steroidal antiinflammatory drug naproxen. The Journal of biological chemistry. 2010 Nov
5;285(45):34950-9. PubMed PMID: 20810665. Pubmed Central PMCID:
2966109.
173

112. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW.
Effect of daily aspirin on long-term risk of death due to cancer: analysis of
individual patient data from randomised trials. Lancet. 2011 Jan 1;377(9759):3141. PubMed PMID: 21144578.
113. Waskewich C, Blumenthal RD, Li H, Stein R, Goldenberg DM, Burton J.
Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX)
inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell
lines. Cancer research. 2002 Apr 1;62(7):2029-33. PubMed PMID: 11929821.
114. Weber A, Yildirim H, Schror K. Cyclooxygenase-independent inhibition of
smooth muscle cell mitogenesis by ibuprofen. European journal of pharmacology.
2000 Feb 11;389(1):67-9. PubMed PMID: 10686297.
115. Wechter WJ, Kantoci D, Murray ED, Jr., Quiggle DD, Leipold DD, Gibson
KM, McCracken JD. R-flurbiprofen chemoprevention and treatment of intestinal
adenomas in the APC(Min)/+ mouse model: implications for prophylaxis and
treatment of colon cancer. Cancer research. 1997 Oct 1;57(19):4316-24.
PubMed PMID: 9331093.
116. Yamamoto Y, Yin MJ, Lin KM, Gaynor RB. Sulindac inhibits activation of
the NF-kappaB pathway. The Journal of biological chemistry. 1999 Sep
17;274(38):27307-14. PubMed PMID: 10480951.
117. Gurpinar E, Grizzle WE, Piazza GA. NSAIDs inhibit tumorigenesis, but
how? Clinical cancer research : an official journal of the American Association for
Cancer Research. 2014 Mar 1;20(5):1104-13. PubMed PMID: 24311630.
Pubmed Central PMCID: 3947450.
118. Gurpinar E, Grizzle WE, Piazza GA. COX-Independent Mechanisms of
Cancer Chemoprevention by Anti-Inflammatory Drugs. Frontiers in oncology.
2013;3:181. PubMed PMID: 23875171. Pubmed Central PMCID: 3708159.
119. Kwon IK, Schoenlein PV, Delk J, Liu K, Thangaraju M, Dulin NO,
Ganapathy V, Berger FG, Browning DD. Expression of cyclic guanosine
monophosphate-dependent protein kinase in metastatic colon carcinoma cells
blocks tumor angiogenesis. Cancer. 2008 Apr 1;112(7):1462-70. PubMed PMID:
18260092.
120. Lee HC, Park IC, Park MJ, An S, Woo SH, Jin HO, Chung HY, Lee SJ,
Gwak HS, Hong YJ, Yoo DH, Rhee CH, Hong SI. Sulindac and its metabolites
inhibit invasion of glioblastoma cells via down-regulation of Akt/PKB and MMP-2.
Journal of cellular biochemistry. 2005 Feb 15;94(3):597-610. PubMed PMID:
15546138.
121. Oprea TI, Sklar LA, Agola JO, Guo Y, Siberberg M, Roxby J, Vestling A,
Romero E, Surviladze Z, Murry-Krezan C, Waller A, Ursau O, Hudson L,
174

Wandinger-Ness A. Novel activities of select NSAID R-enantiomers against Rac1
and Cdc42 GTPases. PloS one. 2015;in press.
122. Handley DA, Cervoni P, McCray JE, McCullough JR. Preclinical
enantioselective pharmacology of (R)- and (S)- ketorolac. Journal of clinical
pharmacology. 1998 Feb;38(2 Suppl):25S-35S. PubMed PMID: 9549656.
123. Dorfman RI. Chemistry and pharmacology of naproxen. ArzneimittelForschung. 1975 Feb;25(2A):278-81. PubMed PMID: 1173774.
124. Segre EJ. Naproxen sodium (Anaprox): pharmacology, pharmacokinetics
and drug interactions. The Journal of reproductive medicine. 1980 Oct;25(4
Suppl):222-5. PubMed PMID: 7001021.
125. Sadok A, Marshall CJ. Rho GTPases: masters of cell migration. Small
GTPases. 2014;5:e29710. PubMed PMID: 24978113. Pubmed Central PMCID:
4107589.
126. Leve F, Morgado-Diaz JA. Rho GTPase signaling in the development of
colorectal cancer. Journal of cellular biochemistry. 2012 Aug;113(8):2549-59.
PubMed PMID: 22467564.
127. Grise F, Bidaud A, Moreau V. Rho GTPases in hepatocellular carcinoma.
Biochimica et biophysica acta. 2009 Apr;1795(2):137-51. PubMed PMID:
19162129.
128. Vetter IR, Wittinghofer A. The guanine nucleotide-binding switch in three
dimensions. Science. 2001 Nov 9;294(5545):1299-304. PubMed PMID:
11701921.
129. Yang J, Zhang Z, Roe SM, Marshall CJ, Barford D. Activation of Rho
GTPases by DOCK exchange factors is mediated by a nucleotide sensor.
Science. 2009 Sep 11;325(5946):1398-402. PubMed PMID: 19745154.
130. Kulkarni K, Yang J, Zhang Z, Barford D. Multiple factors confer specific
Cdc42 and Rac protein activation by dedicator of cytokinesis (DOCK) nucleotide
exchange factors. The Journal of biological chemistry. 2011 Jul
15;286(28):25341-51. PubMed PMID: 21613211. Pubmed Central PMCID:
3137105.
131. Leonard DA, Lin R, Cerione RA, Manor D. Biochemical studies of the
mechanism of action of the Cdc42-GTPase-activating protein. The Journal of
biological chemistry. 1998 Jun 26;273(26):16210-5. PubMed PMID: 9632678.
132. Richnau N, Aspenstrom P. Rich, a rho GTPase-activating protein domaincontaining protein involved in signaling by Cdc42 and Rac1. The Journal of
biological chemistry. 2001 Sep 14;276(37):35060-70. PubMed PMID: 11431473.
175

133. Schwartz SL, Tessema M, Buranda T, Pylypenko O, Rak A, Simons PC,
Surviladze Z, Sklar LA, Wandinger-Ness A. Flow cytometry for real-time
measurement of guanine nucleotide binding and exchange by Ras-like GTPases.
Analytical biochemistry. 2008 Oct 15;381(2):258-66. PubMed PMID: 18638444.
Pubmed Central PMCID: 2633595.
134. Agola JO, Hong L, Surviladze Z, Ursu O, Waller A, Strouse JJ, Simpson
DS, Schroeder CE, Oprea TI, Golden JE, Aube J, Buranda T, Sklar LA,
Wandinger-Ness A. A competitive nucleotide binding inhibitor: in vitro
characterization of Rab7 GTPase inhibition. ACS chemical biology. 2012 Jun
15;7(6):1095-108. PubMed PMID: 22486388. Pubmed Central PMCID: 3440014.
135. Buranda T, Basuray S, Swanson S, Agola J, Bondu V, Wandinger-Ness A.
Rapid parallel flow cytometry assays of active GTPases using effector beads.
Analytical biochemistry. 2013 Nov 15;442(2):149-57. PubMed PMID: 23928044.
136. Hapuarachchige S, Montano G, Ramesh C, Rodriguez D, Henson LH,
Williams CC, Kadavakkollu S, Johnson DL, Shuster CB, Arterburn JB. Design
and synthesis of a new class of membrane-permeable triazaborolopyridinium
fluorescent probes. Journal of the American Chemical Society. 2011 May
4;133(17):6780-90. PubMed PMID: 21473622. Pubmed Central PMCID:
3244355.
137. Surviladze Z, Ursu O, Miscioscia F, Curpan R, Halip L, Bologa C, Oprea T,
Waller A, Strouse J, Salas V, Wu Y, Edwards B, Wandinger-Ness A, Sklar L.
Three small molecule pan activator families of Ras-related GTPases. Probe
Reports from the NIH Molecular Libraries Program. Bethesda (MD)2010.
138. Surviladze Z, Waller A, Strouse JJ, Bologa C, Ursu O, Salas V, Parkinson
JF, Phillips GK, Romero E, Wandinger-Ness A, Sklar LA, Schroeder C, Simpson
D, Noth J, Wang J, Golden J, Aube J. A Potent and Selective Inhibitor of Cdc42
GTPase. Probe Reports from the NIH Molecular Libraries Program. Bethesda
(MD)2010.
139. Hong L, Guo Y, BasuRay S, Agola JO, Romero E, Simpson DS,
Schroeder CE, Simons P, Waller A, Garcia M, Carter M, Ursu O, Gouveia K,
Golden JE, Aube J, Wandinger-Ness A, Sklar LA. A Pan-GTPase Inhibitor as a
Molecular Probe. PloS one. 2015;10(8):e0134317. PubMed PMID: 26247207.
Pubmed Central PMCID: 4527730.
140. Oprea TI, Sklar LA, Agola JO, Guo Y, Siberberg M, Roxby J, Vestling A,
Romero E, Surviladze Z, Waller A, Ursa O, Wandinger-Ness A, Hudson LG.
Novel activities of select NSAID R-enantiomers against Rac1 and Cdc42
GTPases. under revision.
141. Blum R, Cox AD, Kloog Y. Inhibitors of chronically active ras: potential for
treatment of human malignancies. Recent patents on anti-cancer drug discovery.
2008 Jan;3(1):31-47. PubMed PMID: 18289122.
176

142. Sun D, Xu D, Zhang B. Rac signaling in tumorigenesis and as target for
anticancer drug development. Drug resistance updates : reviews and
commentaries in antimicrobial and anticancer chemotherapy. 2006 Dec;9(6):27487. PubMed PMID: 17234445.
143. Wiemer AJ, Wiemer DF, Hohl RJ. Geranylgeranyl diphosphate synthase:
an emerging therapeutic target. Clinical pharmacology and therapeutics. 2011
Dec;90(6):804-12. PubMed PMID: 22048229.
144. Rane C, Minden A. P21 activated kinases: Structure, regulation, and
functions. Small GTPases. 2014 Mar 21;5(1). PubMed PMID: 24658305.
145. Zhao ZS, Manser E. PAK family kinases: Physiological roles and
regulation. Cellular logistics. 2012 Apr 1;2(2):59-68. PubMed PMID: 23162738.
Pubmed Central PMCID: 3490964.
146. Pickup MW, Mouw JK, Weaver VM. The extracellular matrix modulates
the hallmarks of cancer. EMBO reports. 2014 Dec;15(12):1243-53. PubMed
PMID: 25381661. Pubmed Central PMCID: 4264927.
147. Mattila PK, Lappalainen P. Filopodia: molecular architecture and cellular
functions. Nature reviews Molecular cell biology. 2008 Jun;9(6):446-54. PubMed
PMID: 18464790.
148. Parri M, Chiarugi P. Rac and Rho GTPases in cancer cell motility control.
Cell communication and signaling : CCS. 2010;8:23. PubMed PMID: 20822528.
Pubmed Central PMCID: 2941746.
149. Lawson CD, Burridge K. The on-off relationship of Rho and Rac during
integrin-mediated adhesion and cell migration. Small GTPases. 2014;5:e27958.
PubMed PMID: 24607953. Pubmed Central PMCID: 4114617.
150. Evers EE, Zondag GC, Malliri A, Price LS, ten Klooster JP, van der
Kammen RA, Collard JG. Rho family proteins in cell adhesion and cell migration.
European journal of cancer. 2000 Jun;36(10):1269-74. PubMed PMID: 10882865.
151. Noritake J, Watanabe T, Sato K, Wang S, Kaibuchi K. IQGAP1: a key
regulator of adhesion and migration. Journal of cell science. 2005 May 15;118(Pt
10):2085-92. PubMed PMID: 15890984.
152. Baker NM, Yee Chow H, Chernoff J, Der CJ. Molecular pathways:
targeting RAC-p21-activated serine-threonine kinase signaling in RAS-driven
cancers. Clinical cancer research : an official journal of the American Association
for Cancer Research. 2014 Sep 15;20(18):4740-6. PubMed PMID: 25225063.
Pubmed Central PMCID: 4166583.

177

153. Heasman SJ, Ridley AJ. Mammalian Rho GTPases: new insights into their
functions from in vivo studies. Nature reviews Molecular cell biology. 2008
Sep;9(9):690-701. PubMed PMID: 18719708.
154. Ridley AJ. Rho GTPases and cell migration. Journal of cell science. 2001
Aug;114(Pt 15):2713-22. PubMed PMID: 11683406.
155. Courtneidge SA. Cell migration and invasion in human disease: the Tks
adaptor proteins. Biochemical Society transactions. 2012 Feb;40(1):129-32.
PubMed PMID: 22260678. Pubmed Central PMCID: 3425387.
156. Price LS, Collard JG. Regulation of the cytoskeleton by Rho-family
GTPases: implications for tumour cell invasion. Seminars in cancer biology. 2001
Apr;11(2):167-73. PubMed PMID: 11322835.
157. Jacob A, Jing J, Lee J, Schedin P, Gilbert SM, Peden AA, Junutula JR,
Prekeris R. Rab40b regulates trafficking of MMP2 and MMP9 during invadopodia
formation and invasion of breast cancer cells. Journal of cell science. 2013 Oct
15;126(Pt 20):4647-58. PubMed PMID: 23902685. Pubmed Central PMCID:
3795337.
158. C M. A Pilot Trial to Study the Availability and Effect of Post-OP IV
Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer, Cells
Retrieved From the Peritoneal Cavity: New Mexico Cancer Care Alliance; [cited
2015
May
18].
Available
from:
https://clinicaltrials.gov/ct2/show/NCT01670799?term=ketorolac+and+ovarian+ca
ncer&rank=1.
159. Shepherd TG, Theriault BL, Campbell EJ, Nachtigal MW. Primary culture
of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from
patients. Nature protocols. 2006;1(6):2643-9. PubMed PMID: 17406520.
160. Humphries MJ. Cell adhesion assays. Molecular biotechnology. 2001
May;18(1):57-61. PubMed PMID: 11439699.
161. Bellone S, Siegel ER, Cocco E, Cargnelutti M, Silasi DA, Azodi M,
Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Overexpression of epithelial
cell adhesion molecule in primary, metastatic, and recurrent/chemotherapyresistant epithelial ovarian cancer: implications for epithelial cell adhesion
molecule-specific immunotherapy. International journal of gynecological cancer :
official journal of the International Gynecological Cancer Society. 2009
Jul;19(5):860-6. PubMed PMID: 19574774.
162. Taylor DD, Gercel-Taylor C, Parker LP. Patient-derived tumor-reactive
antibodies as diagnostic markers for ovarian cancer. Gynecologic oncology. 2009
Oct;115(1):112-20. PubMed PMID: 19647308. Pubmed Central PMCID: 2760307.

178

163. Dummler B, Ohshiro K, Kumar R, Field J. Pak protein kinases and their
role in cancer. Cancer metastasis reviews. 2009 Jun;28(1-2):51-63. PubMed
PMID: 19165420. Pubmed Central PMCID: 3923596.
164. Bokoch GM, Reilly AM, Daniels RH, King CC, Olivera A, Spiegel S, Knaus
UG. A GTPase-independent mechanism of p21-activated kinase activation.
Regulation by sphingosine and other biologically active lipids. The Journal of
biological chemistry. 1998 Apr 3;273(14):8137-44. PubMed PMID: 9525917.
165. Diaz-Munoz MD, Osma-Garcia IC, Iniguez MA, Fresno M.
Cyclooxygenase-2 deficiency in macrophages leads to defective p110gamma
PI3K signaling and impairs cell adhesion and migration. Journal of immunology.
2013 Jul 1;191(1):395-406. PubMed PMID: 23733875.
166. Arjonen A, Kaukonen R, Ivaska J. Filopodia and adhesion in cancer cell
motility. Cell adhesion & migration. 2011 Sep-Oct;5(5):421-30. PubMed PMID:
21975551. Pubmed Central PMCID: 3218609.
167. Jett MF, Ramesha CS, Brown CD, Chiu S, Emmett C, Voronin T, Sun T,
O'Yang C, Hunter JC, Eglen RM, Johnson RM. Characterization of the analgesic
and anti-inflammatory activities of ketorolac and its enantiomers in the rat. The
Journal of pharmacology and experimental therapeutics. 1999 Mar;288(3):128897. PubMed PMID: 10027870.
168. Reyners AK, de Munck L, Erdkamp FL, Smit WM, Hoekman K, Lalisang
RI, de Graaf H, Wymenga AN, Polee M, Hollema H, van Vugt MA, Schaapveld M,
Willemse PH, DoCaCel Study G. A randomized phase II study investigating the
addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as
first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube
or primary peritoneal carcinomas: the DoCaCel study. Annals of oncology :
official journal of the European Society for Medical Oncology / ESMO. 2012
Nov;23(11):2896-902. PubMed PMID: 22689176.
169. Forget P, Vandenhende J, Berliere M, Machiels JP, Nussbaum B, Legrand
C, De Kock M. Do intraoperative analgesics influence breast cancer recurrence
after mastectomy? A retrospective analysis. Anesthesia and analgesia. 2010 Jun
1;110(6):1630-5. PubMed PMID: 20435950.
170. Patil R, Laguerre A, Wielens J, Headey SJ, Williams ML, Hughes ML,
Mohanty B, Porter CJ, Scanlon MJ. Characterization of two distinct modes of
drug binding to human intestinal fatty acid binding protein. ACS chemical biology.
2014 Nov 21;9(11):2526-34. PubMed PMID: 25144524.
171. Dormond O, Foletti A, Paroz C, Ruegg C. NSAIDs inhibit alpha V beta 3
integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading,
migration and angiogenesis. Nature medicine. 2001 Sep;7(9):1041-7. PubMed
PMID: 11533708.
179

172. Forget P, Berliere M, van Maanen A, Duhoux FP, Machiels JP, Coulie PG,
Bouche G, De Kock M, Ketorolac in Breast Cancer trial g. Perioperative ketorolac
in high risk breast cancer patients. Rationale, feasibility and methodology of a
prospective randomized placebo-controlled trial. Medical hypotheses. 2013
Oct;81(4):707-12. PubMed PMID: 23937996.
173. Bid HK, Roberts RD, Manchanda PK, Houghton PJ. RAC1: an emerging
therapeutic option for targeting cancer angiogenesis and metastasis. Molecular
cancer therapeutics. 2013 Oct;12(10):1925-34. PubMed PMID: 24072884.
Pubmed Central PMCID: 3823055.
174. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J
Clin. 2010 Sep-Oct;60(5):277-300. PubMed PMID: 20610543.
175. Stengel K, Zheng Y. Cdc42 in oncogenic transformation, invasion, and
tumorigenesis. Cellular signalling. 2011 Sep;23(9):1415-23. PubMed PMID:
21515363. Pubmed Central PMCID: 3115433.
176. Mack NA, Whalley HJ, Castillo-Lluva S, Malliri A. The diverse roles of Rac
signaling in tumorigenesis. Cell cycle. 2011 May 15;10(10):1571-81. PubMed
PMID: 21478669. Pubmed Central PMCID: 3127158.
177. Vega FM, Ridley AJ. Rho GTPases in cancer cell biology. FEBS letters.
2008 Jun 18;582(14):2093-101. PubMed PMID: 18460342.
178. Mardilovich K, Olson MF, Baugh M. Targeting Rho GTPase signaling for
cancer therapy. Future oncology. 2012 Feb;8(2):165-77. PubMed PMID:
22335581.
179. Friesland A, Zhao Y, Chen YH, Wang L, Zhou H, Lu Q. Small molecule
targeting Cdc42-intersectin interaction disrupts Golgi organization and
suppresses cell motility. Proceedings of the National Academy of Sciences of the
United States of America. 2013 Jan 22;110(4):1261-6. PubMed PMID: 23284167.
Pubmed Central PMCID: 3557054.
180. Surviladze Z, Waller A, Wu Y, Romero E, Edwards BS, Wandinger-Ness A,
Sklar LA. Identification of a small GTPase inhibitor using a high-throughput flow
cytometry bead-based multiplex assay. Journal of biomolecular screening. 2010
Jan;15(1):10-20. PubMed PMID: 20008126. Pubmed Central PMCID: 3433230.
181. Surviladze Z, Young SM, Sklar LA. High-throughput flow cytometry beadbased multiplex assay for identification of Rho GTPase inhibitors. Methods in
molecular biology. 2012;827:253-70. PubMed PMID: 22144280. Pubmed Central
PMCID: 4467469.
182. Oprea TI, Bauman JE, Bologa CG, Buranda T, Chigaev A, Edwards BS,
Jarvik JW, Gresham HD, Haynes MK, Hjelle B, Hromas R, Hudson L, Mackenzie
DA, Muller CY, Reed JC, Simons PC, Smagley Y, Strouse J, Surviladze Z,
180

Thompson T, Ursu O, Waller A, Wandinger-Ness A, Winter SS, Wu Y, Young SM,
Larson RS, Willman C, Sklar LA. Drug Repurposing from an Academic
Perspective. Drug discovery today Therapeutic strategies. 2011 Winter;8(3-4):619. PubMed PMID: 22368688. Pubmed Central PMCID: 3285382.
183. Guo Y, Kenney SR, Jr., Muller CY, Adams S, Rutledge T, Romero E,
Murray-Krezan C, Prekeris R, Sklar LA, Hudson LG, Wandinger-Ness A. Rketorolac Targets Cdc42 and Rac1 and Alters Ovarian Cancer Cell Behaviors
Critical for Invasion and Metastasis. Molecular cancer therapeutics. 2015 Jul 23.
PubMed PMID: 26206334.
184. Forget P, Bentin C, Machiels JP, Berliere M, Coulie PG, De Kock M.
Intraoperative use of ketorolac or diclofenac is associated with improved diseasefree survival and overall survival in conservative breast cancer surgery. British
journal of anaesthesia. 2014 Jul;113 Suppl 1:i82-7. PubMed PMID: 24464611.
185. Mroszczak E, Combs D, Chaplin M, Tsina I, Tarnowski T, Rocha C, Tam
Y, Boyd A, Young J, Depass L. Chiral kinetics and dynamics of ketorolac. Journal
of clinical pharmacology. 1996 Jun;36(6):521-39. PubMed PMID: 8809637.
186. Phenomenex. Phenomenex Chiral Column Protocols-online. APP ID:
20367.
187. Vakily M, Corrigan B, Jamali F. The problem of racemization in the
stereospecific assay and pharmacokinetic evaluation of ketorolac in human and
rats. Pharmaceutical research. 1995 Nov;12(11):1652-7. PubMed PMID:
8592665.
188. Bast RC, Jr., Hennessy B, Mills GB. The biology of ovarian cancer: new
opportunities for translation. Nature reviews Cancer. 2009 Jun;9(6):415-28.
PubMed PMID: 19461667. Pubmed Central PMCID: 2814299.
189. Kenney SR, Roxby J, Romero E, Ursa O, Oprea T, Sklar L. Enantiomer
specific inhibition of Rac1 and Cdc42 in ovarian cancer. Molec Biol Cell.
2012;22:abstr 1363.
190. Forget P, Machiels JP, Coulie PG, Berliere M, Poncelet AJ, Tombal B,
Stainier A, Legrand C, Canon JL, Kremer Y, De Kock M. Neutrophil:lymphocyte
ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in
different cohorts of patients undergoing breast, lung, and kidney cancer surgery.
Annals of surgical oncology. 2013 Dec;20 Suppl 3:S650-60. PubMed PMID:
23884751.
191. Inoue T, Murano M, Yoda Y, Kuramoto T, Kakimoto K, Ishida K,
Kawakami K, Abe Y, Morita E, Murano N, Tokioka S, Maemura K, Umegaki E,
Higuchi K. R-etodolac induces E-cadherin and suppresses colitis-related mouse
colon tumorigenesis. Oncology reports. 2010 Dec;24(6):1487-92. PubMed PMID:
21042743.
181

192. Yasui H, Hideshima T, Hamasaki M, Roccaro AM, Shiraishi N, Kumar S,
Tassone P, Ishitsuka K, Raje N, Tai YT, Podar K, Chauhan D, Leoni LM, Kanekal
S, Elliott G, Munshi NC, Anderson KC. SDX-101, the R-enantiomer of etodolac,
induces cytotoxicity, overcomes drug resistance, and enhances the activity of
dexamethasone in multiple myeloma. Blood. 2005 Jul 15;106(2):706-12. PubMed
PMID: 15802527. Pubmed Central PMCID: 1895170.
193. Kolluri SK, Corr M, James SY, Bernasconi M, Lu D, Liu W, Cottam HB,
Leoni LM, Carson DA, Zhang XK. The R-enantiomer of the nonsteroidal
antiinflammatory drug etodolac binds retinoid X receptor and induces tumorselective apoptosis. Proceedings of the National Academy of Sciences of the
United States of America. 2005 Feb 15;102(7):2525-30. PubMed PMID:
15699354. Pubmed Central PMCID: 548323.
194. Feng R, Lentzsch S. Treatment of multiple myeloma with SDX-308. Drug
news & perspectives. 2007 Sep;20(7):431-5. PubMed PMID: 17992265.
195. Lindhagen E, Nissle S, Leoni L, Elliott G, Chao Q, Larsson R, Aleskog A.
R-etodolac (SDX-101) and the related indole-pyran analogues SDX-308 and
SDX-309 potentiate the antileukemic activity of standard cytotoxic agents in
primary chronic lymphocytic leukaemia cells. Cancer chemotherapy and
pharmacology. 2007 Sep;60(4):545-53. PubMed PMID: 17186240.
196. Robak P, Smolewski P, Robak T. The role of non-steroidal antiinflammatory drugs in the risk of development and treatment of hematologic
malignancies. Leukemia & lymphoma. 2008 Aug;49(8):1452-62. PubMed PMID:
18608871.
197. Yasui H, Hideshima T, Ikeda H, Ocio EM, Kiziltepe T, Vallet S, Okawa Y,
Neri P, Sukhdeo K, Podar K, Chauhan D, Richardson PG, Raje N, Carrasco DR,
Anderson KC. Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity
in multiple myeloma cells associated with inhibition of beta-catenin/TCF pathway.
Leukemia. 2007 Mar;21(3):535-40. PubMed PMID: 17268521.
198. Gonzalez-Villasana V, Fuentes-Mattei E, Ivan C, Dalton HJ, RodriguezAguayo C, Fernandez-de Thomas RJ, Aslan B, Del CMP, Velazquez-Torres G,
Previs RA, Pradeep S, Kahraman N, Wang H, Kanlikilicer P, Ozpolat B, Calin G,
Sood AK, Lopez-Berestein G. Rac1/Pak1/p38/MMP-2 Axis Regulates
Angiogenesis in Ovarian Cancer. Clinical cancer research : an official journal of
the American Association for Cancer Research. 2015 Jan 16. PubMed PMID:
25595279.
199. Kintscher C, Groemping Y. Characterisation of the nucleotide exchange
factor ITSN1L: evidence for a kinetic discrimination of GEF-stimulated nucleotide
release from Cdc42. Journal of molecular biology. 2009 Mar 27;387(2):270-83.
PubMed PMID: 19356586.

182

200. Zhang B, Zhang Y, Wang Z, Zheng Y. The role of Mg2+ cofactor in the
guanine nucleotide exchange and GTP hydrolysis reactions of Rho family GTPbinding proteins. The Journal of biological chemistry. 2000 Aug
18;275(33):25299-307. PubMed PMID: 10843989.
201. Musrap N, Diamandis EP. Revisiting the complexity of the ovarian cancer
microenvironment--clinical implications for treatment strategies. Molecular cancer
research : MCR. 2012 Oct;10(10):1254-64. PubMed PMID: 22896662.
202. Smolle E, Taucher V, Haybaeck J. Malignant ascites in ovarian cancer
and the role of targeted therapeutics. Anticancer research. 2014 Apr;34(4):155361. PubMed PMID: 24692682.
203. Latifi A, Luwor RB, Bilandzic M, Nazaretian S, Stenvers K, Pyman J, Zhu
H, Thompson EW, Quinn MA, Findlay JK, Ahmed N. Isolation and
characterization of tumor cells from the ascites of ovarian cancer patients:
molecular phenotype of chemoresistant ovarian tumors. PloS one.
2012;7(10):e46858. PubMed PMID: 23056490. Pubmed Central PMCID:
3466197.
204. Lengyel E, Burdette JE, Kenny HA, Matei D, Pilrose J, Haluska P,
Nephew KP, Hales DB, Stack MS. Epithelial ovarian cancer experimental models.
Oncogene. 2014 Jul 10;33(28):3619-33. PubMed PMID: 23934194. Pubmed
Central PMCID: 3990646.
205. Chu Y, Tang H, Guo Y, Guo J, Huang B, Fang F, Cai J, Wang Z. Adiposederived mesenchymal stem cells promote cell proliferation and invasion of
epithelial ovarian cancer. Experimental cell research. 2015 Sep 10;337(1):16-27.
PubMed PMID: 26209607.
206. Yeung TL, Leung CS, Yip KP, Au Yeung CL, Wong ST, Mok SC. Cellular
and molecular processes in ovarian cancer metastasis. A Review in the Theme:
Cell and Molecular Processes in Cancer Metastasis. American journal of
physiology Cell physiology. 2015 Oct 1;309(7):C444-56. PubMed PMID:
26224579. Pubmed Central PMCID: 4593771.
207. White EA, Kenny HA, Lengyel E. Three-dimensional modeling of ovarian
cancer. Advanced drug delivery reviews. 2014 Dec 15;79-80:184-92. PubMed
PMID: 25034878. Pubmed Central PMCID: 4426864.
208. Cunnea P, Stronach EA. Modeling platinum sensitive and resistant highgrade serous ovarian cancer: development and applications of experimental
systems. Frontiers in oncology. 2014;4:81. PubMed PMID: 24860781. Pubmed
Central PMCID: 4029026.
209. Tomao F, Papa A, Rossi L, Strudel M, Vici P, Lo Russo G, Tomao S.
Emerging role of cancer stem cells in the biology and treatment of ovarian cancer:
basic knowledge and therapeutic possibilities for an innovative approach. Journal
183

of experimental & clinical cancer research : CR. 2013;32:48. PubMed PMID:
23902592. Pubmed Central PMCID: 3734167.
210. Chen X, Zhang J, Zhang Z, Li H, Cheng W, Liu J. Cancer stem cells,
epithelial-mesenchymal transition, and drug resistance in high-grade ovarian
serous carcinoma. Human pathology. 2013 Nov;44(11):2373-84. PubMed PMID:
23850493. Pubmed Central PMCID: 3797876.
211. Wang JY, Yu P, Chen S, Xing H, Chen Y, Wang M, Tang K, Tian Z, Rao
Q, Wang J. Activation of Rac1 GTPase promotes leukemia cell chemotherapy
resistance, quiescence and niche interaction. Molecular oncology. 2013
Oct;7(5):907-16. PubMed PMID: 23726395.
212. Akunuru S, Palumbo J, Zhai QJ, Zheng Y. Rac1 targeting suppresses
human non-small cell lung adenocarcinoma cancer stem cell activity. PloS one.
2011;6(2):e16951. PubMed PMID: 21347385. Pubmed Central PMCID: 3036726.
213. Yoon CH, Hyun KH, Kim RK, Lee H, Lim EJ, Chung HY, An S, Park MJ,
Suh Y, Kim MJ, Lee SJ. The small GTPase Rac1 is involved in the maintenance
of stemness and malignancies in glioma stem-like cells. FEBS letters. 2011 Jul
21;585(14):2331-8. PubMed PMID: 21704033.
214. Zucha MA, Wu AT, Lee WH, Wang LS, Lin WW, Yuan CC, Yeh CT.
Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in
ovarian cancer. Oncotarget. 2015 May 30;6(15):13255-68. PubMed PMID:
26036311. Pubmed Central PMCID: 4537012.
215. Wang D, Fu L, Sun H, Guo L, DuBois RN. Prostaglandin E Promotes
Colorectal Cancer Stem Cell Expansion and Metastasis in Mice.
Gastroenterology. 2015 Aug 7. PubMed PMID: 26261008.
216. Chang JK, Li CJ, Wu SC, Yeh CH, Chen CH, Fu YC, Wang GJ, Ho ML.
Effects of anti-inflammatory drugs on proliferation, cytotoxicity and osteogenesis
in bone marrow mesenchymal stem cells. Biochemical pharmacology. 2007 Nov
1;74(9):1371-82. PubMed PMID: 17714695.
217. Qiu W, Wang X, Leibowitz B, Liu H, Barker N, Okada H, Oue N, Yasui W,
Clevers H, Schoen RE, Yu J, Zhang L. Chemoprevention by nonsteroidal antiinflammatory drugs eliminates oncogenic intestinal stem cells via SMACdependent apoptosis. Proceedings of the National Academy of Sciences of the
United States of America. 2010 Nov 16;107(46):20027-32. PubMed PMID:
21041628. Pubmed Central PMCID: 2993406.
218. He QZ, Luo XZ, Wang K, Zhou Q, Ao H, Yang Y, Li SX, Li Y, Zhu HT,
Duan T. Isolation and characterization of cancer stem cells from high-grade
serous ovarian carcinomas. Cellular physiology and biochemistry : international
journal of experimental cellular physiology, biochemistry, and pharmacology.
2014;33(1):173-84. PubMed PMID: 24504111.
184

219. Cole JM, Joseph S, Sudhahar CG, Cowden Dahl KD. Enrichment for
chemoresistant ovarian cancer stem cells from human cell lines. Journal of
visualized experiments : JoVE. 2014 (91):51891. PubMed PMID: 25285606.
220. Retsky M, Demicheli R, Hrushesky WJ, Forget P, De Kock M, Gukas I,
Rogers RA, Baum M, Sukhatme V, Vaidya JS. Reduction of breast cancer
relapses with perioperative non-steroidal anti-inflammatory drugs: new findings
and a review. Current medicinal chemistry. 2013;20(33):4163-76. PubMed PMID:
23992307. Pubmed Central PMCID: 3831877.
221. Bailard NS, Flores RA. Could opioid sparing, rather than a direct nonsteroidal anti-inflammatory drug effect, be responsible for improved survival after
conservative breast surgery? British journal of anaesthesia. 2015 Mar;114(3):527.
PubMed PMID: 25694564.

185

